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1   INTRODUCTION 
1.1    The natriuretic peptide system  
The natriuretic peptide system (NPS) has been well characterized over the last 
decades. It represents a dynamic hormonal system involved in physiological, but also 
pathophysiological processes1. The NPS regulates salt and body-fluid balance as well 
as vascular tone and cardiac remodeling, thus playing a pivotal role in the 
maintenance of blood pressure and cardiovascular function2-4. Hence, the system 
strongly influences the development of cardiovascular diseases like hypertension5 
and heart failure6 including the formation of cardiac hypertrophy and fibrosis7. These 
effects are in part also resulting from its antagonistic actions towards other blood 
pressure-regulating peptide systems in the body e.g. the renin-angiotensin system 
(RAS)5, 8 and the endothelin system9. Additionally, the NPS is essentially involved in 
fetal development10, 11 including bone growth12, and cardiac maturation11, 13 as well as 
in other elementary mechanisms like lipid metabolism14, 15.  
The NPS is conserved in all vertebrates ranging from simple species like Drosophila 
to humans16. Recently, there was even evidence for the existence of a similar system 
in plants17.  
The NPS is composed of the natriuretic peptides and the natriuretic peptide 
receptors, which mediate the intracellular signaling upon binding of the natriuretic 
peptides and are in part also involved in the clearance of them18. Additionally, several 
enzymes are associated with the NPS regulating the natriuretic peptide generation, 
processing19, and inactivation20. 
1.1.1  Discovery of natriuretic peptides 
The three main peptide hormones of the natriuretic peptide system are the atrial 
natriuretic peptide (ANP), the B-type natriuretic peptide (BNP) and the C-type 
natriuretic peptide (CNP). The existence of ANP was first described in 1981 by de 
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Bold et al., who injected extracts of atrial tissues into rats and observed a decrease in 
arterial pressure as well as an increase in urinary water and sodium excretion in 
these animals21. Two years later, the responsible peptide has been isolated and its 28-
amino acid (aa) sequence was deciphered22. According to its origin and its natriuretic 
properties, the newly identified substance was named atrial natriuretic peptide. In 
1988, Sudoh et al. identified a second structurally related natriuretic peptide 
consisting of 32 amino acids in porcine brain and named it accordingly brain 
natriuretic peptide or BNP23. In the following years, it was revealed that BNP is 
mainly expressed in ventricular and also atrial cardiomyocytes rather than in the 
brain, where it was discovered24, 25. However, both, ANP and BNP transcripts were 
also found in the central nervous system, lung, thyroid, adrenal, kidney, spleen, small 
intestine, ovary, and uterus in levels approximately 1-2 orders of magnitude lower 
than in cardiac tissues26. In 1990 the third member of the natriuretic peptide system, 
the 22-amino acid long CNP, was also discovered in porcine brain by Sudoh et al.27. 
Now it is known that CNP is abundantly produced in vascular endothelium28 and also 
the central nervous system29. 
The existence of two more endogenously expressed natriuretic peptides has been 
reported in the literature. Urodilatin (URO) was extracted from human urine in 
198830. The 32-amino acid residue peptide is generated by alternative processing of 
the ANP precursor peptide taking place in the kidney tubules30, 31. However, URO 
seems to have less biological activity compared to ANP31. Dendroaspis natriuretic 
peptide (DNP), harboring 38 amino acids, was originally isolated from the venom of 
the green mamba in 199232. Due to the discovery of DNP-like immunoactivity in 
human plasma and atrial tissue, the existence of DNP in men is anticipated33, 34.  
1.1.2  Structure and secretion of the mature natriuretic   
peptides 
The mature forms of the three classical natriuretic peptides, ANP, BNP, and CNP, are 
similar in their amino acid sequence and secondary structure. They are derived from 
distinct cleavage of their precursors, the pro-natriuretic peptides, leading to the 
formation of two peptide portions, the N-terminal fragments, so called NT-pro-
natriuretic peptides and the C-terminal fragments35. These C-terminal fragments 
represent the mature and bioactive forms of the natriuretic peptides (Figure 1). The 
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bioactive ANP consists of 28 aa (ANP1-28)22; BNP of 32 aa (BNP1-32)36, and CNP of 
22 aa (CNP1-22)37. These bioactive forms are often just named ANP, BNP, and CNP 
without any indication of their sequence length. All three mature peptides share a 
17-aa ring structure formed by an intramolecular disulfide bridge. This structure is 
likely formed by cardiac protein disulfide isomerases, whose expression has been 
reported to be up-regulated during cardiopathological conditions38. The ring 
structure is essential for the biological activity of these natriuretic peptides39. High 
sequence similarity between the peptides is present within this cyclic structure 
(Figure 1, highlighted in grey), while the C- and N-terminal regions are very 
divergent, especially for CNP, which lacks a C-terminal extension. 
Upon synthesis, ANP is transported through the Golgi complex and packaged into 
membrane bound atrial granules40. It has been suggested that BNP is also transported 
towards such granules and that both, ANP and BNP, are stored together41. The main 
stimulus for ANP and BNP secretion is wall stretch of the myocardium induced by 
raising blood pressure accompanied with atrial and ventricular volume overload42-44. 
Moreover, a constitutive release through passive diffusion in the absence of stimuli 
has been described as well as basal secretion depending on the degree of newly 
synthesized pepetide45-47. CNP secretion is not accompanied with increased wall 
stretch, since CNP is neither predominantly expressed in heart tissue nor stored in 
secretory granules48. Its release from endothelial cells seems to be regulated through 
paracrine secretion28. It was shown that ANP and BNP stimulate the production and 
secretion of CNP from endothelial cells49. Beside, ANP and BNP, also cytokines like 
Figure 1: Secondary structures of the bioactive murine atrial natriuretic peptide (ANP) with 28 amino 
acids, B-type natriuretic peptide (BNP) with 32 amino acids, and C-type natriuretic peptide (CNP) with 
22 amino acids. Conserved amino acids are highlighted in grey. The first amino acid at the N-terminus 
and the last amino acid at the C-terminus are numbered. 
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tumor necrosis factor alpha (TNFα) and interleukin 6 (Il6) are able to induce CNP 
release28.  
1.1.3  Natriuretic peptide receptors and principal signaling 
Biological actions of the natriuretic peptides are mediated by membrane-bound cell-
surface receptors, the natriuretic peptide receptors A, B, and C (NPRA, NPRB and 
NPRC). The relative effectiveness of the peptides to bind and activate NPRA has been 
reported as: ANP ≥ BNP >> CNP, whereby for CNP no significant activation of the 
NPRA has been detected50, 51. On the contrary, the affinity of CNP towards the NPRB 
receptor is 50- to 500-fold higher than for ANP and BNP (CNP >> ANP = BNP). Thus, 
ANP and BNP are ligands for NPRA50, while CNP binds to NPRB50, 51 (Figure 2).  
Both, NPRA and NPRB, contain two intracellular kinase homology (KH) domains and 
guanylyl cyclase (GC) domains52. Upon extracellular binding of the ligand, the binding 
domain of the receptor undergoes a twist motion, which is suggested to facilitate the 
binding of adenosine triphosphate (ATP) on the KH domain. Once ATP is bound, a 
Figure 2: Natriuretic peptide receptors A (NPRA) and B (NPRB) with their ligands atrial natriuretic 
peptide (ANP), B-type natriuretic peptide (BNP) and C-type natriuretic peptide (CNP). Upon ligand 
binding, a conformational change of the kinase honology domain is induced, which relieves its 
inhibitory effect on the guanylyl cyclase domain. Active guanylyl cyclases generate cyclic guanosine 
monophosphate (cGMP) from guanosine triphosphate (GTP)56,57.  
 
ligand-binding
domain
kinase homology
domain
guanylyl cyclase
domain
2 GTP 2 cGMP 2 GTP 2 cGMP
NPRA                  NPRB                  
ANP/BNP                  CNP
Cell membrane
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conformational change occurs in the KH domain relieving its normal inhibitory effect 
on the GC domains53-55. Subsequently, the two GC domains associate with each other 
and form two active sites per receptor55. Activated GC is catalyzing the formation of 
the second messenger cyclic guanosine monophosphate (cGMP) from guanosine 
triphosphate (GTP)56, 57. Intracellular cGMP stimulates a broad variety of effector 
molecules, e.g. cGMP-dependent protein kinases (PKG), cGMP-dependent phospho-
diesterases (PDE), and cGMP-dependent ion-gated channels (CNG)58. These effectors 
influence a vast number of signaling pathways mainly by regulating intracellular Ca2+ 
release59 and protein kinases, like mitogen-activated protein kinase (MAPK)60, 61 as 
well as protein kinase C (PKC)62. Physiological effects of the natriuretic peptide/NPRA 
and natriuretic peptide/NPRB axis are described in more detail in section 1.1.5. 
The extracellular domain of NPRC shares high structural similarity with that of the 
NPRA and NPRB18 (Figure 3) and possesses high and similar affinity for all 
natriuretic peptides, which has been reported as: ANP ≥ CNP ≥ BNP50. However, NPRC 
is lacking the intracellular GC domain63, but is associated with Gi-proteins and binding 
of the ligands to the NPRC activates Gi-protein-dependent pathways64, 65. In 
cardiomyocytes the Giα-subunit inhibits adenylyl cyclase leading to a reduction of 
intracellular cAMP and inhibition of Ca2+ influx. In cardiac fibroblasts the Giβγ subunit 
activates phopsholipase C stimulating Ca2+ influx66. Despite these actions, NPRC is 
commonly considered to be a clearance receptor for the natriuretic peptides67, 68. 
Cell membrane
NPRC                  
ANP/BNP/CNP                  
ligand-binding 
domain
G-protein domain
Giα
Giβ Giγ
Figure 3: Natriuretic peptide receptors C (NPRC) with its ligands atrial natriuretic peptide (ANP), 
B-type natriuretic peptide (BNP) and C-type natriuretic peptide (CNP). Upon binding of the ligand, 
Gi-protein domains (Gα-, Gβ- and Gγ-subunits) are activated64,65. 
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1.1.4  Physiological effects of the natriuretic peptide system 
1.1.4.1    The ANP & BNP/NPRA axis 
The discovery of ANP and BNP, and their secretion from the myocardium revealed 
that the heart is not only a pump driving the circulation of blood, but is also an 
endocrine organ regulating the cardiovascular system. The NPRA axis counteracts 
plasma volume expansion and thus regulates blood pressure homeostasis35, 69. On the 
one hand, this is achieved through its ability to induce natriuresis as well as diuresis, 
and by its direct vasodilatory effects35, 57, 70. At the same time, it regulates thirst and 
salt appetite71, 72 as well as the sympathetic nervous system by inhibiting sympathetic 
activity73, 74. The NPRA axis also counteracts the development and progression of 
cardiac remodeling e.g. cardiac hypertrophy75 and fibrosis76. Notably, it was 
discovered, that NPRA expression is downregulated in heart failure77. 
Several genetically altered animal models have been developed for the investigation 
of the physiological functions of ANP and BNP through NPRA. The group around O. 
Smithies generated mice with a disruption of the gene encoding for the ANP 
precurser proANP78. In the homozygous model no circulating ANP can be found. 
These animals suffer from substantially increased blood pressure. In contrast to this, 
BNP knockout mice do not exhibit hypertension, but develop severe cardiac fibrosis76. 
In NPRA knockout mice, the lack of all ANP- and BNP- mediated effects can be 
observed79. Such animals exhibit chronic hypertension and significant reductions in 
natriuresis and diuresis in response to volume overload. Moreover, these knockout 
mice exert cardiac hypertrophy with extensive interstitial fibrosis resulting in 
increased lethal vascular events similar to those observed in untreated hypertensive 
patients80. It was predicted that the ANP- and BNP- mediated stimulation of NPRA 
leads to the inhibition of the Ca2+ channels known to positively regulate ‘calcineurin-
nuclear factor of activated T cells’ (NFAT) - signaling, which is involved in the 
development of cardiac hypertrophy through increasing the hypertrophy-related 
gene expression81, 82 as demonstrated in Figure 4. It was also revealed that NPRA-
signaling leads to an inactivation of the nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) and thus to a reduction of extracellular remodeling 
including fibrosis83 (Figure 4).  
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Interestingly, mice absent for NPRA in cardiomyocytes only, also develop cardiac 
hypertrophy, suggesting that the NPRA axis acts as a local antihypertrophic 
regulator84. 
Smooth muscle cell-specific deletion of the NPRA does not alter blood pressure, but 
abolishes ANP-mediated vasodilation of isolated vessels85. On the other hand, 
endothelial-specific deletion of NPRA is accompanied with high blood pressure but 
the direct vasodilatory effect of ANP is preserved86. This indicates that endothelial 
NPRA is critical for water homoestasis, and smooth muscle cell NPRA plays a critical 
role for the acute regulation of vasodilation, respectively.  
1.1.4.2    The CNP/NPRB axis 
In contrast to ANP and BNP, it was shown that CNP acts anti-natriuretic, since 
infusions of the peptide increases renal sodium reabsorption87. Nevertheless, 
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Figure 4: Schematic diagram of how atrial natriuretic peptide (ANP) and B-type natriuretic peptide 
(BNP)-signaling via the natriuretic peptide receptor A (NPRA) prevents the extracellular remodeling, 
induction of the hypertrophic gene program and induces vasorelaxation. Inhibitory pathways are 
highlighted with dashed arrows. The overview is evolved from references 81-83. Abbreviations: 
guanosine triphosphate (GTP), cyclic guanosine monophosphate (cGMP), cGMP-dependent protein 
kinase (PKG), calcineurin-nuclear factor of activated T cells (NFAT), nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB), endoplasmatic reticulum (ER). 
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infusions of CNP decrease mean arterial blood pressure and it was shown that CNP 
acts as local regulator of vascular tone88 and also remodeling89, 90.  
Wang et al. developed an animal model with cardiomyocyte-specific overexpression 
of CNP91. Since CNP is not expressed in the heart under physiological conditions, the 
peptide levels increased up to 100-fold in the right ventricle. Notably, in healthy 
animals no increase of plasma CNP and no influence on blood pressure or heart 
morphology were observed. However, they found that CNP overexpression 
significantly prevents myocardial infarction-induced cardiac hypertrophy compared 
to wild-type controls, indicating that also the NPRB axis plays a role in the regulation 
of hypertrophy. Supporting this hypothesis, NPRB dominant-negative mutants, which 
exert reduced CNP but not ANP-NPRA-dependent cGMP generation, display 
progressive, blood pressure-independent cardiac hypertrophy92. Other than for the 
NPRA knockouts, these animals do not show fibrosis.  
NPRB knockout mice, generated by the replacement of exons encoding for the 
extracellular ligand binding domain of the NPRB by a neomycin resistance gene, show 
a very severe phenotype93. These mice have a drastically reduced survival and 
develop strong dwarfism through impairment of endochronal ossification. Animals 
that survived beyond 100 days were only 60-70% in nasoanal length and had only 
50% of the body weight compared to their wild-type controls. Notably, also mice 
lacking CNP develop severe dwarfism with reduced survival94. Thus, signaling 
through the NPRB axis seems to be important for the bone development. Moreover, 
NPRB knockout females are infertile showing abnormal development of the uterus 
and ovary, whereas no changes were observed in male reproductive organs94. 
1.1.4.3    The natriuretic peptides/NPRC axis 
The NPRC is the most widely and abundantly expressed natriuretic peptide receptor 
and the most represented one in endothelial cells64. At time of the discovery of NPRC, 
it was described as a silent receptor with the only function to remove natriuretic 
peptides from the circulation95. Indeed, up- or downregulation of NPRC influences the 
clearance rate of natriuretic peptides64. NPRC is highly expressed in adipocytes, and 
weight reduction of obese individuals goes along with increased natriuresis and 
diuresis probably caused by the reduced clearance of ANP and BNP and thus higher 
activity on the ANP/BNP/NPRA axis96. Other than for NPRA expression, which is 
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decreased in failing hearts, NPRC expression is increased97, 98. Very recently a cross-
talk between NPRC and NPRA has been suggested, which might cause this effect99.  
Several evidences for a functional NPRC axis involving the action of all three 
natriuretic peptides have been accumulated. It was shown that ANP interacts with 
NPRC in atria and ventricles activating calmodulin through the Gi protein leading in 
part to its hypotensive, natriuretic and diuretic effects100. A functional interaction 
between NPRC and BNP has also been suggested, possibly mediating antiproliferative 
actions in cardiac fibroblasts101.  
The NPRC also plays a critical role in bone growth. NPRC deficient mice show long 
bone over-growth, possibly due to the lack of CNP clearance and thus an increased 
signaling through the NPRB68.  
1.1.4.4    The natriuretic peptide system in fetal development 
It was shown that natriuretic peptides are present in fetal circulation and constitute a 
functional endocrine system responsive to cardiac filling pressure11, 102. Levels of ANP 
are higher in the fetal circulation than in adults103, and fetal ventricles express higher 
levels of ANP than adult ventricles104. Peaks of ANP and BNP expression during 
gestation are associated with significant events in cardiac organogenesis, suggesting 
the involvement in embryonic heart development10. Supportingly, NPRA knockout 
mice present significant, blood pressure-independent cardiac hypertrophy at birth, 
suggesting that the natriuretic peptide/NPRA-axis is involved in myocyte growth 
during fetal development105. ANP and BNP may also help to regulate blood supply to 
the fetus by acting as vasodilators in the placental vasculature106. No CNP has been 
detected in developing hearts10. 
Cardiac ANP and BNP are also increased in fetuses having trisomy in comparison to 
healthy fetuses, which might be the consequence of the high incidences of congenital 
heart defects seen in these individuals and thus may lead to the development of 
nuchal translucency11, 107.  
Natriuretic peptides have also effects on the development of other tissues than heart. 
As stated before, NPRC knockout mice68 and also BNP-overexpressing mice108 
develop skeletal overgrowth, whereas CNP knockout fetuses show dwarfism and 
bone malformation94. 
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1.1.5  Clearance and Inactivation of natriuretic peptides 
1.1.5.1     Half-life of natriuretic peptides 
Natriuretic peptides have short half-life times and are cleared from the circulation 
within minutes109. Two main mechanisms are contributing to this process: binding to 
natriuretic peptide receptors with subsequent internalization95, 110 and enzymatic 
inactivation by peptidases110, 111. Pharmacokinetic measurements revealed a half-life 
of about 2 to 3 min for ANP and CNP in healthy human subjects112, 113. The half-life for 
BNP lasts slightly longer. Mukoyama et al. determined half-life times of 3.9 min for 
BNP and 1.7 min for ANP in normal men114. The half-life of porcine BNP, which was 
injected to human circulation, has been reported to be 3 min115 and in sheep, 
endogenous BNP secreted after acute volume overload was determined with a 
half-life of about 5 min116.  
1.1.5.2    Clearance by natriuretic peptide receptors 
Upon binding of the natriuretic peptides to the natriuretic peptide receptors, 
endocytotic receptor-ligand internalization takes place110, 117. In a subsequent 
process, the natriuretic peptides are hydrolysed in the lysosome while a big portion 
of the receptor is rapidly recycled leading to a constant receptor level on the cell 
surface117, 118. The clearance receptor NPRC is thought to be the receptor mainly 
responsible for the clearance of the natriuretic peptides also because of its abundant 
distribution and high expression64. In transgenic mice, in which NPRC was genetically 
ablated, it was shown that ANP had a 66% longer half-life compared to wilde-type 
animals68. Furthermore, it was shown recently that NPRC, expressed in mouse brain 
capillaries, mediates brain-to-blood efflux of ANP at the blood-brain barrier as a 
pathway of cerebral ANP clearance119. 
1.1.5.3    Inactivation by the peptidase neprilysin 
The main enzyme catabolizing natriuretic peptides was thought to be neprilysin 
(neutral endopeptidase, NEP, EC 3.4.24.11), a zinc-dependent membrane-bound 
metallopeptidase, inactivating natriuretic peptides by a hydrolytic attack on the 
peptides’ ring structure120-122. This hydrolysis opens the typical ring structure of the 
peptides, which is essential for biological activity, and thus leads to the formation of 
inactive fragments123. However, some studies questioned the role of NEP as the 
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central degrading enzyme for all natriuretic peptides, since degradation times for 
BNP last much longer compared to ANP124, 125. In 2004, Walther et al. reported that, in 
contrast to ANP, no differences in the BNP degradation rates in NEP knockout mice 
and their wild-type controls can be observed125. These in vivo studies and additional 
experiments with recombinant NEP revealed that ANP and CNP are indeed quickly 
degraded by NEP, but in comparison to them, BNP is inert to the hydrolytic attack of 
NEP125. Own studies investigating the structural requirements of natriuretic peptides 
to be substrates for NEP, highlighted N- and C-terminal regions of the peptides to be 
decisive for the degradation by NEP20 as presented in Figure 5.  
Although computer modeling revealed that BNP fits into the catalytic cavity of NEP, it 
was shown that BNP is not hydrolyzed by the enzyme. Reason for this is an impaired 
adjustment of the peptide towards the catalytic site of NEP. This impairment is 
caused by its long N- and C-termini, which hinder the peptide to bind to the 
recognition sites within the catalytic cavity of NEP. As a general conclusion it was 
highlighted that shorter natriuretic peptides like ANP (28 aa) and CNP (22 aa) are 
faster degraded by NEP compared to peptides with longer amino acid sequences like 
BNP (32 aa) and DNP (38 aa).  
Figure 5: Simplified mechanism of the orientation of short and long natriuretic peptides within the 
catalytic center of neprilysin (NEP). a) Due to steric clashes caused by long N- and C-terminal regions, 
the peptide cannot be adjusted towards the catalytic center of NEP and the cleavage site is not 
hydrolyzed. b) Shorter N- and C-terminal regions allow the peptide to move and bind to the 
recognitions sites in the cavity. Thus, the orientation of the cleavage site towards the catalytic center of 
NEP is favored and hydrolysis can take place. Adapted from Pankow & Schwiebs et al.20  
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Fitting the model, it was shown recently for a human ANP variant having a 12-amino 
acid extension on the C-terminus caused by a frameshift mutation (fsANP), that its 
degradation through NEP was significantly reduced compared to the mature ANP126. 
1.1.6  Design of natriuretic peptides 
Besides the naturally occurring natriuretic peptides, several variants composed of 
different parts of the endogenous natriuretic peptides, e.g. CU-NP (CNP and URO)127, 
CD-NP (CNP and DNP)128, or ACNP (ANP and CNP)129, 130 have been designed. These 
synthetic peptides are designed to increase proteolytic resistance or biological 
activity, respectively. ACNP is a chimeric peptide composed of the disulfide-linked 
ring of endogenous CNP and the N- and C-terminal part of human ANP (Figure 6). 
In own work it was found that ACNP has altered receptor specificity129. While ANP 
binds to NPRA and CNP binds to NPRB, ACNP is able to bind to both of these 
receptors and stimulate significant cGMP generation. Thus, ACNP combines 
bioactivity of ANP and CNP. 
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Figure 6: Schematic design of ACNP from the N- and C-terminal regions of the atrial natriuretic 
peptide (ANP) and the ring structure of the C-type natriuretic peptide (CNP). The first amino acid at 
the N-terminus and the last amino acid at the C-terminus are numbered. 
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1.2   The B-type natriuretic peptide 
1.2.1   Endogenous BNP: Gene expression and peptide 
processing 
BNP gene expression takes place in atrium and ventricle, while ventricular expression 
increases drastically upon the development of cardiac diseases mainly as a response 
to myocardial stretch131, 132. The synthesis of BNP starts with the transcription of a 
gene composed of 1.3 kb including three exons and two introns located upstream 
from the ANP gene on chromosome 4 in mice133 and chromosome 1 in humans134. The 
promoter of the BNP contains gene elements, which regulate cardiac-specific gene 
expression135, 136. A study using transgenic animals carrying a luciferase gene coupled 
to the proximal region of the BNP promoter showed that this segment is sufficient to 
mediate the ventricle-specific expression and thus expression is higher in ventricles 
than in atrium137, 138. The translation of the mRNA encoding the precursor of the 
peptide results in the generation for the pre-proBNP with 134 amino acids139, 140. 
Already during synthesis, an N-terminal 26-amino acid signal peptide is removed 
resulting in the formation of proBNP (108 aa)141 (Figure 7).  
It might be, that the signal peptide is already removed before the synthesis of the 
precursor is completed and therefore pre-proBNP does probably not exist as an 
entity142. However, in case pre-proBNP is generated, it can in theory be anchored in 
Figure 7: Processing of pre-proB-type natriuretic peptide (pre-proBNP). After removal of the signal 
peptide, furin and corin are generating the N-terminal fragment NT-proBNP with 76 amino acids (aa) 
and the C-terminal fragment BNP1-32 with 32 amino acids19,141,144. 
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cell membranes or be associated with lipid compounds in the circulation since the 
signal peptide is highly hydrophobic. A truncated fragment of the signal peptide has 
been identified in the circulation, indicating that the pre-proBNP might have been 
secreted from the cell or shedded from the cell surface resulting in the generation of 
this fragment143.  
ProBNP is considered to be cleaved by two convertases, intracellular furin and 
membrane-bound corin, both generating two portions of BNP: the N-terminal part 
named NT-proBNP (76 aa) and the bioactive C-terminal part named BNP1-32 
(32 aa)19, 144 (Figure 7). The genes of furin and BNP are co-expressed in 
cardiomyocytes and expression of furin is also elevated under cardiopathological 
conditions145. It has been shown that inhibition of furin in vitro decreases pro-BNP 
processing and cleavage of proBNP in furin-deficient cells is reduced by up to 60%19. 
Furin is mainly located in the trans-Golgi network, while corin, a serine protease, is 
anchored transmembranal and is also present in circulation146, 147. It is thought to 
cleave proBNP and also proANP upon secretion from the cell generating the bioactive 
fragments146, 148, 149. Corin knockout mice develop sustained hypertension 122, 150 and 
very recently corin gene-mutations have been suggested to be associated with 
pre-eclampsia (= pregnancy-induced hypertension)151.  
Both peptides, NT-proBNP and BNP1-32, as well as their precursor proBNP have 
been shown to circulate in the body152, 153.  
In rodents an additional bioactive BNP peptide was found resulting from a differential 
processing of proBNP releasing a C-terminal BNP peptide of 45 amino acids instead of 
32154, 155. This peptide, namely BNP1-45, was not found in humans, respectively. 
1.2.2  Metabolism of the bioactive BNP1-32 by peptidases 
In circulation, peptides are exposed towards the proteolytic activity of enzymes in 
blood and on cellular membranes of organs, leading to their degradation. However, it 
was shown for some vasoactive peptides e.g. for the vasoconstrictory peptides 
Angiotenisn II and endothelin or for the vasorelaxing peptide bradykinin, that before 
degradation, they are metabolised into truncated, but bioactive peptide 
fragments156-158. Only very few studies have shown that BNP1-32 is also processed 
into shorter fragments before being cleared form the circulation159, 160. Such 
fragments still contain the 17-aa ring structure, which is the prerequisite for 
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biological activity of natriuretic peptides39 and thus, such BNP fragments are called 
metabolites rather than degradation products. In 2002, Shimizu et al. identified in 
plasma of heart failure patients that has been spiked with BNP1-32 in vitro, that the 
peptide is metabolized into an N-terminally truncated metabolite152. This BNP 
metabolite is shortened by two amino acids compared to the mature BNP1-32 and 
was subsequently named BNP3-32. In 2006, Brandt et al. reported that the 
conversion of BNP1-32 to BNP3-32 is mediated by dipeptidyl-peptidase IV 
(DPPIV)159. DPPIV is a prolyloligopeptidase that occurs on cell-surfaces as well as in 
soluble form in plasma161. In 2007, Pankow et al. reported the cleavage of murine 
BNP1-32 by renal meprin A resulting in the generation of the BNP metabolite 
BNP7-32160  as presented in Figure 8.  
Figure 8: Metabolism of murine B-type natriuretic peptide 1-32 (BNP1-32) to the metabolite BNP7-32 
by meprin A. BNP7-32 is less biologically active compared to BNP1-32, since its ability to stimulate 
cGMP generation through the natriuretic peptide receptor A (NPRA) is reduced. Moreover, BNP7-32 
can be inactivated by neprilysin (NEP). Adapted from Pankow et al.159 
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Both BNP metabolites have strongly reduced bioactivity compared to the mature 
BNP1-32. A lack of vasodilatory actions and also natriuresis and diuresis was shown 
for BNP3-32 infused into dogs compared to BNP1-32162. Similarly, it was shown that 
the ability of BNP7-32 to induce the generation of cGMP via the NPRA in vitro was 
approximately 50% less compared to BNP1-32160. Furthermore, it was revealed that 
BNP7-32 is no longer resistant towards the proteolytic activity of NEP. According to 
the model introduced in section 1.1.5.3, BNP7-32 can be degraded into inactive 
fragments, due to its shorter N-terminus leading to a better adjustment of the peptide 
in the catalytic center of NEP and thus the peptide can be inactivated through a 
hydrolytic attack within the ring-structure20. 
1.2.3   Physiological effects of BNP and involvement in 
(cardiovascular) diseases 
Besides its systemic actions, like induction of natriuresis163 and vasorelaxation164, 
BNP has direct inhibitory effects on cardiac and vascular remodeling6, 7. It mediates 
cell growth and proliferation, and thus counteracts cardiac hypertrophy via NPRA 
mediated signaling141 and acts as a local anti-fibrotic factor in the heart165 (see also 
Figure 4). Numerous studies have demonstrated an increase of BNP levels in 
cardiovascular disease states including ischemia, arrhythmias, fibrosis, cardiac 
hypertrophy, coronary endothelial dysfunction, and hypertension166-169. In addition, 
plasma BNP concentrations are markedly increased in the early phase of acute 
myocardial infarction, when plasma ANP levels are increased only very slightly170. 
These observations suggest that elevation of BNP levels represent a final common 
pathway for many cardiovascular diseases in order to decrease blood pressure and 
volume, and to prevent extensive cardiac remodeling141, 167-169, 171-173.  
Nakao et al. generated a BNP knockout mouse by replacing exon 1 and 2 of the mouse 
BNP gene with a neomycin-resistance gene leading to the generation of a disrupted 
BNP allele76. This disruption results in a complete loss of BNP mRNA and peptide. 
BNP knockout mice exert extensive fibrosis in the ventricles shown by increased 
collagen mRNA levels developing from week 15 of age and thereafter. These mice also 
exert increased expression of mRNA of the Angiotensin-converting enzyme (ACE), the 
enzyme being responsible for the generation of the vasoconstrictory peptide 
Angiotensin II174. However, these animals do not exert significant differences in blood 
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pressures compared to wildtype animals, suggesting that BNP might not be involved 
in the regulation of blood pressure under physiological conditions in normal healthy 
subjects. On the other hand, ANP mRNA expression and ANP levels were markedly 
increased in the ventricle of these mice, probably representing a compensatory 
mechanism.  
Transgenic mice, overexpressing BNP in liver driven by a serum amyloid P 
component promoter, show a 100-fold increase in BNP and cGMP plasma levels and 
have a significant lower blood pressure and heart weight suggesting that BNP 
especially plays a regulatory role when it circulates in large quantities like in 
cardiopathological states175. Moreover, BNP overexpressing animals that underwent 
unilateral nephrectomy, are protected against glomerular fibrosis and hypertrophy, 
suggesting that BNP can, besides acting intracardially, also act as an antifibrotic and 
antihypertrophic factor in other organs through systemic release176. BNP 
overexpression also has dramatical effects on skeletal development108. Such mice 
develop skeletal abnormalities like kyphosis and become progressively hump-backed. 
Moreover, they have significantly increased bone length without exhibiting an 
increase in body weight. Explanations for these effects are inconclusive so far, since it 
was shown before, that the NPRB axis is responsible for skeletal development93 (see 
section 1.1.4.2), but BNP1-32 is not able to activate this axis (see section 1.1.3). 
1.2.4  BNP as a therapeutic drug 
In 2001, the Federal Drug Administration (FDA) approved the use of recombinant 
human BNP1-32, named Nesiritide®, for the treatment of acutely decompensated 
congestive heart failure177. A literature search to review preclinical and clinical 
information related to Nesiritide® revealed that it has beneficial effects for the 
treatment of heart failure through stimulation of arterial and venous dilatation, 
enhancement of natriuresis and diuresis, and suppression of the renin-angiotensin 
and sympathetic nervous systems178-180. The study ‘Fusion I’ revealed a significant 
improvement of all-cause mortality and all-cause hospitalization in high-risk patients 
receiving Nesiritide® in comparison to standard care179. However, its clinical 
usefulness is discussed181, since studies were made in which Nesiritide® was 
described to have adverse effects on renal function182-184 and was associated with an 
increased risk of death in patients with previous renal dysfunction185. However, in 
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2011, O’Conner et al.183 published data of a cohort of 7141 patients with acute heart 
failure receiving Nesiritide® or placebo. They could not associate the treatment with 
worsening of renal function or risk of death. However, they also couldn’t find any 
significant improvements of the patients disease’ status caused by the administration 
of Nesiritide® in comparison to the placebo group. Thus, the usefulness of Nesiritide® 
is rather unclear. 
1.2.5  BNP as a biomarker: clinical applications 
A dramatically increase of BNP levels occurs with the progression of cardiac 
diseases186-189, which made BNP a useful biomarker190-193 and measurements of BNP 
levels extremely clinically relevant166, 194. Plasma BNP concentrations were shown to 
correlate with echocardiographic parameters obtained from patients with heart 
failure195, which made the determination of such levels precise enough for the 
diagnosis of heart failure independently of the examination of cardiologists196.  
The diagnostic use of BNP has been evaluated in many clinical trials. The study 
‘Breathing Not Properly’ showed the usefulness of determining BNP for implicating or 
excluding congestive heart failure in patients with dyspnoea171. Thus, BNP1-32 has 
emerged as valuable biomarker for patients presenting with chest pain or 
dyspnoea196-199. It was shown by Maisel et al. that increasing BNP levels correlate 
with heart failure stage172. It was disclosed that after acute myocardial infarction 
(MI), BNP levels rise dependent on the severity of the infarct, revealing BNP as a tool 
to monitor etiopathology200. Already in 1999, the first report was published that 
suggested to utilize measurements of plasma concentrations of natriuretic peptides 
as a save method of adjusting the therapy of moderate heart failure201. Since the 
change of plasma BNP levels of patients follows improvement or decline of the 
disease, decreasing BNP values predict improvement of cardiac function and disease 
outcome202-204. It was shown in patients with congestive heart failure and MI, that 
increasing concentrations of BNP correlate with enlargement, decreased contractility, 
and increased stiffness of the left ventricle205. Ganem et al. showed recently, that pre-
operative BNP levels predict the adverse outcome for patients undergoing cardiac 
surgery206. 
At the same time, the utilization of BNP measurements entails economic advantages. 
Importantly, knowledge of BNP levels reduces medical costs (e.g. reduction of 
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echocardiography) and reduces examination time in the emergency room207. As 
evaluated in the ‘IMPROVE’ study207, the rehospitalisation rate over a 60-day period 
was significantly reduced when BNP levels where known and interpreted. In 2006, 
Roche Diagnostics’ proposed at the American Heart Association’s Scientific Sessions 
that the introduction of BNP testing could generate yearly savings up to $600 million 
in the U.S. Healthcare system208. 
However, there are a few studies like the ‘Framingham’ study173 and the 
‘CONSENSUS II’ study209 describing rather poor sensitivity and prognostic values of 
BNP measurements compared to echocardiography or other established techniques, 
in some cardiac diseases. However, in general BNP measurements have turned out to 
be an important non-invasive tool for the diagnosis, risk stratification, and guidance 
of therapy of patients with heart failure200, 210, 211. Thus, utilization of BNP 
measurements is anchored in the guidelines for the diagnosis and management of 
heart failure of the American Heart Association212 and in the guidelines for cardiac 
risk assessment of the European Heart Failure Society213. 
1.2.6  Techniques to detect BNP in patients 
Since BNP level measurements gained increased importance in the routine 
examination of patients in the emergency departments212, 213, several FDA approved 
tests from different companies have been developed. In 2000, the Triage® BNP test 
(Biosite Diagnostics) was introduced as a rapid point-of-care test for determination of 
BNP levels in human plasma214. This non-competitive immunofluorometric assay is 
using a monoclonal antibody against an epitope within the disulfide-linked ring 
structure of the peptide. The method was developed for BNP determination in 
ambulatory or emergency units, where usually only a few samples have to be 
measured in a short time214. The SHIONOSPOT® BNP test (Shionogi & Co., Ltd) uses 
two monoclonal antibodies directed against the ring structure and the C-terminus of 
BNP215. These two antibodies are also used in the Bayer ADVIA Centaur® BNP assay, 
the first fully automated BNP test216. The NT-proBNP test from Roche Diagnostics is 
designed to measure NT-proBNP and is eligible for high throughput217.  
Many of the commercial tests are specific for detection of either NT-pro BNP or the 
bioactive BNP1-32, but all tests have in common that they do crossreact with their 
  INTRODUCTION 
  
28 
precursor proBNP harboring both BNP forms. The Triage® test e.g. does have as much 
as 5 to 20% crossreactivity towards proBNP218.  
Another pitfall of all these tests is that besides the crossreactivity towards proBNP, 
various other forms of BNP that might circulate in the body and harbor the epitope in 
their sequence, are detected, e.g. the BNP metabolites BNP3-32 and BNP7-32 (see 
section 1.2.2). Thus, such tests do not just measure the concentration of BNP1-32, but 
rather the whole pool of different BNP forms. Considering that the bioactivity of 
various BNP metabolites is different, e.g. BNP7-32 has just 50% of the bioactivity of 
BNP1-32160, the determination of the total BNP activityi in plasma does not represent 
100% of that of BNP1-32. Thus, predictions about the biological effectiveness of the 
BNP levels measured in the patient’s plasma are not precise. Other techniques to 
detect BNP in plasma, such as a quantitative mass spectrometry immunoassay, have 
been developed219. Such techniques, based on mass spectrometry, are more specific 
compared to tests utilizing antibodies only, since they can distinguish distinct forms 
of BNP. Disadvantageous is the high complexity and time-consuming procedure, 
which excludes clinical usage. 
Another problem with the detection of BNP-levels is that the tests do not provide 
information about the particular cardiac disease of the patient. Thus, the 
concentration of the whole BNP pool measured cannot be used to distinguish 
between e.g. dilated cardiomyopathy, intrinsic cardiomyopathy, coronary artery 
disease, coronary endothelial dysfunction, hypertension and so forth. Many 
diagnostic strategies using biomarkers are rather unspecific220.  
 
 
 
 
                                                        
i BNP activity = activity of the whole BNP pool including all metabolites   
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1.3   Aim of the study 
The B-type natriuretic peptide (BNP1-32) is an endogenously generated, vasoactive 
and cardioprotective peptide that is utilized as a biomarker for the diagnosis of heart 
failure and as a pharmaceutical drug for the therapy of such. Upon its generation and 
secretion, it is transported within the blood stream to and through organs. Thus, the 
peptide is constantly exposed towards proteolytic activity present in blood and on 
cellular membranes of organs.  
The central hypothesis of this thesis is that BNP1-32 is, similar to other vasoactive 
peptides, metabolized by peptidases into shorter peptide fragments with analog or 
altered biological activity, before it is inactivated by degradation. 
 
This work aims to investigate the metabolism of BNP1-32 to evolve a comprehensive 
model of BNP processing from synthesis towards clearance. The following main 
points are of particular interest: 
 
1 The identification of potential BNP metabolites 
2 The disclosure of enzymes responsible for the formation of BNP 
metabolites 
3 The determination of the biological activity of potential BNP metabolites 
towards the natriuretic peptide receptors in comparison to the mature 
BNP1-32 by the use of in vitro, ex vivo, and in vivo methods. 
 
Based on this work, it is aimed to initially assess the functional role and physiological 
consequence of BNP1-32 metabolism and to reveal the potential of BNP metabolites 
to serve as specific biomarkers or pharmaceutical drugs in the therapy of 
cardiovascular diseases. 
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2   MATERIALS and METHODS 
2.1   Materials 
2.1.1  Chemicals and reagents  
All chemicals and reagents used were of high purity grade and are listed in Table 1. 
 
Table 1: Chemicals and reagents. 
Name Company 
Acetic acid Sigma-Aldrich 
Acetonitrile (ACN) gradient grade Th.Geyer 
Acrylamide Sigma-Aldrich 
Ammonium persulfate (APS) Sigma-Aldrich 
Ampicillin  Sigma-Aldrich 
Bisacrylamide Sigma-Aldrich 
Bovine serum albumin (BSA) Roth 
Braunol Ratiopharm 
Bromophenol blue Sigma-Aldrich 
Calcium chloride Sigma-Aldrich 
Chloroform, Biotech grade Sigma-Aldrich 
Coomassie-Brilliant-Blue R 250 Bio-Rad 
Dimethyl sulfoxide (DMSO) Roth 
Ethanol Stockmeier Chemie Dillenburg 
Ethylenediaminetetraacetic acid (EDTA) Roth 
Glycerol Sigma-Aldrich 
HEPES Sigma-Aldrich 
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Hydrochloric acid  Sigma-Aldrich 
Isoflurane Baxter 
Isopropanol Sigma-Aldrich 
Ketamine Inresa Arzneimittelwerk  
Magnesium sulfate  Roth 
Methanol  VWR 
Monopotassium phosphate  Roth 
N-[Tris(hydroxymethyl)methyl]glycine (tricine) Sigma-Aldrich 
Pancuronium Inresa Arzneimittelwerk  
Perchloric acid  Sigma-Aldrich 
PolyFect® QIAGEN 
Potassium chloride  Roth 
Saline for injections, sterile Diaco 
Sodium chloride  Roth 
Sodium dihydrogen phosphate monohydrate Merck 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich 
Sodium hydrogen carbonate Sigma-Aldrich 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich 
Trifluoracetic acid for spectroscopy Merck 
trishydroxymethylaminomethane (Tris) Sigma-Aldrich 
Trizol® Life Technologies 
Tryptone Sigma-Aldrich 
Urea Roth 
Water for injections, sterile Diaco 
Xylocaine AstraZeneca  
Yeast Extract Sigma-Aldrich 
β-mercaptoethanol Sigma-Aldrich 
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2.1.2  Recombinant natriuretic peptides 
All natriuretic peptides used are listed in Table 2 and have been synthesized at 
BIOSYNTAN Berlin, Germany. The cysteines forming the disulfide-linked ring 
structure are highlighted in bold. 
 
Table 2: Recombinant natriuretic peptides and their sequences. 
Name Sequence 
ANP SLRRSSCFGGRMDRIGAQSGLGCNSFRY 
BNP1-32 NSKVTHISSCFGHKIDRIGSVSRLGCNALKLL 
BNP1-30 NSKVTHISSCFGHKIDRIGSVSRLGCNALK 
BNP1-29 NSKVTHISSCFGHKIDRIGSVSRLGCNAL 
BNP7-32 ISSCFGHKIDRIGSVSRLGCNALKLL 
BNP7-30 ISSCFGHKIDRIGSVSRLGCNALK 
BNP1-45 SQGSTLRVQQRPQNSKVTHISS CFGHKIDRIGSVSRLGCNALKLL 
CNP GLSKGCFGKLKDRIGSMSGLGC  
2.1.3  Media and solutions for cell culture  
The media and solutions used for cell culture are listed in Table 3. 
 
Table 3: Media and solutions for cell culture. 
Name Company 
Gibco® Dulbecco′s Modified Eagle Medium (DMEM) Life Technologies 
Endothelial Cell Basal Medium PromoCell 
Endothelial Cell Supplement Kit PromoCell 
Gibco® Fetal Bovine Serum (FBS) Life Technologies 
Gibco® Glutamine Life Technologies 
Gibco® Non-essential amino acids (NAEE) 100x Life Technologies 
Gibco® Penicillin/streptomycin 100x Life Technologies 
Gibco® RPMI 1640 Life Technologies 
Gibco® Sodium Pyruvate 100mM Life Technologies 
Gibco® Trypsin/EDTA Life Technologies 
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2.1.4  Buffers, solutions and media 
All buffers, solutions and media (Table 4) were prepared using water from the 
Milli-Q Synthesis (Millipore) water purification system. 
 
Table 4: Composition of general buffers, solutions and media. 
Name Composition 
Acrylamide-bisacrylamide [SDS-PAGE] 46.5 g acrylamide, 3 g bisacrylamide in 
100 ml water 
Anode buffer [SDS-PAGE] 100 mM Tris- HCl, pH 8.9 
Cathode buffer [SDS-PAGE] 100 mM Tris, 100 mM tricine, 0.1% SDS 
Denaturating sample buffer [SDS-PAGE] 100 mM Tris-HCl, pH 6.8;  
4% SDS , 20% glycerol , 4% β-
mercaptoethanol , 0.005% (w/v) 
bromophenol blue 
Destaining solution [SDS-PAGE] 10% (v/v) Ethanol, 7% (v/v) Acetic acid  
DMEM culture medium 10 % FBS, 1% Sodium Pyruvate, 1% 
NEAA, 1% Streptomycin/Penicillin in 
DMEM 
Gel buffer [SDS-PAGE] 3 M Tris-HCl, 0.3 % SDS, pH 8.45 
Krebs-Henseleit-solution (KHS) 11 mM D-Glucose , 1 mM MgSO4, 1 mM 
KH2PO4, 4.6 mM KCL, 12 mM NaCl 
Luria-Bertani (LB) medium 1 % tryptone, 1 % NaCl, 0.5 % yeast 
extract in water 
NaH2PO4 buffer 100 mM NaH2PO4 x H20, pH 8.0 
Perchloric acid solution 350 mM perchloric acid in ultrapure 
water 
Pre-perfusion solution 5 mM HEPES, 4 nM CaCl2 in 
Krebs-Ringer solution: 
120 mM NaCl, 4.8 mM KCl, 1.2 mM 
MgSO4, 1.2 mM KH2PO4, 24.4 mM 
NaHCO3 
Solvent A 0.05% TFA in acetonitrile 
Solvent B 0.05% TFA in ultrapure water 
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Staining solution [SDS-PAGE] 0.1% Coomassie-Brilliant-Blue R 250 , 
50% Methanol , 10% Acetic acid  
TE buffer 100 mM Tris, 12 mM EDTA, pH 7.4 
TFA solution for HPLC and LCMS 0.05 % TFA in deionized water 
Tris/BSA buffer 50 mM Tris-HCl, traces of BSA, pH 7.4 
2.1.5  Kits and Assays 
Kits and Assays used to determine levels of poteins and peptides, to isolate DNA as 
well as for quantitative real-time polymerase chain reaction are listed in Table 5. 
 
Table 5: Kits and Assays. 
Name Company 
BCA Protein Assay Kit Bio-Rad 
cGMP complete ELISA Kit for cells Enzo Life Sciences 
cGMP complete ELISA Kit for blood Enzo Life Sciences 
Plasmid Maxi Kit QIAGEN 
QuantiTect® Reverse Transcription Kit QIAGEN 
QuantiTect® SYBR® Green PCR Kit QIAGEN 
2.1.6  Recombinant enzymes 
Table 6: Recombinant enzymes.  
Name Company 
Angiotensin-converting enzyme (ACE) R&D 
Angiotensin-converting enzyme 2 (ACE2) R&D 
Carboxypeptidase A (CPA) Life Technologies 
Carboxypeptidase B (CPB) Life Technologies 
Carboxypeptidase C/Cathepsin A (Cath A) Life Technologies 
Collagenase Type II Life Technologies 
Endothelin-converting enzyme 1 (ECE-1) R&D 
Meprin A R&D 
Neprilysin (NEP) R&D 
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Prolylcarboxypeptidase (PRCP) R&D 
Proteinase K AppliChem 
Trypsin R&D 
2.1.7  Enzyme Inhibitors 
Table 7: Enzyme inhibitors.  
Name Company  
Actinonin  Santa Cruz Biotechnology 
Alliskiren Selleck Chemicals LLC 
Amastatin Sigma-Aldrich 
Aprotinin  Santa Cruz Biotechnology 
Bestatin  Roche Applied Science 
Candoxatrilat  Gift from Dr. W.E. Siems, FMP, Germany 
Captopril Santa Cruz Biotechnology 
Carboxypeptidase inhibitor (CP inhib.) Sigma-Aldrich 
Chymostatin Santa Cruz Biotechnology 
Diprotin A  Bachem 
EDTA Sigma-Aldrich 
F480  Gift from Prof. V. Dive, iBiTec-S, France 
GEMSA Calbiochem 
Kallistop  American Peptide 
Leupeptin  Santa Cruz Biotechnology 
Pepstatin  Bachem 
Roche complete [without EDTA] Roche Applied Science 
SM19712 Sigma-Aldrich 
Trp-inhibitor (trp.inhib.) Merck 
2.1.8  Consumables 
General laboratory consumables (tubes, tips, cell culture dishes and so forth) were 
obtained from Sarstedt or from the suppliers listed in Table 8. 
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Table 8: Consumables and their suppliers. 
Name Company 
Cryo-tubes Greiner Bio-One 
HPLC vials  Chromacol 
Needles BD Microlance 
Osmotic Minipumps [Model 2002] Alzet 
PCR tubes Thermo Scientific 
Scalpels Feather 
Seriological Pipets Becton Dickinson 
Silk Silicam®  Braun 
Suture Ethicon 
Syringes  Braun 
 
2.2  Methods 
2.2.1  Synthesis of BNP1-32 and BNP metabolites 
All BNPs have been synthesized at the BIOSYNTAN GmbH in Berlin, Germany via a 
simultaneous multiple peptide synthesis method using the Fmoc/But strategy 
according to SHEPPARD221. Briefly, the linkage has been performed using Fmoc-aa-
OH/TBTU/N-Methylmorpholin (1:1:2), which was coupled to the polymeric matrix 
Tentagel S Trityl resin (RAPP Polymere, Germany). The cyclisation was performed 
using PBS-buffer with 10% DMSO. The following protective groups have been used: 
Cys(Trt), Arg(Pbf), Ser(But), Thr(But), Tyr(But), Asp(OBut), Glu(OBut), Asn(Trt), 
Gln(Trt), Lys(Boc), His(Trt), Trp(Boc). The elimination of the protection groups was 
achieved with trifluoacetic acid/thioanisole/thiocresol (95:2.5:2.5) within 3 h in the 
presence of 3%  triethylsilane and following administration of 5% Me3SiCl222.  
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2.2.2  Incubation studies 
2.2.2.1 Preparation of organ membranes 
Organs, in particular lungs, livers, kidneys, spleens, and hearts (ventricles and atria) 
have been explanted from male C57BL/6 mice in the age of 4 to 6 month directly after 
cervical dislocation of the animals. Membranes of the organs were prepared by 
homogenizing them in an ice-cold 50 mM Tris buffer (pH 7.4) with a homogenizer. 
After filtration through a nylon gaze samples were centrifuged at 40.000 g to separate 
membranes from the cytosol. After a washing step with 50 mM Tris buffer, the pellet 
was resuspended in the same buffer and stored at -80°C until further processing. The 
total protein contents of the membrane preparations were determined by BCA 
Protein Assay Kit (Bio-Rad, Germany) and adjusted depending on the experiment (see 
section 2.2.2.3). 
2.2.2.2 Preparation of serum, citrate- and heparin blood 
Blood was taken from male C57BL/6 mice in the age of 4 to 6 weeks directly after 
cervical dislocation by cardiac puncture. To prepare serum, blood was left at room 
temperature for 20 min to reach sufficient clotting. After this, the blood was 
centrifuged at 7000 g for 10 min and supernatant was snap frozen in liquid nitrogen. 
Citrate- and heparin blood have been taken with syringes containing 10% citrate or 
heparin. Immediately after blood withdrawal, samples have been centrifuged at 
6000 g for 10 min and supernatants have been snap frozen in liquid nitrogen. 
2.2.2.3  Protein quantification of membrane and blood preparations 
Protein concentration has been determined with the BCA Protein Assay Kit (Bio-Rad, 
Germany) according to their instructions based on the method of Bradford et al.223. In 
brief, the samples have been put in duplicates on a microplate and mixed with a 
reagent containing Coomassie brilliant blue G-250 dye, phosphoric acid, and 
methanol. After 30 min of incubation at 37°C and cooling down to room temperature 
the absorbance has been measured at 562 nm on the VERSAmax tunable microplate 
reader (Molecular Devices, California).  
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2.2.2.4  Incubation of BNP1-32 and BNP metabolites with organ membrane 
preparations 
To investigate the metabolism of BNP1-32 or BNP metabolites by the proteolytic 
activity of cellular membranes of organs, appropriate peptides were incubated with 
organ membrane preparations (see section 2.2.2.1) in a 50 mM Tris/BSA buffer. The 
buffer was supplemented with traces of BSA to minimize adhesion of the peptides on 
the tube walls. Samples have been incubated at 37°C under constant shaking at 300 
U/min using an HLC Cooling-ThermoMixer MKR 13 (DITABIS, Germany). Reactions 
were stopped after appropriate incubation times by inducing a pH change by 
supplementation of ½ vol 0.35 M perchloric acid. After centrifugation at 12.000 g 
supernatants were analyzed by High Performance Liquid Chromatography (HPLC) 
and Matrix-assisted laser-desorption ionization time-of-flight mass spectrometry 
(MALDI-TOF-MS). Conditions for the different experimental settings are described in 
the following passages: 
- For the investigation of proteolysis rates of BNP1-32 with organ membrane 
preparations 10 µM of the peptide have been incubated with 60 µg protein of the 
organ preparations in a reaction volume of 100 µl for 90 min. 
- For the investigation of initial product peaks of BNP1-32 metabolism by organ 
membrane preparations, 10 µM of BNP1-32 have been incubated with 60 µg 
protein of the organ membrane incubations in a reaction volume of 100 µl for the 
following times: 90 min for heart and spleen, 60 min for lung, 50 min for liver, and 
15 min for kidney incubations. 
2.2.2.5  Incubation of BNP1-32 with organ membrane preparations in the 
presence of enzyme inhibitors 
Ten µM of BNP1-32 were incubated with 60 µg protein of organ membrane 
preparations in a 50mM Tris/BSA buffer in the presence of the following enzyme 
inhibitors: actinonin [10 µM], alliskiren [10 µM], aprotinin [10 µM], candoxatrilat 
[10 µM], captopril [10 µM], CP.inhib [10 µM], Chymostatin [5µM], diprotin A [10 µM], 
EDTA [5 µM], F480 [1 µM], GEMSA [10 µM], Kallistop [10 µM], Leupeptin [10 µM], 
pepstatin [10 µM], roche cocktail 10x [1 µl], SM19712 [10 µM], tryp.inhib [10 µM], 
ZPP [100 µM] in a reaction volume of 100 µl. The buffer was supplemented with 
traces of BSA to minimize adhesion of the peptides on the tube walls. Samples have 
been incubated at 37°C under constant shaking at 300 U/min using an HLC 
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Cooling-ThermoMixer MKR 13 (DITABIS, Germany). Reactions were stopped after the 
following incubation times: 120 min for heart, atrium, ventricle, and spleen, 60 min 
for lung, 50 min for liver by inducing a pH change by supplementation of ½ vol 0.35 M 
perchloric acid. After centrifugation at 12.000 g supernatants were analyzed by HPLC 
and MALDI-TOF-MS. 
2.2.2.6 Incubation of BNP1-32 and BNP metabolites with serum, citrate- 
and heparin plasma with or without enzyme inhibitors 
To investigate the metabolism of BNP1-32 or BNP metabolites by the proteolytic 
activity in blood, appropriate peptides were incubated with blood preparations in a 
50 mM Tris/BSA buffer. The buffer was supplemented with traces of BSA to minimize 
adhesion of the peptides on the tube walls. Samples have been incubated at 37°C 
under constant shaking at 300 U/min using an HLC Cooling-ThermoMixer MKR 13 
(DITABIS, Germany). Reactions were stopped after appropriate incubation times by 
inducing a pH change by supplementation of ½ vol 0.35 M perchloric acid. After 
centrifugation at 12.000 g supernatants were analyzed by HPLC and MALDI-TOF-MS. 
Conditions for the different experimental settings are described in the following 
passages: 
- For the investigation of BNP1-32 proteolysis rates and identification of BNP 
metabolites, 10 µM BNP1-32 have been incubated with 140 µg protein of the 
blood preparations in a reaction volume of 100 µl for 90 min. 
- For the investigation of proteolytic stability of BNP1-32 and BNP metabolites, 10 
µM BNP1-32 have been incubated with 14 µg protein of the blood preparations in 
in a reaction volume of 100 µl for 10, 20, 30, and 40 min. For BNP1-29 and 
BNP1-32 incubations additional time points have been investigated (0-240 min). 
- For the investigation of proteolysis rates of BNP1-30 and BNP7-30 in serum in the 
presence of GEMSA, 10 µM BNP1-30 or BNP7-30 were incubated with 14 µg 
protein of serum in the presence of 10 µM GEMSA in a reaction volume of 100 µl 
for 10 min 
2.2.2.7 Incubation of BNP1-32 and BNP metabolites with recombinant 
enzymes 
ANP, CNP, BNP1-32, or BNP metabolites were incubated with one of the following 
recombinant enzymes: ACE, ACE2, CathA, CPA, CPB, ECE-1, meprin A, or NEP in a 
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50 mM Tris/BSA buffer. Specific activities of the enzymes are indicated in the figure 
legends of the graphs demonstrating the results of the particular approaches. The 
concentrations of ANP, CNP, BNP1-32, or BNP metabolites in the incubation were 
5 µM for the incubations with PRCP and CathA or 10 µM for all other incubations. The 
buffer was supplemented with traces of BSA to minimize adhesion of the peptides on 
the tube walls. Samples have been incubated at 37°C under constant shaking at 300 
U/min using an HLC Cooling-ThermoMixer MKR 13 (DITABIS, Germany). Reactions 
were stopped after appropriate incubation times that are indicated in the figure 
legends of the particular approaches by inducing a pH change by supplementation of 
½ v 0.35 M perchloric acid. After centrifugation at 12.000 g supernatants were 
analyzed by HPLC and MALDI-TOF-MS. 
 2.2.3 Analysis and quantification of natriuretic peptides with 
High Performance Liquid Chromatography (HPLC) 
After the incubation studies, samples have been investigated for emerging product 
peaks resulting from the cleavage of BNP1-32 or BNP metabolites (see section 2.2.2). 
Furthermore, these product peaks have been quantified. Peptide analysis was 
performed by reversed phase chromatography using the UFLC-2020 System with 
UV-detection (Shimadzu, Germany). After a sample was centrifuged for 10 min at 
12.000 g, 100 µl of the supernatant were loaded by the autosampler onto a RP 
Nucleosil 100 C12 column (Phenomenex, Germany; column dimensions: 
250 x 4.6 mm, 5 μm). The sample and the mobile phase have been pumped through 
the system with a flow rate of 1 ml/min. The temperature of the column and the 
samples was regulated by a column oven and a cooling system connected to the 
autosampler. The temperature has been set to 25°C during all measurements. After 
getting initial chromatograms, HPLC methods have been optimized using these 
samples or recombinant peptides to allow good separation of peaks of BNP1-32, BNP 
metabolites, and other natriuretic peptides like ANP and CNP (Method 1-3).  
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Furthermore, a cleaning method and methods for the recovery of the column have 
been developed (Method 4-7): 
 
Method 1  =  Separation of BNP metabolites in organ membrane preparations 
Method 2  =  Separation of BNP metabolites in blood preparations 
Method 3  =  Separation on ANP and CNP 
Method 4  =  Cleaning  
Method 5  =  Recovery of initial solvent mixtures (Method 1) 
Method 6  =  Recovery of initial solvent mixtures (Method 2) 
Method 7  =  Recovery of initial solvent mixtures (Method 3) 
 
For all methods different linear gradients using 0.05% trifluoracetic acid in 
acetonitrile (Solvent A) and 0.05% trifluoracetic acid in ultrapure water (Solvent B) 
were used (Table 9). Every ten injections the column has been cleaned with a 
cleaning method (Method 4) followed by a short method to recover the initial solvent 
mixture (Method 5-7). The peaks were detected at 205 nm and peak areas have been 
determined by peak integration with the LabSolutions software version 5.11.160 
(Shimadzu, Germany). A linear correlation between peak areas and peptide 
concentrations was confirmed before analysis. 
 
Table 9: Methods used for High Performance Liquid Chromatography to separate natriuretic peptides. 
Solvent A: 0.05% trifluoroacetic acid in acetonitrile; Solvent B:  0.05% trifluoroacetic acid in ultrapure 
water. 
 
 Gradient phase Recovery phase 
Solvent A 
[%] 
Solvent B 
[%] 
Time 
[min] 
Solvent A 
[%] 
Solvent B 
[%] 
Time 
[min] 
Method 1 18-35 82-65 20 18 82 5 
Method 2 17-26 83-74 10 17 83 5 
Method 3 20-32 80-68 9 20 80 5 
Method 4 1-70 99-30 50 - - - 
Method 5 - - - 18 82 10 
Method 6 - - - 17 83 10 
Method 7 - - - 20 80 10 
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2.2.4  Matrix-assisted laser-desorption ionization time-of-flight 
mass spectrometry (MALDI-TOF-MS) 
MALDI-TOF-MS has been performed in collaboration with Prof. Lochnit at the Protein 
Analytics facility, University of Giessen, Germany. MALDI-TOF-MS was performed on 
an Ultraflex I TOF/TOF mass spectrometer equipped with a nitrogen laser and a LIFT-
MS/MS facility (Bruker Daltonics, Germany). The instrument was operated in the 
positive-ion reflectron mode. Sum spectra consisting of 200–400 single spectra were 
acquired. One µl of the sample has been mixed with one µl of the matrix consisting of 
2.5-dihydroxybenzoic acid and methylendiphosphonic acid dissolved in a solution of 
trifluoroacetic acid, acetonitrile, and water. The sample has been placed on the 
MALDI target (MPT AnchorChip 800-384, Bruker Daltonics, Germany). After the 
solvents were vaporized, the analyte molecules were left embedded into the 
recrystallized matrix, which has been analysed. For external calibration a peptide 
standard (Bruker Daltonics, Germany) was used. For data processing and instrument 
control the Compass 1.1 software package consisting of FlexControl 2.4, FlexAnalysis 
3.0 and BioTools 3.0 (Bruker Daltonics, Germany) was used. 
2.2.5  Quantitative real-time polymerase chain reaction 
The quantitative real-time polymerase chain reaction (RT-PCR) was carried out in 
three steps including (I) isolation of RNA, (II) reverse transcription, and (III) SYBR 
Green-based RT-PCR. All steps are described in the following sections. 
2.2.5.1 (I) Isolation and quantification of RNA 
RNA has been isolated from cardiac tissue of male spontaneously hypertensive rats 
(SHR) after appropriate experiments (see section 2.2.11.3). A small piece of the 
ventricle has been homogenized in 1 ml TRIzol (100 mg organ in 1 ml TRIzol). To one 
ml of the homogenate 0.2 ml of chloroform has been added and mixed firmely. After 
30 min centrifugation at 4°C and 10,000 g, ½ v isopropanol has been added to the 
supernatant. After 10 min of incubation at room temperature, the samples have been 
centrifuged 10 min at 4°C and 12,000 g. 1.5 ml ice-cold 70% ethanol has been 
transferred to the dried pellet. After mixing and centrifugation for 8 min at 4°C and 
7,500 g the pellet has been air-dried again. The pellet was resuspended in RNAse free 
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water. The samples have been used for RNA quantification with a NanoDrop™ 
Spectrophotometer (ThermoScientific, Delaware). One microliter of a sample was 
applied to the target and absorption has been measured at 260 nm. The purity was 
evaluated by the A260/A280 value. A ratio of ~2.0 was generally accepted as pure for 
RNA.  
Subsequently, one microliter of RNA of each sample has been used for reverse 
quantification. 
2.2.5.2 (II) Reverse transcription 
The QuantiTect® Reverse Transcription Kit (QIAGEN, Germany) was used according to 
the manufacturers‘ instructions224. In brief, the procedure comprised two main steps: 
the elimination of genomic DNA using a wipeout buffer and the reverse transcription 
using a reverse transcriptase with RNA-dependent DNA-polymerase activity and 
RNase H activity. Generated cDNA was directly used for RT-PCR. 
2.2.5.3 (III) SYBR Green-based RT- PCR 
Quantitative RT-PCR was performed with the QuantiTect SYBR Green PCR (QIAGEN, 
Germany) according to the manufacturers recommendations225 using the iQ5 Real 
Time PCR system (Bio-Rad, Germany). Primer pairs used for the amplification of 
specific cDNA regions are listed in Table 10.  
 
Table 10: Primer sequences of reverse primer (R) and forward primer (F) used for quantitative 
real-time polymerase chain reaction. 
 
Name Sequence 
COL1A1 rat R 5'-TGC CAG CGG GAC CAA CAG CG-3' 
COL1A1 rat F 5'-GCC CGT GGA CAG GCT GGT GTC-3' 
ANP rat R 5'-TCC TCC AGG TGG TCT AGC AGG TTC TTG-3' 
ANP rat F 5'-GGC CTT TTG GCT CCC AGG CCA-3' 
BNP rat R 5'-AGG TGG TCC CAG AGC TGG GGA AAG A-3' 
BNP rat F 5'-CGC TTG GGC TGT GAC GGG CT-3' 
HPRT1 rat R 5'-CCC TTC AGC ACA CAG AGG GCC AC-3' 
HPRT1 rat F 5'-CCC TCA GTC CCA GCG TCG TGA TTA GT-3' 
 
  MATERIALS and METHODS 
  
44 
Reactions were carried out in total volumes of 20 μl and included 200 nM of each, 
forward (F) and reverse (R) primer, 1 μl of the primed cDNA, 12.5 µl of SYBR 
Green-based RT-PCR Master Mix (QIAGEN, Germany), and sterile water. The RT-PCR 
conditions are listed in Table 11. 
 
Table 11: Conditions used for quantitative real-time polymerase chain reaction.  
 
The cycle threshold (CT) was determined in each sample for both, the BNP gene 
amplification and the amplification of the house keeping gene HPRT1, encoding for 
the hypoxanthine phosphoribosyltransferase 1, during the beginning of the 
exponential phase. The relative mRNA expression levels were calculated using the 
formula 2ΔΔCT. Melting curve analyses were performed after RT-PCR reactions to 
confirm correct amplification.  
2.2.6  Development of tricine- sodium dodecyl sulfate 
polyacrylamide gel electrophoresis for separation of BNP 
metabolites 
For the separation of BNP metabolites a protocol was developed on the basis of the 
tricine sodium dodecyl sulfate polyacrylamide gel electrophoresis (Tricine-SDS-PAGE) 
from H. Schaegger226. The gel was made from three single gels, the separating gel, the 
spacer gel and the stacking gel. Table 12 presents the composition of each gel. All 
gels were, upon mixing and loading on a vertical electrophoresis apparatus (Bio-Rad, 
Germany), left for 20 min to polymerise. Isopropanol was applied on the top of each 
gel to allow the formation of a smooth surface. Ten µg of the peptide was mixed 1:1 
with the denaturating sample buffer and water and were incubated for 15 min at 
37°C. Ten µl of each sample has been loaded onto the stacking gel and electrophoresis 
was performed until the sample buffer left the gel. 
Steps Time Temperature Cycles 
Initial Heat activation   15 min 95 1 
Denaturation 15 sec 94  
Annealing 30 sec 58 40 
Elongation 30 sec 72  
Melting point analysis    1 min  1 
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Table 12: Composition of gels used in the tricine- sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (Tricine-SDS-PAGE). 
 
Reagent Separating gel Spacer gel Stacking gel 
Acrylamide-bisacrylamide buffer 10 ml 6 ml 1 ml 
Gel buffer 10 ml 10 ml 6 ml 
Glycerol - 3 g - 
Urea 10.8 g - - 
Water 30 ml 30 ml 12 ml 
APS (10%) 100 µl 150 µl 90 µl 
TEMED 10 µl 15 µl 9 µl 
 
The staining of proteins on the gels was performed with Coomassie-Brilliant-Blue R 
250 solution for 20 min at room temperature. The excess staining was removed with 
destaining solution. 
2.2.7  Microbiological methods 
2.2.7.1 Transformation of competent Escherichia coli DH5α 
50 μl of a competent cell suspension of Escherichia coli DH5α was thawed on ice. 
Plasmid DNA with genes either encoding for the natriuretic peptide receptor A or B 
was added to the bacterial cells and incubated for 30 min on ice. A thermal shock of 
42˚C was applied for 45 sec and the cells were cooled on ice for 1-2 min afterwards. 
After addition of 1 ml LB-medium, cell suspensions have been incubated for 1 h at 
37°C. Subsequently cells were spread on agar plates with the appropriate antibiotic 
selection and incubated overnight at 37˚C. 
2.2.7.2  Over Night culture and amplification of the plasmids 
A single colony of transfected bacterial cells was picked with a sterile pipette tip and 
incubated in 5 ml LB-medium over night at 37°C with the appropriate anitibiotics. 
This culture was diluted with 200 ml of LB-medium with appropriate antibiotics and 
cultured for 16 to 18 h at 37°C. Thereafter, cells were harvested by centrifugation. 
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2.2.7.3  Preparation of glycerol stocks  
800 μl of an overnight culture were mixed with 200 μl of sterile glycerol and stored 
at -80˚C. 
2.2.7.4  Isolation of plasmid DNA from Escherichia coli DH5α 
Cells were centrifuged at 3,000 g for 10 min. Plasmid DNA was isolated using the Plasmid 
Maxi Kit (QIAGEN, Germany) according to the manufacturer’s protocol. In brief, cells have 
been lysed by an alkaline lysis buffer, followed by binding of plasmid DNA to an anion-
exchange resin under appropriate low salt and pH conditions. After three 
washing-steps with a washing buffer provided in the Kit, plasmid DNA has been 
eluted with 10 mM Tris buffer, pH 8.5. 
2.2.8  Cell culture 
2.2.8.1 Defrosting of mammalian cell stocks  
Mammalian cells were stored in DMEM containing 10% DMSO in liquid nitrogen. The 
cells were thawed and immediately resuspended in DMEM to dilute the DMSO. Cells 
were centrifuged at 1000 g for 10 min at 4˚C. The medium was removed and the cells 
were resuspended in fresh DMEM and seeded on a 10 cm cell culture dish. Human 
embryonic kidney (HEK293) cells were cultures in DMEM culture medium (see 
Table 4). Human dermal microvascular endothelial cells (HDMEC) were cultured in 
Endothelial Cell Basal Medium supplemented with growth factors present in the 
Endothelial Cell Supplement Kit. The cultures were maintained at 37°C in a 5% CO2 
humidified incubator. 
2.2.8.2 Passaging of mammalian cell lines 
All mammalian cell lines were split in the same way. After removing the medium, cells 
were rinsed with PBS and incubated at 37˚C with 0.05% trypsin/EDTA until they 
were detached from the culture dish. The reaction was stopped by adding DMEM 
culture medium. After centrifugation at 1000g for 10 min at 4°C, cells were 
resuspended in fresh culture medium. HEK293 cells were split every 2-3 days when 
they reached 70-80% confluency at a ratio of 1:3 to 1:5. HDMEC were split once per 
week at a ratio of 1:3.  
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2.2.8.3 Preparation of cryostocks of mammalian cell lines 
To prepare the cells for cryoconservation in liquid nitrogen, a confluent monolayer 
from a 10 cm plate was trypsinised with trypsin/EDTA, resuspended in cold DMEM 
culture medium and centrifuged at 1000 g for 10 min at 4˚C. The pellet was 
resuspended in 900 µl DMEM culture medium and 100 ml DMSO. The cells were put 
in cryotubes at -20˚C over night and were then transferred to liquid nitrogen on the 
following day. 
2.2.8.4 Transfection of HEK293 cells 
One day after seeding, HEK293 cells were transferred into 24-well cell culture dishes. 
Another 24 h later, transfections with the plasmid encoding NPRA or NPRB, or the 
empty plasmid were performed using PolyFect® reagent in DMEM culture medium 
with 1% FCS instead of 10% FCS. For that 0.25 µg DNA per well was incubated with 
5 µl Polyfect® and 5 µl DMEM for 15 min at room temperature. Transfection solution 
was carefully applied to the cells without disrupting the monolayer. Cells transfected 
with the empty plasmid served as controls. After 24 hours cells were used for 
bioactivity measurements of natriuretic peptides (see section 2.2.9.1) 
2.2.8.5 Isolation and culture of vascular smooth muscle cells 
Vascular smooth muscle cells have been isolated from the explants of the thoracic 
aortas227 of 4 to 6 weeks old male C57BL/6 mice. Vessels were opened longitudinally 
and incubated for 30 min with 4 mg/ml collagenase type II. Cells were seeded in small 
6 cm culture dishes and grown in DMEM culture medium supplemented with 
2 mmol/l glutamine160. Cells were harvested for passaging every 2 to 3 weeks. Cells 
have been used for stimulation experiments at passage 2 to 3. For experiments on the 
bioactivity of BNP metabolites, cells have been seeded into 24-well plates. 
2.2.8.6 Isolation and culture of mesangial cells 
Mesangial Cells have been isolated from explanted kidneys of 4 to 6 weeks old male 
C57BL/6 mice228. The kidneys were decapsulated and minced in ice-cold RPMI 1640 
medium. Homogenates were dispersed with 5 ml chilled RPMI 1640 medium to a 
100 μm nylon filter and then the filtrate transferred to a 70 μm nylon filter. After 
decapsulated, the glomerular ‘cores’ were digested with collagenase type II for 
approximately 30 min, then centrifuged at 1000 g for 10 min. The pellet was 
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resuspended in RPMI 1640 medium supplemented with 17% FCS, 
penicillin/streptomycin, and 0.1 U/ml insulin, and cultured at 37°C in a humidified 
5% CO2 incubator228. Cells were harvested for passaging every 2 weeks. Cells have 
been used for stimulation experiments at passage 2 to 3. For experiments on the 
bioactivity of BNP metabolites, cells have been seeded into 24-well plates. 
2.2.9  Bioactivity of BNP1-32 and BNP-metabolites in vitro 
2.2.9.1  Bioactivity Measurements of BNPs in cells 
Determination of bioactivity of BNP1-32 and BNP-metabolites was performed in 
transfected HEK293 cells or VSMC, HDMEC, and MC seeded in 24-well plates using 
the cGMP complete ELISA Kit for cells (Enzo Life Sciences, Loerrach, Germany) for the 
determination of cGMP levels. Medium was removed and vehicle or the appropriate 
solutions of the natriuretic peptides have been gently applied in each well without 
destroying the monolayer. Cells were incubated for 5 minutes at 37 °C. Afterwards, 
solutions were removed and a mixture of 150 µL of 0.1 M HCl and 0.1% Triton X100 
was applied for the lysis of the cells. The plate has been incubated for another 10 min 
at 37°C. After harvesting the cells and centrifugation at 600 g, cGMP has been 
measured in the supernatants (see section 2.2.10.2).  
2.2.9.2 Detection of cGMP in cells  
Concentrations of cGMP were measured with the cGMP complete ELISA Kit for cells 
(Enzo Life Sciences, Loerrach, Germany) according to the instructions of the 
manufacturer. In brief, after neutralization of the samples with a neutralizing reagent 
provided in the Kit, samples have been pipeted into a goat anti-rabbit IgG-coated 
microtiter plate. A conjugate of alkaline phosphatase and cGMP was added. 
Afterwards a rabbit polyclonal antibody to cGMP was added to bind in a competitive 
manner either cGMP of the conjugate or the samples. After a 2 hour incubation time at 
room temperature and three washing steps with a buffered saline solution containing 
detergents, p-nitrophenyl phosphate was added. The remaining conjugated 
phosphatase bound by the antibody forms p-nitrophenol, which reacts under alkaline 
conditions forming p-nitrophenolate as follows:  
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P-nitrophenolate has a yellow color. The intensity of the color is inversely 
proportional to the concentration of cGMP initially present in the samples. The 
absorbance was detected at 405 nm with a correction at 570 nm and 590 nm. 
2.2.10  Bioactivity of BNP1-32 and BNP metabolites ex vivo  
Investigations on isolated vessels using the myograph system have been performed in 
teamwork with Dr. Yong Wang in the ECCPS, Giessen. Mesenteric resistance arteries 
from male Sprague Dawley rats (4 month old) were used for all experiments. The 
arteries were dissected from the surrounding connective tissue and placed in 
Krebs-Henseleit solution (KHS). Second order artery segments, approximately 1 mm 
in length, were cut and mounted in a myograph chamber (Danish Myo Technology, 
Denmark). Each of the four myograph units is attached to the force transducer on one 
side and to a micrometer on the other side. All segments have individually controlled 
gas inflow and temperature control permitting the preparations in all four chambers 
to be kept under 37°C, in the constantly bubbled (95% O2 plus 5% CO2) KHS ensuring 
an examination under isometric conditions. Each vessel ring was placed under 
optimal stretch of approximately 100 mmHg by determining passive length-tension 
relationships using normalization software (ADInstruments, Germany). 
The rings were precontracted with an enriched KHS (125 mM KCl) to determine the 
maximum contractility and then washed with normal KHS several times. Endothelium 
integrity was assessed by contracting the segments with noradrenalin, followed by 
stimulation with acetylcholine. After washing to restore tension to baseline level the 
rings where allowed to stabilize for 30 min. 
Alkaline phosphatase
water
p-nitrophenyl phosphate p-nitrophenol p-nitrophenolate
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2.2.11  Bioactivity of BNP1-32 and BNP metabolites in vivo 
2.2.11.1  Acute infusion of BNP1-32 and BNP metabolites in mice 
Male C57BL/6 mice of about 16 weeks were initially anesthetized with 4% isoflurane 
and were intubated for artificial ventilation with a mixture of 20% oxygen and 80% 
room air through a rodent ventilator, to which 2% to 2.5% isoflurane was added for 
continuous anesthesia. During surgery, animals were kept on a homeothermic 
blanket to maintain body temperature. The right common carotid artery and the right 
internal jugular vein have been dissected. A Mikro-Tip® mouse pressure catheter 
(Millar instruments, Texas) was inserted into the carotid artery and a cannula has 
been inserted into the jugular vein. Baseline blood pressure and heart rate were 
monitored and recorded for 10 minutes with a pressure transducer system and a 
blood pressure monitoring software (TSE systems GmbH, Germany). Through the 
cannula a single bolus injection of BNP1-32, BNP1-30, BNP1-29, BNP7-32, BNP7-30, 
BNP1-45 (100 µl/30 g body weight of a 5x10-6 M solution), or saline has been 
performed. The hemodynamic parameters were measured for 4 min after injection. 
Subsequent to the measurement, EDTA blood was taken by puncturing of the left 
ventricle. Blood samples were centrifuged, and the plasma was snap frozen in liquid 
nitrogen and stored at -80°C until further processing. Plasma cGMP levels were 
measured using the cGMP complete ELISA Kit for blood (Enzo Life Sciences, Loerrach, 
Germany) according to the manufacturer’s instructions (see section 2.2.12.2). Animal 
numbers used are mentioned in the appropriate sections (see Results section 3.7). 
2.2.11.2 Detection of cGMP in plasma 
Concentrations of cGMP in plasma were measured with the cGMP complete ELISA Kit 
for blood (Enzo Life Sciences, Loerrach, Germany) according to the instructions of the 
manufacturer. In brief, cGMP has been extracted from the plasma by adding 2 vol % of 
95% ethanol to the collected plasma. After incubation for 5 min, samples have been 
centrifuged for 10 min at 600 g. The supernatant has been dried down in a 
concentrator (Eppendorf, Germany) and reconstituted in assay buffer provided in the 
Kit. Subsequently, the samples have been pipeted into a goat anti-rabbit IgG-coated 
microtiter plate. A conjugate of alkaline phosphatase and cGMP was added. 
Afterwards a rabbit polyclonal antibody to cGMP was added to bind in a competitive 
manner either cGMP of the conjugate or the samples. After a 2 hour incubation time at 
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room temperature and three wash-steps with a buffered saline solution containing 
detergents, p-nitrophenyl phosphate was added. The remaining conjugated 
phosphatase bound by the antibody forms p-nitrophenol, which reacts under alkaline 
conditions forming p-nitrophenolate having a yellow color. The intensity of the color 
is inversely proportional to the concentration of cGMP initially present in the 
samples. The absorbance is detected at 405 nm with a correction at 570 nm and 
590 nm. 
2.2.11.3  Continuous administration of BNP1-32 and BNP1-30 using the    
spontaneous hypertensive rat-model 
Osmotic minipumps (Alzet, California; pump rate: 0.5 µl/h) have been put into sterile 
saline solution for three hours for preconditioning. After that, minipumps were filled 
each with either sterile saline, or filtered solutions of BNP1-32 or BNP1-30 to allow 
the administration of 300 ng/kg/min. Male spontaneously hypertensive rats (SHR) at 
the age of 12 weeks have been anesthetized through injection with 
ketamin/xylocaine/saline (3:0.5:6.5; 100 µl/100 g) and have been put under an 
infrared heating lamp to maintain body temperature. A small part of the fur on the 
backside was removed using depilatory crème (Reckitt Benckiser, England). Next, a 
primed osmotic minipump was implanted under the skin on the backside of the 
animal. Wounds have been closed with clips. After the animals woke up, they were 
kept in appropriate cages with normal housing and food for three days. For the 
determination of hemodynamic parameters, animals have been anesthetized with 4% 
isoflurane and were kept ventilated with a mixture of 20% oxygen and 80% room air 
through a rodent ventilator, to which 2% to 2.5% isoflurane was added for 
continuous anaesthesia. Animals were kept on a homeothermic blanket to maintain 
body temperature. The right common carotid artery has been dissected. A Mikro-
Tip® rat pressure catheter (Millar instruments, Texas) was placed into the right 
carotid artery to measure arterial blood pressure and heart rate. Parameters were 
recorded for 10 minutes with a blood pressure monitoring software (TSE systems 
GmbH, Germany). The experimental procedure was performed in accordance to 
similar procedures described previously91, 229.  
Finally, EDTA blood was taken by puncturing of the left ventricle. Blood samples were 
centrifuged, and the plasma was snap frozen in liquid nitrogen and stored at -80°C 
until further processing. Plasma cGMP levels were measured using the cGMP 
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complete ELISA Kit for blood (Enzo Life Sciences, Loerrach, Germany) according to 
the manufacturer’s instructions (see section 2.2.12.2). Animal numbers used are 
mentioned in the appropriate sections (see Results section 3.8). 
2.2.12  Liver perfusion in situ 
After anesthesia through injection with ketamin/xylocaine/saline (3:0.5:6.5; 
10 µl/10 g), a male C57BL/6 mouse has been placed on a homeothermic blanket to 
maintain body temperature. The abdominal cavity has been opened and the vena 
portae and into the vena cava inferior have been dissected. The recirculation into the 
heart was prevented by the ligation of the vena cava inferior in front of the heart. A 
cannula has been inserted into vena portae and into the vena cava inferior. The 
pre-perfusion solution has been infused manually through the vena portae trying to 
maintain a constant pressure. The escaped blood and pre-perfusion solution has been 
collected through the vena cava inferior. This pre-perfusion allowed the removal of all 
blood in the liver. After the pre-perfusion phase, 3 ml of a pre-perfusion solution 
supplemented with 10-5 M BNP1-32 was infused through the vena portae into the 
liver and fractions of 150 µl each have been collected from the vena cava inferior. 
After the whole BNP1-32 solution was infused, the pre-perfusion solution was infused 
again and additional fractions have been collected to ensure that all infused 
quantities of BNP1-32 were eluted from the liver. All perfusion solutions have been 
heated to 37°C beforehand. All elution fractions collected were qualitatively and 
quantitatively analyzed with HPLC and MALDI-TOF-MS.  
2.2.13 Experiments on animals 
Experiments on animals, blood collection, and organ explanations were performed in 
accordance with the Animals (Scientific Procedures) Act 1986 of the Parliament of the 
United Kingdom, the Federal Law on the Use of Experimental Animals in Germany 
and were approved by the local authorities (Home Office London or 
Regierungspraesidium  Giessen). 
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2.2.14  Statistics 
For statistical comparisons, Student’s t test, One-way ANOVA or Two-way ANOVA 
with Bonferroni's Multiple Comparison (Graph Pad Prism 5.01; Graph Pad Software 
Inc., San Diego, California) were performed (mean ± SEM). Significance was 
considered at a value of P < 0.05. It has been highlighted in the text or in the figure 
legends which of the statical tests have been used and which significances were 
calculated. 
  RESULTS 
  
54 
 
3 RESULTS 
3.1   Metabolism of BNP1-32  
BNP1-32 is synthesized in the heart and partly in other organs26. Moreover, it is 
transported to various organs within the blood stream. Thus, BNP1-32 is 
permanently exposed towards the catalytic activity of extracellular and membrane-
bound enzymes.  
It was aimed to investigate the metabolism of BNP1-32 and the formation of 
corresponding BNP metabolites by this catalytic activity. Firstly, the metabolism of 
BNP1-32 by membrane-bound enzymes of different organs highly supplied with 
blood has been determined and compared.  
3.1.1  Metabolism of BNP1-32 by the proteolytic activity of 
different organs 
3.1.1.1  Comparison of the proteolytic activity of organs towards BNP1-32  
BNP1-32 has been synthesized as recombinant peptide via solid-phase synthesis (see 
Method section 2.2.1). The quality and purity of the synthetic peptide has been 
proven by HPLC and mass spectrometry. Recombinant BNP1-32 was incubated with 
murine membrane preparations of different organs harboring intact peptidase 
activities (see Method section 2.2.2). In particular, preparations of heart, lung, liver, 
kidney, and spleen were used. The remaining concentration of BNP1-32 in these 
incubations was quantified by HPLC and compared between the different organs at 
one distinct point of time. The experiment has been designed to get a qualitative 
overview about the proteolytic activity of the organ preparations towards BNP1-32. 
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Figure 9 illustrates that proteolytic activity towards BNP1-32 is very divergent 
between the organs investigated. Although protein concentration of the membrane 
preparations has been analyzed before and was normalized for each sample, the 
proteolysis of BNP1-32 was unequal. Hardly any proteolysis of BNP1-32 occurred in 
incubations with heart and spleen preparations, while only a small part of the initial 
peptide concentration was left when incubated with kidney preparations. The 
proteolysis of BNP1-32 observed in lung and liver preparations was similar. 
However, both organ preparations showed higher proteolytic activity towards 
BNP1-32 compared to heart and spleen but much less compared to kidney. 
This first dataset highlights that proteolytic activities towards BNP1-32 diversifies 
between the organs indicating that the amount of proteolyzing enzymes differs from 
organ to organ. However, at the same time it is also likely that each organ does harbor 
different peptidases responsible for BNP1-32 proteolysis. Thus, emerging products of 
BNP1-32 proteolysis might vary between the preparations due to different enzymatic 
activity present in these organs. Such BNP products have been determined in each 
organ preparation in the following investigations. 
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Figure 9: Quantification of the remaining concentration of BNP1-32 in percent after incubation with 
membrane preparations of heart, lung, liver, kidney and spleen for 90 min. The initial BNP1-32 
concentration before incubation was set to 100%. Membrane preparations were normalized to protein 
concentration. 
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3.1.1.2  Investigation of initial proteolytic products of BNP1-32 
The formation of initial products emerging from the proteolysis of BNP1-32 has been 
investigated for each organ. The peptide has been incubated with the membrane 
preparations until proteolysis of 20 to 25 % was achieved. The emerging BNP1-32 
cleavage products have been separated by HPLC (Figure 10).  
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Figure 10: HPLC chromatograms of (a) BNP1-32 alone, and BNP1-32 incubated with membrane 
preparations of (b) heart, (c) lung, (d) liver, (e) kidney, and (f) spleen until 20-25% of the initial 
BNP1-32 concentration was proteolyzed. According to their retention times, initial cleavage products 
are labeled with PM1, PM2 and to PM3. HPLC method 1 was used to separate peaks. 
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An optimal HPLC method has been established beforehand to allow distinct peak 
separation (see Methods section 2.2.3). For the identification of significant products, 
an automatic threshold for the integration of the peaks was set. 
Figure 10a shows the peak of pure BNP1-32. Its retention time (rt) emerging from its 
interaction with the column with the set conditions is 17.7 min. Besides this peak, 
new peaks with different retention times occurred in the chromatograms obtained 
from the incubations with the different organ preparations (Figure 10b-f). These 
peaks represent cleavage products of BNP1-32. Two peaks were generated through 
incubation with heart (PM1&2), and one each in incubations with lung (PM1), liver 
(PM1), kidney (PM3) and spleen (PM1). 
Among these six product peaks, three had the same retention time. Peak PM1, eluting 
first, (rtPM1 = 12.3 min) occurred in all approaches except for kidney. Conversely to 
PM1, peak PM3 (rtPM3 = 19.0 min) occurred in kidney only. Peak PM2 (rtPM2 = 13.9 min) 
was found in heart only.  
It could be revealed that the generation of PM1 was highest in liver compared to other 
organ preparations used. A comparison of the amount of PM1 generated in the organs 
within 90 min, is shown in Figure 11, in which the peakarea of PM1 in liver was set to 
100%. The absolute peakarea of PM1 in liver approximates 40% of the initial peak of 
BNP1-32. 
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Figure 11: Quantification of the generation of PM1 from BNP1-32 in percent after incubation with 
membrane preparations of heart, lung, liver, kidney and spleen for 90 min. Membrane preparations 
were normalized to protein concentration. The highest amount of PM1 generation was set to 100%.  
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The occurrence of these different product peaks indicates that the enzymatic 
processing of BNP1-32 varies between the organs. The identification of the amino 
acid sequence of these products and hence the cleavage sites of BNP1-32, is described 
in the next chapter. 
3.1.1.3 Identification of the initial proteolytic products of BNP1-32 
Each peak has been manually fractionated after chromatographic separation for 
analysis with MALDI-TOF MS to obtain masses (see Methods section 2.2.4).  
As expected, the six peaks could be identified as three different BNP peptide 
fragments varying in their sequence lengths. Figure 12a shows the MALDI-TOF 
spectra of the three products with their corresponding masses.  
 
         
 
 
 
 
 
 
Figure 12b displays the peptides’ amino acid sequences conducted from their 
masses. For comparison also BNP1-32 is shown. The BNP fragments represented by 
the peaks PM1 and PM2 are C-terminally truncated, while the peptide of peak PM3 is 
N-terminally truncated compared to the mature BNP1-32. PM1, which occurred in all 
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Figure 12: a) MADLI-TOF-MS spectra of the three different BNP products generated through 
incubation with organ membrane preparations. Each spectrum shows the isotope distribution of the 
mass peaks; b) Amino acid sequences of BNP1-32 and the three identified BNP products PM1, PM2 and 
PM3 conducted from their masses. Relevant amino acids are numbered according to their order, 
beginning with the N-terminus of the mature BNP1-32.  
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incubations except for the one with kidney, is truncated by the two C-terminal leucine 
(L), decreasing the number of amino acids to 30. Subsequently, this peptide is named 
BNP1-30. The peptide represented by PM2 is additionally shortened by lysine (K), 
reducing the number of amino acids to 29. Thus, the peptide is named BNP1-29. The 
third product, PM3, is truncated by six amino acids at the N-terminal side and is 
named BNP7-32. BNP7-32 has been described before in 2007 by an approach of 
Pankow et al. as the renal meprin A (EC 3.4.24.18) cleavage product of BNP1-32160. 
According to the monoisotopic peptide masses obtained from MALDI-TOF-MS and the 
comparison with the linear forms of the peptides, it was revealed that the two 
cysteines at positions 10 and 26 are present in a non-reduced form and are involved 
in a disulfide bridge (C10-C26). Thus, all truncated forms obtained in this approach still 
harbor the disulfide-linked ring structure, which is the prerequisite for biological 
activity of natriuretic peptides39 (see Introduction section 1.1.2). Hence, the three 
identified BNP products are referred to as metabolites rather than degradation 
products. 
3.1.1.4 Overview of the proteolysis of BNP1-32 by organ membrane 
preparations 
The investigation of the initial metabolism of BNP1-32 revealed that proteolytic 
activities towards the peptide vary between the organs. Kidney preparations had the 
highest proteolytic activity against BNP1-32, whereas the peptide was relatively 
stable in heart and spleen preparations (Figure 9). Moreover, the formation of three 
BNP metabolites was observed (Figure 10). The C-terminally truncated BNP1-30 was 
generated through the proteolytic activity of all organs except kidney. Comparing all 
organs, BNP1-30 was accumulating the most using liver membrane preparations 
(Figure 11). BNP7-32, the N-terminally truncated BNP metabolite was emerging in 
kidney only. The third BNP metabolite, BNP1-29 was generated in heart only. These 
results highlight that BNP metabolism is organ-dependent.  
Moreover, it is possible that the BNP metabolites are further metabolized. To 
complement the results, the metabolites found have been further investigated for 
their metabolism. 
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3.1.1.5   Metabolism of the identified BNP metabolites  
The identified metabolites BNP1-30, BNP1-29, and BNP7-32 have been synthesized 
via solid-phase synthesis and were incubated with the organ preparations to see if 
they are further processed.  
Table 13 summarizes the results of this approach. Incubation of BNP1-30 led to a 
dominant formation of BNP1-29 in all organ preparations except for kidney. BNP1-29 
has also been present in heart preparations incubated with BNP1-32, thus, BNP1-30 
might function as an intermediate product for the formation of BNP1-29. The 
significant accumulation of BNP1-29 in heart which is initially not present in other 
organs also generating BNP1-30 might be due to an increased concentration of the 
peptidase responsible for the generation of BNP1-29 or a decreased concentration of 
the peptidase degrading BNP1-29.  
Proteolysis of BNP1-29 led to the formation of another new BNP metabolite, 
BNP7-29, occurring in heart, lung and kidney but not in liver and spleen. Moreover, 
also BNP1-30 was metabolized to another new BNP metabolite, BNP7-30, in the same 
tissues, indicating that a proteolytic activity is able to remove the six N-terminal 
amino acids from both substrates similar to the formation of BNP7-32 in these 
tissues.  
Incubation of BNP7-32 with organ preparations led to the generation of BNP7-30 in 
lung, heart, liver, and spleen. In kidney itself, the C-terminally truncation forming 
BNP7-30 was, similarly to BNP1-30, not happening.  
 
Table 13: Summary of BNP metabolites occurring after incubation of the initial BNP metabolites 
BNP1-30, BNP1-29 and BNP7-32 with membrane preparations of heart, lung, liver, kidney and spleen. 
 
 
Formation of metabolites with membrane preparations of: 
heart lung liver kidney spleen 
BNP1-30 1-29 
7-30 
1-29 
7-30 
1-29 
- 
- 
7-30 
1-29 
- 
BNP1-29 7-29 7-29 - 7-29 - 
BNP7-32 7-30 7-30 7-30 - 7-30 
 
In conclusion, BNP1-32 and BNP metabolites can be C-terminally and N-terminally 
truncated in heart and lung. On the contrary, in kidney, only an N-terminal truncation 
is possible, whereas in liver and spleen only a C-terminal truncation of the peptides is 
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observed. This evolves the hypothesis that BNP metabolism is organ-specific and that 
full proteolysis of BNP1-32 needs the coactions of different organs and different 
peptidases.  
To get a more physiological insight in the metabolism of BNP1-32 and to confirm the 
above results, it was decided to perform an organ perfusion in situ, exemplarily done 
in liver.  
3.1.2  Metabolism of BNP1-32 during liver perfusion in situ 
3.1.2.1  Formation of BNP1-32 products during liver perfusion 
Murine liver was selected as organ of choice, since the generation of BNP1-30, which 
was found in nearly all tissues, was highest in this organ. After setting up the 
experiment and performing a pre-perfusion of the organ, the mature BNP1-32 was 
infused through the vena portae into the liver (see Method section 2.2.12). Twenty 
four fractions of the eluting BNP1-32-solution have been collected from the vena cava 
inferior over time and have been quantitatively and qualitatively analyzed with HPLC 
(Method 1) and MALDI-TOF-MS.  
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Figure 13: a) HPLC chromatogram of the perfusion solution containing BNP1-32. BNP1-32 occurs as a 
distinct peak with a retention time of 18.2 min; b) HPLC chromatogram of fraction 8 obtained during 
perfusion of the liver displaying the initial BNP1-32 peak and two BNP products, PLP1 and PLP2. HPLC 
method 1 was used. 
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The chromatogram in Figure 13a shows the distinct peak of BNP1-32 in the 
perfusion solution before passing the organ. In the elution fractions collected after the 
perfusion, exemplarily shown for the fraction 8 in Figure 13b, three different peaks 
occurred in the chromatogram, whereby one of these peaks (rt = 18.2 min) 
represents the initially infused BNP1-32. BNP1-32 concentration was reduced by 
approx. 40% compared to the pure perfusion solution. The additional two peaks PLP1 
(rt = 12.7 min) and PLP2 (16.7 min) are BNP products generated by peptidase 
activities in this organ. The products and the initial BNP1-32 have been quantified in 
all fractions (Figures 14a-c). The first three fractions after beginning of the perfusion 
contained the pre-perfusion solution and no peptide peaks. Thus the volume of these 
fractions, which was about 450 µl, represents the dead volume of the liver.  
 
 
 
 
 
 
 
 
 
 
Figure 14: Quantification of a) BNP1-32 and BNP1-32 products b) PLP1 and c) PLP2 in the fractions 
obtained during liver perfusion in mAU. 
 
From fraction 4 on, BNP1-32 levels began to rise (Figure 14a) followed by the 
appearance of two product peaks PLP1 and PLP2 (Figure 14b&c), indicating that 
BNP1-32 was successfully perfused trough the organ and that peptidase activities 
were present in the liver model. Summing up the peak areas of the two products and 
the remaining BNP1-32, less than 10% of the peptide concentration disappeared by 
e.g. retaining in the organ or by leakage, respectively. From fraction 10 on, the 
infusion of the BNP1-32-solution was stopped and exchanged with the pure perfusion 
solution. The slope seen in the peptide concentrations around this time was caused 
by the handling. From fraction 15 on the concentration of the peptides strongly 
started to decline, since peptide infusion was stopped and remaining peptide 
amounts were eluted. 
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3.1.2.2  Identification of BNP products formed during perfusion 
With MALDI-TOF-MS the masses of the two products have been examined. Product 1 
(PLP1) could be assigned to the peptide BNP1-30, whose generation was already 
observed using the membranes of liver and also other organ preparations in vitro. 
The slight drift in the retention time compared to the approach using organ 
membrane preparations occurred due to the progressed life-time of the HPLC 
column.  
Additionally a C- and N-terminally truncated peptide could be assigned to the mass of 
product 2 (PLP2, 2313.6 Da). This peptide is truncated on the N- and C-terminus and 
was named according to its amino acid sequence BNP4-24 (Figure 15). BNP4-24, is 
very likely a biologically inactive peptide fragment since the cleavage site 24’-25’ lies 
within the ring and destroys this structure. Thus, BNP4-24 is a degradation product 
rather than a metabolite and did not receive further attention in the following 
investigations. 
The data confirm above results using liver membrane preparations and demonstrate 
that BNP1-30 is a major cleavage product of BNP1-32.  
Beside the exposure of BNP1-32 to membrane-bound enzymes, BNP1-32 is also in 
contact with extracellular proteolytic activity present in the circulation. In the 
following chapter, metabolism of BNP1-32 by proteolytic activity of blood has been 
investigated. 
 
Figure 15: Amino acid sequences of BNP1-32 and the two identified BNP products PLP1 and PLP2, 
conducted from their masses. Relevant amino acids are numbered according to their order beginning 
with the N-terminus of the mature BNP1-32. 
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3.1.3   Metabolism of BNP1-32 by proteolytic activity of serum 
and plasma 
3.1.3.1 Comparison of proteolytic activity towards BNP1-32 of different 
blood preparations 
BNP1-32 is circulating in the blood and is thus transported to and through different 
organs. Chapter 3.1.1 demonstrated how BNP1-32 is metabolized by the proteolytic 
activity of distinct organs initially generating BNP1-30, BNP1-29, and BNP7-32. The 
blood itself contains major protein sources and high peptidase activities, e.g. for the 
breakdown of peptides. Thus, its proteolytic activity towards BNP1-32 was 
investigated. 
The blood was taken from mice and diluted preparations of serum or plasma by 
adding heparin or citrate for anticoagulation have been made from it (see Method 
section 2.2.2). EDTA was not used as an anticoagulant in this approach to avoid 
inhibition of metallopeptidase activities in the blood that might influence BNP 
metabolism. However, citrate binds calcium ions, which decreases activity of enzymes 
using Ca2+ as cofactors.  
Figure 16: Quantification of the remaining concentration of BNP1-32 in percent after incubation with 
diluted serum, heparin plasma, or citrate plasma for 90 min. The initial concentration of BNP1-32 was 
set to 100%. 
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After incubation of BNP1-32 with the different blood preparations, about 40% of 
BNP1-32 has been proteolyzed in serum and citrate blood (Figure 16). However, in 
heparin blood preparations 80% of the peptide has been removed in the same time. It 
might be possible that heparin does not interfere as much as citrate with the 
proteolyzing enzymes of the blood and thus, more BNP1-32 is proteolyzed.  However, 
in serum where no anticoagulant was added, some enzymatic activity might be lost 
caused by coagulation and thus, BNP1-32 proteolysis is less pronounced compared to 
proteolysis in heparin plasma. To reveal initial emerging BNP products, the 
chromatograms of the incubations have been analyzed in detail. 
3.1.3.2 Investigation of proteolytic products of BNP1-32 in blood 
preparations 
Figure 17 shows representative chromatograms of BNP1-32 incubated with diluted 
serum, heparin, or citrate plasma (red line). For comparison the chromatograms of 
serum, citrate, and heparin plasma alone have been displayed in the same figure 
(black line). This allows discrimination between peaks naturally occurring in the 
blood and peaks generated through BNP1-32 cleavage. For better peak separation, 
the HPLC method was optimized (Method 2) as such that the full spectrum of eluting 
peaks can be displayed in the chromatogram. The changes in the methods led to a 
shift of retention times for all peptides compared to those emerging from the method 
used in section 3.1.1. (Method 1). The intransparent peak areas in the beginning of 
the chromatograms represent compounds in the buffer and the sample that do not 
bind to the column but directly rinse through.  
In the chromatograms of serum, citrate, and heparin blood alone (black line), two or 
three naturally occurring peaks were found. Two peaks with the retention times of 
5.8 min and 7.9 min occurred in all preparations while an additional peak with the 
retention time of 6.6 min occurred in the serum only. Another very dominant peak 
with a retention time of 11.5 min occurred in the heparin blood preparations. The 
peak represents the compound heparin. All other peaks have been fractionated and 
analyzed with MALDI-TOF-MS. It was not aimed to identify these compounds, but to 
determine, if the peaks are related to BNP. Although it is very unlikely to see 
endogenous BNP fragments in unpurified blood samples with UV-detection, the 
analysis was performed to rule out any doubts. As expected it was revealed that none 
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of the peaks referred to a truncated BNP sequence. To investigate proteolytic 
products of BNP1-32, the peptide was spiked into the diluted blood preparations.  
BNP1-32 can be seen as a clear peak with a retention time of 9.9 min in all 
chromatograms (red line). After incubation for 90 min, two peaks PB1 and PB2 were 
observed in the chromatograms. PB1 has a retention time of 7.9 min. Coincidentally, 
the peak had the same retention time as an endogenous peak of the blood 
preparations and the overlay led to an increase of the whole peak area. As stated 
before, the endogenous peak was not related to any BNP metabolite. PB1 was only 
marginally occurring in citrate blood incubations, which might indicate that it was 
formed by a Ca2+-dependent enzyme. 
 
 
 
 
Figure 17: Overlay of chromatograms of diluted a) serum, b) heparin plasma or c) citrate plasma 
alone (black lines) and incubated with BNP1-32 for 90 min (red lines). Emerging peaks from the 
incubations are labelled with PB1 and PB2. Unlabeled peaks are present in the blood samples itself at 
5.8 min and 6.6 min. Intransparent peaks with a retention time of 2 to 4 min represent compounds 
with low binding affinity to the column. HPLC method 2 was used to separate peaks. 
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Moreover, a second small peak (PB2) with a retention time of 7.3 min was occurring 
in the heparin preparations. This peak occurred marginally also in the other two 
chromatograms. It might have been larger in heparin preparations compared to the 
others, since here the reduction of the BNP1-32 peak was also highest and thus more 
of the product was generated. An additional peak occurred in chromatogram a) and 
c) right at the end of the elution phase. This peak is an artefact caused by the method. 
In the following chapter, the BNP products behind the peaks PB1 and PB2 have been 
investigated. 
3.1.3.3 Identification of BNP1-32cleavage products in blood 
The new peaks have been fractionated and analyzed with MALDI-TOF-MS. The mass 
of the dominant peak PB1 corresponds to a new truncated BNP metabolite harboring 
31 amino acids. This metabolite is shortened by one leucine at the C-terminus 
compared to BNP1-32 and was subsequently named BNP1-31 (Figure 18). Peak PB2 
could be identified as BNP1-29, which was initially found in membrane preparations 
of the heart (see section 3.1.1.3) and was moreover formed from BNP1-30 in lung, 
liver and spleen (see section 3.1.1.5).  
 
 
 
 
The renal metabolite BNP7-32 and also the new metabolite BNP1-30, which were 
generated in lung, liver, spleen and heart incubations, did not occur in the 
chromatogram of the blood samples. However, this does not necessarily mean that 
these metabolites were not generated. Especially the generation of BNP1-30 is very 
likely since its potential precursor BNP1-31 and its subsequent cleavage product 
BNP1-29 were discovered. The result might indicate that BNP1-30 has reduced 
proteolytic stability compared to other metabolites in blood. In this case, BNP1-30 
would not occur in the chromatogram, since the de novo generated peptide would 
directly be metabolized or degraded further, and a distinct peak cannot accumulate. 
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Figure 18: Amino acid sequences of BNP1-32 and the two BNP products PB1 and PB2 identified in 
blood, conducted from their masses. Relevant amino acids are numbered according to their order, 
beginning with the N-terminus of the mature BNP1-32. 
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To test this hypothesis, the stability of the different BNP metabolites in blood 
preparations was tested. 
3.1.3.4 Proteolytic stability of BNP1-32 and BNP metabolites  
Since the identified BNP metabolites expose different C- or N-termini, their 
proteolytic stability can be altered compared to the mature BNP1-32. In this 
approach, BNP1-32 and the initial BNP metabolites BNP1-30, BNP1-29 and BNP7-32 
have been incubated with serum, citrate, or heparin plasma to reveal their 
proteolysis. Since with all blood preparations the same results have been achieved, 
the data are only shown exemplarily for serum incubations (Figure 19).  
After first testing it was observed, that BNP1-30 has dramatically reduced stability in 
the blood preparations and subsequently the serum has been additionally diluted to 
highlight this difference as seen in Figure 19. While BNP1-32, BNP1-29, and BNP7-32 
were stable over 40 min in the diluted blood preparations, BNP1-30 had an 
approximate half-life of only 5 min. The exposure of the C-terminal lysine in BNP1-30 
is obviously unfavorable for its stability. However, the additional removal of the 
C-terminal lysine forming BNP1-29 seems to stabilize the peptide again against 
proteolytic activity of the blood.  
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Figure 19: Quantification of the remaining concentrations of BNP1-32, BNP1-30, BNP1-29 and 
BNP7-32 in percent after incubation with serum over time (use of plasma results in the same values). 
In contrast to the approaches before, serum has been additionally diluted by factor 10 to enable the 
demonstration of the rapid proteolysis of BNP1-30. 
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The N-terminal truncation in BNP7-32 does also not decrease its stability in the time 
investigated.  
Analysis of BNP1-30 proteolysis revealed that the peptide is one-to-one cleaved into 
the metabolite BNP1-29, which is accumulating over time (Figure 20). In an 
additional experiment it could be observed that once BNP1-29 is generated from 
BNP1-30, it is as stable as BNP1-32 over time in the diluted serum. 
It is likely, that the metabolite BNP7-30 which is a cleavage product from BNP1-30 or 
BNP7-32 has also the same reduced stability as BNP1-30 has, since it exerts the same 
C-terminal lysine. In a subsequent experiment, proteolysis rate BNP7-30 has been 
investigated. Moreover it was revealed which cleavage product emerges from the 
proteolysis of the peptide (Figure 21).  
Congruent with the above hypothesis, BNP7-30 (blue line) was similarly unstable as 
BNP1-30. Obviously, the C-terminal removal of the two leucine seems to be decisive 
for the proteolysis rate. Notably, it was revealed that BNP7-30 was converted 
completely into into BNP7-29 (red line) which was accumulating over time. The 
removal of the C-terminal lysine at position 30 as in BNP1-29 and BNP7-29 seems to 
stabilize the peptide against cleavage. 
 
Figure 20: a) Quantification of the remaining concentration of BNP1-30 (green line) and the 
generation of its cleavage product BNP1-29 (pink line) after incubation with serum over time; b) 
Quantification of the remaining concentration of BNP1-32 in comparison to BNP1-29 (pink line) after 
its generation from BNP1-30.  
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The metabolite BNP7-29 and also BNP1-31 have not been available as synthetic 
peptides and could thus not been tested for their stability. However, BNP7-29 was 
after its generated from BNP7-30 accumulating within 30 min (Figure 21). 
Thereafter, proteolysis of the peptide started which indicates that the peptide is less 
stable compared to BNP1-29 (Figure 20 a). BNP1-31 was accumulating through 
incubation of BNP1-32 with serum or plasma. Thus, it can be concluded that BNP1-31 
is at least more stable as BNP1-30. 
3.1.3.5  Overview about the metabolism of BNP1-32 in blood 
Proteolysis of BNP1-32 in blood preparations led to the formation of the BNP 
metabolites BNP1-31 and BNP1-29. However, it is very likely that BNP1-30 is also 
formed. Since its proteolytic stability in blood was drastically reduced compared to 
other BNPs it did not accumulate in the incubations and was thus not visible in the 
chromatograms. It might be possible that carboxypeptidase activity in the blood led 
to a successive removal of C-terminal amino acids from BNP1-32. All BNP peptides 
discovered still contain the disulfide-linked ring structure.  
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Figure 21: Quantification of the remaining concentration of BNP7-30 (blue line) and the generation of 
its cleavage product BNP1-29 (red line) after incubation with serum over time. 
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3.1.4  Summary of the metabolism of BNP1-32 
Figure 22 displays the secondary structures of BNP1-32 and the BNP products 
identified by performing experiments with membrane preparations (see section 
3.1.1), blood preparations (see section 3.1.3), and liver perfusion (see section 3.1.2).  
 
 
 
 
Figure 22:  Secondary structures of BNP1-32 (mature BNP) and the BNP metabolites BNP1-31, 
BNP1-30, BNP1-29, BNP7-32, BNP7-30, and BNP7-29. 
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In summary, four different metabolites have been found initially. Three metabolites 
namely BNP1-31, BNP1-30 and BNP1-29 are C-terminally truncated, whereas the 
fourth metabolite BNP7-32 is N-terminally truncated. Metabolism of the initial 
metabolites led to the formation of BNP7-30 and BNP7-29 (see section 3.1.1.5). 
The BNP metabolite BNP1-30 was found in most approaches. Besides its formation in 
all membrane preparations except kidney and its formation during liver perfusion it 
was most likely also formed in blood. Thus, it was aimed to investigate the enzymes 
responsible for its generation. 
3.2   Identification of enzymes generating BNP1-30  
3.2.1  Strategy for the identification of enzymes from 
membrane preparations generating BNP1-30  
To identify the BNP1-30-generating enzyme(s) present in the membrane 
preparations of each organ generating BNP1-30, enzyme inhibitors have been added 
to the incubations (see Method section 2.2.2.5 and Table 14). These inhibitors can 
diminish the activity of their corresponding enzyme within the membrane 
preparations and thus reduce or decline the generation of BNP1-30 from BNP1-32. 
On the one hand, general enzyme inhibitors inhibiting a class of enzymes e.g. EDTA as 
a metallopeptidase inhibitor or aprotinin as serine-type peptidase inhibitor were 
used to reveal the peptidase(s) family. On the other hand, specific inhibitors, 
inhibiting distinct peptidases, have been used. 
 
Table 14: List of peptidase inhibitors and their specificity used to reveal the peptidases generating 
BNP1-30. 
Inhibitor  Inhibited peptidases /peptidase 
families  
Actinonin  Meprin A  
Alliskiren Renin 
Aprotinin  Serine-type peptidases  
Candoxatrilat  Neprilysin (NEP) 
Captopril Angiotensin-converting enzyme (ACE) 
Carboxypeptidase inhibitor  (CP inhib.) Carboxypeptidases, mostly  A, B and C 
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Chymostatin Serine peptidases and most cysteine-
peptidases 
Diprotin A  Dipeptidyl-peptidase IV (DPPIV) 
EDTA  Metallopeptidases  
F480  Angiotensin-converting enzyme 2 (ACE2) 
GEMSA Carboxypeptidase B-like enzymes 
Kallistop  Kallikrein  
Leupeptin  Serine- and cysteine-type peptidases  
Pepstatin  Aspartylproteases (e.g. renin) 
Roche cocktail [without EDTA] Serine peptidases, cysteine peptidases  
SM19712 Endothelin-converting enzyme 1 (ECE-1)  
Trypsin inhibitor (trp.inhib.) Trypsin-like peptidases  
Z-pro-prolinal (ZPP) Prolylcarboxypeptidase (PRCP), 
prolylendopeptidase (PREP)   
3.2.2  Identification of BNP1-30-generating enzymes in heart 
Figure 23 shows the amount of BNP1-30 accumulated through incubation with 
membrane preparations of the heart in the presence of enzyme family-specific 
inhibitors (white bars) or enzyme-specific inhibitors (grey bars). The amount of 
BNP1-30 generated with the membranes in the absence of peptidase inhibitors was 
set to 100% (black bar). One-Way ANOVA was used to determine statistical 
differences, which was rather insensitive for small changes in BNP1-30 accumulation 
caused by the multitude of groups analysed in parallel. However, this was thought 
reasonable, since the enzyme inhibitors can also influence BNP metabolism of 
cleavage products of BNP1-30. Thus, inhibitors can have influence on accumulation of 
BNP1-30, which is not caused by the inhibition of the particular peptidase generating 
the metabolite but on other peptidases e.g. proteolyzing BNP1-30. It was anticipated 
that rather big decreases of BNP1-30 concentrations are caused mainly by the 
inhibition of peptidases generating the metabolite. The generation of BNP1-30 using 
membrane preparations of heart could be strongly reduced by two enzyme inhibitors. 
The serine-type peptidase inhibitor aprotinin decreased the generation of BNP1-30 
by 2/3 and the carboxypeptidase inhibitor (CP inhib.) by 80%. Other family-specific 
inhibitors and specific inhibitors for enzymes known to be involved in the generation 
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of vasoactive peptides like ACE or ACE2, and peptidases known to cleave BNP 
(Meprin A, DPPIV, NEP) did not show significant effects on BNP1-30 accumulation. 
To get a more detailed insight into the metabolism of BNP1-32 in the heart, atrium 
and ventricle have been investigated separately.  
The use of the inhibitors showed a slightly different profile for the two heart tissues 
(Figure 24a&b). Whereas the carboxypeptidase inhibitor decreased the formation of 
BNP1-30 by 80% in the heart, it showed a much higher effect in the ventricle alone, 
where the generation of BNP1-30 was completely abolished. Vice versa, the effect in 
atrium was less pronounced. Aprotinin had approximately the same effect in both 
tissues. Since aprotinin and also the carboxypeptidase inhibitor reduced BNP1-30 
generation, it was anticipated that a serine-carboxypeptidase is responsible for the 
generation of BNP1-30 in heart membranes. 
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Figure 23: Quantification of the accumulation of BNP1-30 in percent in the presence of family-specific 
enzyme inhibitors (white bars) and enzyme-specific inhibitors (grey bars) using heart membrane 
preparations. The initial concentration of BNP1-30 generated in the incubations with heart membrane 
preparations without the use of inhibitors was set to 100% (black bar). For abbreviations of the 
inhibitors see Table 2. Significances were calculated with One-way ANOVA; *** P < 0.001 vs. no 
inhibitor. 
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In the numerical classification scheme for enzymes four different serine-
carboxypeptidases are described. One of them, the serine-type D-Ala-D-Ala 
carboxypeptidase (EC 3.4.16.4) can be found in bacteria only and cleaves 
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Figure 24: Quantification of the accumulation of BNP1-30 in percent in the presence of family-specific 
enzyme inhibitors (white bars) and enzyme specific inhibitors (grey bars) using a) membrane 
preparations of atria or b) membrane preparations of ventricles. The initial concentration of BNP1-30 
generated in the incubations with heart membrane preparations without the use of inhibitors was set 
to 100% (black bar). For abbreviations of the inhibitors see Table 2. Significances were calculated with 
One-way ANOVA; *** P < 0.001 vs. no inhibitor. When no error bar is seen, variations are within the 
bar. 
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preferentially after alanin230. The second candidate, Prolylcarboxypeptidase 
(Angiotensinase C, PRCP, EC 3.4.16.2), belongs to the S28 class of serine proteases 
firstly isolated from swine kidney lysosomal fractions231. It cleaves bradykinin and 
angiotensin II231. Because of its actions, PRCP is considered to be a cardioprotective 
enzyme232, also since PRCP polymorphism is linked to hypertension and pre-
eclampsia233, 234 and its depletion leads to vascular dysfunction and hypertension in 
mice235. PRCP favorably proteolyzes penultimate C-terminal prolines and is thus not 
an optimal candidate to cleave BNP1-32 which harbors a penultimate leucine. 
Moreover, the prolyloligopeptidase inhibitor Z-Pro-Prolinal (ZPP), which is also 
described as a PRCP inhibitor235 had no effect on BNP1-30 generation (Figure 24). 
Additionally, recombinant PRCP has been incubated with BNP1-32 and no formation 
of BNP1-30 could be observed (Figure 25a). 
The other two candidates are Carboxypeptidase C and D. CPD (EC 3.4.16.6) is 
involved in the processing of growth factors and hormones in Drosophila236 and 
human237, however, it preferentially releases C-terminal arginines or lysines, which 
are not present at the C-terminus of BNP1-32. The CPC or better known as Cathepsin 
A (CathA, EC 3.4.16.5) is widely distributed in mammalian tissues on the cell surface 
but is also present in lysosome and is secreted from the cell238. CathA has a broad 
substrate spectrum, since this enzyme works multifunctional as deamidase, esterase, 
and carboxypeptidase with a preference for substrates with hydrophobic amino acid 
residues at the C-terminus239. CathA can hydrolyse several regulatory peptides, 
Recombinant PRCP
0 15 30 45 60
0
1
2
3
4
5
time [min]
re
m
a
in
in
g
 B
N
P
1
-3
2
 [
µ
M
]
Figure 25: Quantification of the remaining concentration of BNP1-32 after incubation of 5 µM 
BNP1-32 with a) 2.5 mU Prolylcarbocypeptidase (PRCP) and b) 0.15 mU Cathepsin A (CathA) over 
time. 
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including substance P, met-enkephalin, and oxytocin and has a high activity against 
the vasoactive peptide endothelin-1240 and also against angiotensin (Ang) I by 
releasing a C-terminal leucine and converting it to Ang-(1-9)241. The mouse model of 
CathA deficiency shows significantly increased arterial blood pressure240. To test its 
actions on BNP1-30 formation, recombinant CathA was incubated with BNP1-32. No 
formation of BNP1-30 was observed (Figure 25b). 
Since none of the serine-carboxypeptidases investigated was able to generate BNP1-
30 from BNP1-32, it was hypothesized that the sought after peptidase might be a 
carboxypeptidase that is not a serine peptidase but is nevertheless in part inhibitable 
by aprotinin. Aprotinin is a single-chain polypeptide with a molecular weight of 6.5 
kDa. It is a typical Kunitz-type protease inhibitor and inhibits especially trypsin and 
related proteolytic enzymes by the tight binding of its lysine in the active site of such 
peptidases. Aprotinin gained special importance in the treatment of influenca, since it 
targets trypsin-like proteases responsible for influenza virus hemagglutinin cleavage 
and virus activation in infected organism242. Moreover, it has a long history in medical 
practice in the treatment of pancreatitis and post-operative bleeding243, 244, and 
several licensed compounds of aprotinin are available including TrasylolTM (Bayer AG, 
Germany) or AntagosanTM (Sanofi Aventis, France)245. Since aprotinin seems to be 
involved in many pathways it might be possible that it can interfere with a 
carboxypeptidase not being a typical serine peptidase. For this purpose other 
recombinant carboxypeptidases have been tested for their ability to form BNP1-30, 
subsequent to this chapter. However, prior, enzymes generating BNP1-30 in lung, 
liver and spleen have been investigated. 
3.2.3   Identification of BNP1-30-generating enzymes in lung 
Other than for the heart, aprotinin and carboxypeptidase inhibitor had no significant 
effects on BNP1-30 generation in lung, although its concentration was in trend 
reduced compared to other incubations (Figure 26). However, the metallopeptidase 
inhibitor EDTA reduced BNP1-30 generation by approx. 50% indicating the 
involvement of a peptidase from the family of metallopeptidases. The group of 
metallopeptidases includes a variety of enzymes and specific metallopeptidase-
inhibitors for enzymes well known to catabolize natriuretic peptides or vasoactive 
peptides e.g. meprin A (actinonin), DPPIV (diprotin A), NEP (candoxatrilat), and ACE 
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(captopril) have been investigated in detail. None of them showed an inhibition on 
BNP1-30 formation. 
The administration of the NEP inhibitor candoxatrilat even increased the peak area of 
BNP1-30 indicating that the degradation of BNP1-30 or of one of its own cleavage 
products is performed by NEP. Since EDTA also inhibits NEP, and NEP inhibition 
leads to an increase of the BNP1-30 peak, the inhibitory effect of EDTA on BNP1-30 
formation might be even higher than seen. 
Interestingly, instead of the inhibitors known to be involved in BNP proteolysis, 
another inhibitor named SM19712 led to a pronounced and significant reduction of 
BNP1-30 generation by about 75%. SM19712 is a selective inhibitor of endothelin-
converting enzyme 1 (ECE-1; EC 3.4.24.71)246. ECE-1 belongs to the family of neutral 
metallopeptidases, which also includes NEP, and was first isolated and purified from 
aortic endothelial cells247, 248. ECE-1 is involved in the cleavage of beta-amyloid, 
bradykinin, and substance P249 and generates endothelin-1 from Big-endothelin-1248.  
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Figure 26: Quantification of the accumulation of BNP1-30 in percent in the presence of family-specific 
enzyme inhibitors (white bars) and enzyme specific inhibitors (grey bars) using lung membrane 
preparations. The initial concentration of BNP1-30 generated in the incubations with lung membrane 
preparations without the use of inhibitors was set to 100% (black bar). For abbreviations of the 
inhibitors see Table 2. Significances were calculated with One-way ANOVA; * P < 0.05; ** P < 0.01 vs. no 
inhibitor. When no error bar is seen, variations are within the bar. 
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Since the inhibitor of ECE-1 had a strong effect on BNP1-30 generation, the 
degradation rate of BNP1-32 in lung was investigated in the presence of this inhibitor 
to reveal, if ECE-1 inhibition increases BNP1-32 concentration compared to non-
treated samples. Notably, the presence of the inhibitor did not change BNP1-32 
proteolysis rates significantly over time, however in trend the proteolysis was 
decreased (Figure 27). This data indicates that also other peptidases than ECE-1 are 
involved in the degradation of BNP1-32 in lung.  
3.2.4   Identification of BNP1-30-generating enzymes in liver 
Similar to the situation in lung but less pronounced, EDTA and also the ECE-1 
inhibitor SM19712 suppressed the formation of BNP1-30 in the incubations of liver 
membranes and BNP1-32 (Figure 28). The carboxypeptidase inhibitor and also the 
trypsin inhibitor increased the formation of BNP1-30 indicating that BNP1-30 was 
further cleaved by carboxypeptidases and trypsin in liver. 
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Figure 27: Quantification of the remaining concentration of BNP1-32 in percent after incubation with 
lung membrane preparations with (black symbols) or without (clear symbols) the presence of the 
specific ECE-1 inhibitor SM19712 over time.  
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3.2.5   Generation of BNP1-30 in spleen 
Similar to the heart membranes, aprotinin and the carboxypeptidase inhibitor 
inhibited BNP1-30 generation using spleen membranes (Figure 29). However, the 
effect was less pronounced compared to the heart. EDTA, SM19712, and other 
inhibitors had no significant influences, although EDTA seemed to increase BNP1-30 
formation, which is in full contrast to the situation in lung and liver where EDTA 
reduced BNP1-30 formation. Most likely, EDTA was inhibiting an enzyme in spleen 
proteolyzing BNP1-30 and thus more peptide was accumulated compared to non-
inhibition. 
Moreover, ZPP seems to decrease BNP1-30 generation. The One-way ANOVA analysis 
did not show any significance, however, the student’s t-test showed P < 0.01. As 
stated before, ZPP is inhibiting PRCP, but it was revealed that recombinant PRCP is 
not able to form BNP1-30 from BNP1-32 (see section 3.2.2). Besides PRCP, ZPP is 
inhibiting prolylendopeptidase (PREP). However, similar to the PRCP, PREP requires 
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Figure 28: Quantification of the accumulation of BNP1-30 in percent in the presence of family-specific 
enzyme inhibitors (white bars) and enzyme specific inhibitors (grey bars) using liver membrane 
preparations. The initial concentration of BNP1-30 generated in the incubations with liver membrane 
preparations without the use of inhibitors was set to 100% (black bar). For abbreviations of the 
inhibitors see Table 2. Significances were calculated with One-way ANOVA; * P < 0.05; ** P < 0.01 vs. no 
inhibitor. When no error bar is seen, variations are within the bar. 
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a proline next to the peptide bond it is cleaving250 and is thus, not able to cleave 
BNP1-32, respectively. 
3.2.6  Overview of BNP1-30-generating enzymes present in 
membranes of organs 
In the first chapters it was described that both, proteolysis rates of BNP1-32 and 
subsequent BNP metabolite formation is different in each organ. However, it was 
observed that BNP1-30 formation was abundant among the majority of organs. 
Thereupon, it has been investigated which peptidase or rather which peptidases are 
responsible for its generation. Interestingly, the above results disclosed that the 
proteolytic activity responsible for the formation of BNP1-30 is not equal in each 
organ. In lung and liver ECE-1 is responsible for BNP1-30 formation, whereas in heart 
and spleen other carboxypeptidases generate the peptide. The data indicate that the 
generation of BNP1-30 plays an overriding role, since different enzymes with 
different localisations appear to catalyze BNP1-30 formation. 
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Figure 29: Quantification of the accumulation of BNP1-30 in percent in the presence of family-specific 
enzyme inhibitors (white bars) and enzyme specific inhibitors (grey bars) using liver membrane 
preparations. The initial concentration of BNP1-30 generated in the incubations with liver membrane 
preparations without the use of inhibitors was set to 100% (black bar). For abbreviations of the 
inhibitors see Table 2. Significances were calculated with One-way ANOVA; * P < 0.05 vs. no inhibitor. 
When no error bar is seen, variations are within the bar. 
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To confirm the just revealed results, recombinant ECE-1 has been investigated for its 
ability to form BNP1-30. Moreover, other recombinant carboxypeptidases despite the 
ones that have been tested already (PRCP, CathA; see section 3.2.2) have been 
investigated for their ability to form BNP1-30. Also recombinant meprin A, which is 
catalyzing the formation of BNP7-32 from BNP1-32160 has been used to reveal its 
further role in BNP metabolism. 
3.3  Particular recombinant enzymes generating BNP 
metabolites 
3.3.1  BNP metabolism with endothelin-converting enzyme-1 
According to the above results performing incubations with membrane preparations 
of lung and liver in combination with enzyme inhibitors, ECE-1 could be identified as 
one enzyme cleaving BNP1-32 into BNP1-30. To confirm this data, recombinant ECE-
1 has been incubated with BNP1-32. The overlay of two chromatograms in Figure 30 
shows that the incubation with the enzyme led to the formation of BNP1-30 (red line) 
similarly as during incubation of BNP1-32 with liver membrane preparations (black 
line). Additionally, the product peak has been fractionated and analyzed with 
MALDI-TOF-MS, revealing, that the emerging mass matched with the mass of the 
metabolite BNP1-30. Thus, it was confirmed that recombinant ECE-1 is able to 
generate BNP1-30 from BNP1-32.  
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Figure 30:  Overlay of HPLC chromatograms of the incubation of BNP1-32 with recombinant 
endothelin-converting enzyme 1 (ECE-1, red line) and BNP1-32 incubated with liver membrane 
preparations (black line); HPLC method 1 was used. 
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Moreover, ECE-1 was incubated with other BNP metabolites including BNP7-32, 
which has the same C-terminus as BNP1-32. Figure 31 shows a comparison of all 
incubations. BNP7-32 was cleaved by ECE-1 to a similar extend as BNP1-32. 
 
 
 
 
 
 
 
 
 
 
 
Analysis of the product peak with MALDI-TOF-MS revealed that ECE-1 was forming 
BNP7-30 from BNP7-32. Other C-terminally truncated BNP metabolites like BNP1-29 
and also the peptides BNP1-30 and BNP7-30 were not further processed by the 
enzyme. Additionally, it has been tested whether ECE-1 is able to truncate other 
natriuretic peptides. Thereby it was revealed that ANP and CNP were not cleaved by 
the enzyme (Figure 31). 
It has been shown that BNP1-30 is also formed by other enzymes than ECE-1 in heart 
and spleen. PRCP and CathA have been excluded to be able to catalyze the reaction 
(see section 3.2.1). Thus, additional recombinant carboxypeptidases like the 
angiotensin-converting enzymes and the carboxypeptidases A and B, which are also 
inhibitable by the carboxypeptidase inhibitor used in the incubations in section 3.2 
have been investigated as described in the next chapter. 
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Figure 31:  Quantification of the remaining concentration of BNP1-32 and the BNP metabolites 
BNP1-30, BNP1-29, BNP7-32, and BNP7-30 as well as ANP and CNP after incubation with 0.1 mU 
recombinant endothelin-converting enzyme 1 (ECE-1) over time. 
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3.3.2  BNP metabolism with recombinant carboxypeptidases 
3.3.2.1  BNP metabolism with angiotensin-converting enzymes 
Angiotenin-converting enzyme (ACE; EC 3.4.15.1) and ACE2 (EC 3.4.17.23) are 
classical carboxypeptidases of the renin-angiotensin system metabolizing and 
catabolizing vasoactive peptides251. 
The renin-angiotensin system plays an important role in the pathophysiology of 
hypertension252 and heart failure253. Its activity is controlled by renin, an aspartyl 
peptidase, which cleaves angiotensinogen to generate AngI254. ACE, a 
zinc-metallopeptidase, mediates the crucial step in which the vasoconstricting 
peptide AngII (Ang-(1-8)) is formed from the inactive AngI (Ang-(1-8)) by cleaving 
two amino acids at the C-terminus255, 256. Its homologue ACE2 cleaves AngII, releasing 
Ang-(1-7), which counteracts many of the detrimental effects of AngII257.  
It was shown before that inhibitors of both enzymes did not show significant effects 
in organ incubations (see section 3.2). However, since both enzymes are 
carboxypeptidases and especially ACE as a dipeptidylcarboxypeptidase is able to 
cleave a C-terminal dipeptide that can by hydrophobic258, they have been tested for 
their ability to form BNP1-30 as well as to cleave BNP metabolites. However, the 
proteolytic activity of ACE towards the BNPs was compared to its ability to cleave 
AngI. Figure 32a shows that while 70% of AngI were cleaved by ACE, all BNP 
metabolites were left unaltered.  
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Figure 32:  a) Quantification of the concentration of Angiotensin I (AngI), BNP1-32, BNP1-30, 
BNP1-29, BNP7-32 and BNP7-30 after incubation with 0.1 mU recombinant angiotensin-converting 
enzyme (ACE) for 20 min; b) Quantification of the concentration of AngII BNP1-32, BNP1-30, BNP1-29, 
BNP7-32 and BNP7-30 after incubation with 0.08 mU recombinant ACE2 for 20 min. Where error bars 
are not indicated, SEM is within the bars. 
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Similar to ACE, ACE2 did not show any proteolytic effect on BNP1-32 or BNP 
metabolites using the same specific activity of the enzyme that was able to cleave 
AngII (Figure 32b). 
3.3.2.2  Metabolism with carboxypeptidase A 
Recombinant carboxypeptidase A (CPA, EC 3.4.17.1) has been described before to 
mediate the formation of Ang1-9 form AngI259 by the removal of the C-terminal 
leucine. Since BNP1-32 also harbors a C-terminal leucine it was hypothesized that this 
enzyme can cleave the peptide. Incubation of recombinant CPA with the peptides 
indeed revealed that BNP1-32 but also BNP1-29 and BNP7-32 were proteolyzed by 
the enzyme (Figure 33). As expected, BNP1-30 and BNP7-30 were stable since CPA is 
not able to cleave the C-terminal lysine260.  
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Figure 33: Quantification of the remaining concentration of BNP1-32 or the BNP metabolites BNP1-30, 
BNP1-29, BNP7-32, and BNP7-30 after incubation with 0.025 mU recombinant carboxypeptidase A 
(CPA) over time. 
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Analysis with HPLC and MALDI-TOF-MS revealed that CPA successively cleaved 
BNP1-32 leading to the generation of BNP1-31 and BNP1-30 (Figure 34). Since the 
C-terminal lysine of BNP1-30 cannot be further cleaved by the enzyme, the metabolite 
is accumulating over time through the ongoing metabolism of BNP1-31 (red and blue 
line).  
Similarly, it was revealed that BNP7-32 is cleaved into BNP7-30 forming the 
intermediate product BNP7-31 (Figure 34b). Also here, BNP7-30 was accumulating 
over time, since CPA was not able to further metabolize the peptide. 
3.3.2.3 Metabolism with carboxypeptidase B 
Recombinant CPB (EC 3.4.17.2) preferentially hydrolyzes C-terminal arginine and 
lysine261. Thus, BNP1-32 is an unfavorable substrate for this enzyme, however 
BNP1-30 and BNP7-30, which harbour a C-terminal lysine, were hypothesized to be 
substrates for CPB. As shown in Figure 35a, CPB was indeed able to cleave BNP1-30 
Figure 23: Overlay of HPLC chromatograms of the incubation of BNP1-32 with recombinant CPA at 1 min 
(black line), 6 min (red line), and 15 min (blue line). HPLC method 2 was used. 
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Figure 34: Overlay of HPLC chromatograms of the incubation of a) BNP1-32 and b) BNP7-32 with 
recombinant carboxyepeptidase A (CPA) at 1 min (black line), 6 min (red line), and 15 min (blue line). 
HPLC method 2 was used. 
 
  RESULTS 
  
87 
and BNP7-30. In parallel, BNP1-32, BNP1-29 and BNP 7-32 were not cleaved by the 
enzyme. 
Analysis of the cleavage products with HPLC and MALDI-TOF-MS revealed that 
BNP1-30 is cleaved in a one-to-one ratio into BNP1-29 and similarly BNP7-30 is 
cleaved in a one-to-one ratio into BNP7-29 (Figure 35b).  
Interestingly, these results reflect the situation observed in the incubations of the 
substrates in serum (see section 3.1.3.4). In these experiments, BNP1-30 and 
BNP7-30 were also completely cleaved into BNP1-29 and BNP7-29, whereas other 
BNP metabolites have not been metabolized in the same time. Thus, it was aimed to 
reveal if CPB is the enzyme in serum responsible to catalyze these reactions. 
Therefore, GEMSA, an inhibitor of CPB-like enzyme activity that was specifically 
Figure 35: a) Quantification of the remaining concentration of BNP1-32 and of the BNP metabolites 
BNP1-30, BNP1-29, BNP7-32, and BNP7-30 after incubation with 0.1 mU recombinant 
carboxypeptidase B (CPB)  for 10 min; b) Quantification of the remaining concentration of BNP1-30 
and BNP7-30 after incubation with 0.1 mU recombinant CPB for 10 min (white bars). Next to the 
substrate-bars the concentration of the corresponding CPB cleavage products BNP1-29 and BNP7-29 
are displayed (black bars); c) overlay of chromatograms displaying the separation of peaks after 
incubation of BNP1-30 with recombinant CPA forming BNP1-29 (green line) or incubation of BNP7-30 
with recombinant CPA forming BNP7-29(blue line). HPLC method 2 was used. 
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shown to inhibit CPB262 has been supplemented into the incubations of the peptides 
with serum. Product formation has again been analysed with MALDI-TOF-MS and 
peaks have been quantified with HPLC. Results are plotted in Figure 36. Importantly 
this experiment disclosed that enzyme activity forming BNP1-29 and BNP7-29 was 
nearly completely inhibited by GEMSA. 
3.3.3   Metabolism with meprin A 
As shown before by an approach of Pankow et al.160, BNP1-32 is metabolized by renal 
meprin A into the metabolite BNP7-32. Here, it was furthermore investigated if 
besides BNP1-32 also the newly identified metabolites BNP1-30 and BNP1-29 are 
substrates for meprin A. Therefore, the peptides have been incubated with 
recombinant meprin A and cleavage products have been analysed with 
MALDI-TOF-MS as well as quantified with HPLC. As shown in Figure 37, recombinant 
meprin A catalyzes the formation of BNP7-32 from BNP1-32. Similarly, the incubation 
with BNP1-30 led to the formation of BNP7-30 and the incubation with BNP1-29 led 
to the formation of BNP7-29. Since the proteolysis rates between the peptides did not 
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Figure 36: Quantification of the remaining concentration of BNP1-30 (fascinated) or BNP7-30 
(horizontal stripes) after incubation with serum for 10 min with or without the presence of the 
carboxypeptidase B (CPB) inhibitor GEMSA. The stacked bars show in parallel the generation of their 
corresponding cleavage products BNP1-29(fascinated grid) or BNP7-29 (horizontal grid) with or 
without the presence of GEMA. 
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significantly differ, it can be anticipated that the enzyme has similar substrate 
specificity towards the three peptides. Thus, it is likely, that renal meprin A is also be 
able to form the metabolites BNP7-30 and BNP7-29 under physiological conditions if 
the corresponding substrates are present in the kidney. 
3.3.4  Overview of enzymes metabolizing BNP1-32 
The above results confirm that recombinant ECE-1 is able to generate BNP1-30 from 
BNP1-32, indicating that ECE-1 activity present in lung and liver as revealed by the 
use of the specific ECE-1 inhibitor is likely responsible for the generation of BNP1-30 
in these tissues. Moreover, it could be disclosed that CPA is also able to generate 
BNP1-30 through the intermediate product BNP1-31. Importantly, the enzyme CPB 
was discovered being able to cleave BNP1-30 and BNP7-30 forming their 
corresponding C-terminal cleavage products BNP1-29 and BNP7-29 similar to the 
situation seen in blood preparations. It was moreover shown, that other 
carboxypeptidases like CathA, PRCP, and the key enzymes of the renin-angiotensin 
system, ACE and ACE2, did not show activity towards BNP1-32 or investigated BNP 
metabolites with the specific activity used. Meprin A, which generates BNP7-32, is 
also able to proteolyze other BNP metabolites, such as BNP1-30 and BNP1-29, 
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Figure 37:  Quantification of the remaining concentration of BNP1-32, BNP1-30 and BNP1-29 after 
incubation with 0.1 mU recombinant meprin A for 20 min (white bars). Next to the substrate-bars the 
concentration of the corresponding meprin A proteolysis products BNP7-32, BNP7-30, and BNP7-29 
are displayed (black bars).  
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Table 15: Overview about enzymes cleaving BNP1-32 and BNP metabolites forming other BNP 
metabolites. 
 
 
 
forming BNP7-30 and BNP7-29. In summary, for each BNP metabolite, discovered 
during incubation with membrane preparations or blood preparation, at least one 
enzyme was identified being responsible for its formation. Results are summarized 
in Table 15.  
 
Substrate Enzyme Product 
BNP1-32 
Endothelin-converting enzyme-1 BNP1-30 
Carboxypeptidase A BNP1-31 and BNP1-30 
Meprin A BNP7-32 
BNP1-30 
Carboxypeptidase B BNP1-29 
Meprin A BNP7-30 
BNP1-29 
Carboxypeptidase A not defined 
Meprin A BNP7-29 
BNP7-32 
Endothelin-converting enzyme-1 BNP7-30 
Carboxypeptidase A BNP7-31 and BNP7-30 
BNP7-30 Carboxypeptidase B BNP7-29 
 
This collection of data strongly indicates that many enzymes are involved in the 
metabolism of BNP1-32. Finally, it was of particular interest if NEP is able to 
inactivate BNP metabolites. 
3.4  Degradation of BNP metabolites by NEP 
NEP was thought to be the main enzyme catabolizing and thus inactivating natriuretic 
peptides120, 122. Structural principles were shown previously to this work making 
clear that the amino acid sequence and especially the lengths of the natriuretic 
peptides are decisive for the ability of NEP to inactivate them20. Thus, it was tested if 
the newly identified BNP metabolites are better substrates for NEP in contrast to 
BNP1-32. For comparison, ANP and CNP degradation by NEP has been displayed too. 
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The incubation with recombinant NEP revealed no statistical difference between 
degradation of BNP1-32 and BNP1-30 within 20 min, whereas CNP was already 
degraded by 75% (Figure 38).  
However, the trend indicates that BNP1-30 degradation might be faster compared to 
BNP1-32 with longer incubations times. The metabolites BNP1-29, BNP7-32 and 
BNP7-30 were degraded in a much faster way compared to BNP1-32 and BNP1-30, 
reaching similar values as ANP. The missing lysine at the C-terminus of BNP1-29 
seems to have a very favorable influence on the peptides’ degradability by NEP. 
It can be confirmed that NEP is not directly degrading BNP1-32, but favors shorter 
BNP metabolites. Thereby, the loss of the C-terminal lysine or the loss of the six 
N-terminal amino acids achieved by meprin A are increasing degradation levels to be 
comparable to ANP. The data also indicate that BNP metabolism is an important 
prerequisite for BNP clearance by NEP.  
Since the opening of the ring structure of the natriuretic peptides leads to their 
inactivation, it is anticipated that the BNP metabolites, which still harbor this 
structure, exert biological activity. This hypothesis was investigated in different 
approaches described in the next chapters. 
Figure 38: Quantification of the remaining concentration of ANP, CNP, BNP1-32, BNP1-30, BNP1-29, 
BNP7-32, and BNP7-30 in percent after incubation with 0.25 mU recombinant neprilysin (NEP) for 20 
min. Significances have been calculated with One-way ANOVA: *** P < 0.001 vs. BNP1-32; ### P < 0.001 
vs. BNP1-30. 
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3.5   Biological activity of BNP1-32 and BNP 
metabolites in vitro 
BNP1-32 and the BNP metabolites BNP1-30, BNP1-29, BNP7-32, and BNP7-30 were 
tested for their biological activity by determining their ability to stimulate natriuretic 
peptide receptors (see Method section 2.2.9). The bioactivity of the metabolites is 
positively correlating to the amount of cGMP being generated in the cells upon 
natriuretic peptide receptor stimulation. The emerging cGMP concentrations have 
been measured by immunosorbant assays (see Method section 2.2.9.2). 
3.5.1  Natriuretic peptide receptor-transfected HEK293 cells 
3.5.1.1 Functionality of the receptors 
HEK293 cells have been transfected with the receptors NPRA or NPRB. First of all, the 
transfection and functional expression of the receptors was proven by stimulating the 
transfected cells with ANP, BNP1-32, and CNP and determining the cGMP generation 
in comparison to that of cell culture medium (DMEM)-stimulated cells, which served 
as controls. 
Figure 39 shows the quantification of the cGMP amount generated by the stimulation 
of such transfected cells. Stimulation of NPRA-transfected HEK293 cells with ANP and 
BNP1-32 led to the generation of about 300 pmol/ml cGMP (Figure 39a). Stimulation 
Figure 39: Quantification of cGMP levels after stimulation of a) NPRA- and b) NPRB-transfected 
HEK293 cells with cell culture medium (control),  or ANP, BNP1-32 or CNP with a peptide 
concentration of 10-7 M. Significances were calculated with One-way ANOVA: *** P < 0.001 vs. control 
[n = 3, in triplicates]. 
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with CNP did not lead to cGMP formation, since CNP only has a marginal affinity 
towards NPRA, but has a high affinity towards the NPRB (see Introduction section 
1.1.3). Thus, conversely, CNP stimulation of NPRB-transfected HEK293 cells led to the 
generation of about 250 pmol/ml cGMP, whereas ANP and BNP1-32 stimulation did 
not lead to a noteworthy generation of the second messenger (Figure 39b).   
3.5.1.2 Stimulation of NPRA-transfected HEK293 cells  
Since functionality of the receptors has been proven, NPRA-transfected HEK293 cells 
have been stimulated with BNP1-32 and BNP metabolites. Figure 40 summarizes the 
amount of cGMP generated after such stimulation.  
All metabolites were able to stimulate significant cGMP generation compared to the 
control confirming the hypothesis that, although the new BNP metabolites are 
truncated on different positions, they are still bioactive.  
Notably, only the renal metabolite BNP7-32 was less active compared to BNP1-32, 
while all other metabolites showed similar activities or were even more efficient in 
stimulating cGMP formation. In fact, the C-terminally truncated metabolites BNP1-30 
and BNP1-29 were more bioactive compared to BNP1-32. The shortest metabolite 
BNP7-30 was in contrast to the N-terminally truncated peptide BNP7-32 similarly 
bioactive compared to BNP1-32. Obviously, the negative influence of an N-terminal 
Figure 40:  Quantification of cGMP levels after stimulation of NPRA-transfected HEK293 cells with cell 
culture medium (control), BNP1-32, BNP1-30, BNP1-29, BNP7-32, and BNP7-30 with a peptide 
concentration of 10-7 M. Significances were calculated with One-way ANOVA: *** P < 0.001 vs. control; 
# P < 0.05; ## P < 0.01; ### P < 0.001 vs. BNP1-32 [n = 4, in triplicates]. 
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truncation like in BNP7-32 seems to be buffered by an additional C-terminal 
truncation in BNP7-30. 
3.5.1.3 Stimulation of NPRB-transfected HEK293 cells 
It was demonstrated before that BNP1-32 does stimulate NPRA but not NPRB 
(Figure 39). To investigate if the C- and N-terminal truncations of the peptide do 
influence receptor specificity, NPRB-single-transfected HEK293 cells have been 
stimulated (Figure 41).  
As stated before, BNP1-32 is only marginally able to stimulate cGMP generation in 
comparison to CNP. As seen in Figure 41, the stimulation with the peptide led to the 
generation of approx. 3 pmol/ml cGMP. Surprisingly, BNP1-30 showed much higher 
effects on NPRB-transfected cells compared to BNP1-32. Although cGMP levels were 
still low compared to those arising from NPRA-stimulation, the amount of cGMP 
generated is tripled in comparison to usual levels achieved by stimulation with 
BNP1-32. Notably, other metabolites did not show this increased effect on NPRB.  
3.5.1.4 Stimulation of NPRA & NPRB double-transfected HEK293 cells  
Since the experiments on the NPRB revealed that BNP1-30 stimulation led to a 
significantly higher cGMP generation compared to BNP1-32, it was tested whether 
the stimulation of both receptors in parallel would lead to an additional increase in 
Figure 41:  cGMP levels after stimulation of NPRB-transfected HEK293 cells with cell culture medium 
(control), BNP1-32, and BNP metabolites with a peptide concentration of 10-7 M. Significances were 
calculated with One-way ANOVA: # P < 0.05; *** P < 0.001 vs. BNP1-32 [n = 4, in triplicates]. 
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cGMP formation upon stimulation with BNP1-30. Thus, to complete the 
investigations, the bioactivity of BNP1-32 and the BNP metabolites was investigated 
in NPRA&B-double-transfected HEK293 cells. 
As shown in Figure 42a, all metabolites were able to stimulate significant cGMP 
generation compared to the control. The graph shows the same pattern as for the 
NPRA-single transfected cells, since this receptor is the major effector for cGMP 
formation by BNPs. Notably, cGMP values were lower in comparison to those 
measured in NPRA-single transfected cells, although same plasmid concentration was 
used in both approaches. Very recently, it was discovered in our working group, that 
subunits of NPRA and NPRB can interact with each other forming heterodimers with 
altered ligand affinities263.Thus, cGMP values from single-transfected cells might not 
necessarily summarize. To provide insight into the potency of the peptides, 
experiments with different concentrations of the peptides have been made and dose 
response curves have been calculated. Figure 42b shows the different curves for 
each metabolite applied. As revealed before, BNP1-29 showed highest efficacy with a 
top value of 86 pmol/ml, whereas BNP7-32 had the lowest with a top value of 
Figure 42: a) Quantification of the cGMP levels after stimulation of NPRA & B-cotransfected HEK293 
cells with BNP1-32, BNP1-30, BNP1-29, BNP7-32, and BNP7-30 with a peptide concentration of 10-7 M 
.Significances were calculated with One-way ANOVA: *** P < 0.001 vs. control; ## P < 0.01; ### P < 0.001 
vs. BNP1-32; §§ P < 0.01 vs. BNP1-30 [n = 3 in triplicates] b) dose response curves obtained from the 
stimulation of NPRA & B-cotransfected HEK293 cells with BNP1-32, BNP1-30, BNP1-29, BNP7-32, and 
BNP7-30. Significances were calculated with Two-way ANOVA:  ###P < 0.001 vs. BNP1-32 (although not 
indicated, all curves are *** P < 0.001 vs. control) [n = 3 in triplicates]. 
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47 pmol/ml with a peptide concentration of 5 x 10-7 M (Table 16). The EC50 values 
were similar for all peptides (also Table 16). Significance towards BNP1-32 was 
reached only for BNP1-29 using Two-way ANOVA caused by the high number of 
groups being compared. In a comparison using only one curve in comparison to that 
of BNP1-32, BNP1-30 and BNP7-30 are also significantly different to BNP1-32. 
 
Table 16:  Summary of EC50 and Top values from dose response curve. 
 
Besides using receptor-transfected cells, bioactivity of the BNP metabolites was also 
tested using cells endogenously expressing natriuretic peptide receptors. Cell types, 
which are known to be essential in blood pressure homeostasis, have been utilized 
for such investigations. Results are described in the next chapter.  
3.5.2   Cells endogenously expressing natriuretic peptide 
receptors 
Vascular smooth muscle cells (VSMC), expressing both, NPRA and NPRB, have been 
isolated from murine aortas and cultured until passage 2 to 3 (see Method section 
2.2.9.5). Since the cell number varied between the single experiments due to 
methodogical reasons, cGMP generation upon BNP stimulation has been calculated as 
percentage and is illustrated as a summary of all experiments in Figure 43. Also here, 
BNP1-30 and BNP1-29 were more efficient in stimulating the receptors compared to 
BNP1-32. However, the bioactivity of BNP1-29 was comparable to BNP1-30 and not 
higher as seen in NPR-double transfected cells. BNP7-30- and BNP7-32-mediated 
cGMP generation was similar to BNP1-32. 
 
BNP1-32 BNP1-30 BNP1-29 BNP7-32 BNP7-30 
EC50 1.979e-008 1.312e-008 2.389e-008 3.620e-008 1.955e-008 
Top 47.03 57.36 86.37 46.92 55.32 
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Stimulation of primary human dermal microvascular endothelial cells (HDMEC), 
dominantly expressing endogenous NPRA, revealed a similar stimulation pattern 
compared to NPRA-transfected HEK293 cells (Figure 44a). The metabolites BNP1-30 
and BNP1-29 exerted stronger effects on the cells compared to BNP1-32, with 
BNP1-29 being again most active. BNP7-32 and BNP1-30 were similarly active 
compared to BNP1-32.  
Next, the stimulation of mesangial cells (MC), primarily expressing NPRB and 
influencing small resistance vessels in the kidney under physiological conditions, was 
performed (Figure 44b). Since the culture of these cells has been delicated and cell 
numbers were low, investigations were limited to BNP1-32 and the two most 
bioactive metabolites BNP1-30 and BNP1-29. 
BNP1-30 was again significantly more effective than BNP1-32 in stimulating cGMP 
formation. In contrast, BNP1-29 stimulation led to the generation of similar cGMP 
amounts compared to BNP1-32. Notably, this reflects what was observed in 
NPRB-transfected HEK293 cells (see section 3.5.1.3), however here the increased 
effects of BNP1-30 are less pronounced. 
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Figure 43:  Quantification of the cGMP levels after stimulation of vascular smooth muscle cells (VSMC) 
with BNP1-32, BNP1-30, BNP1-29, BNP7-32, and BNP7-30 with a peptide concentration of 10-7 M. 
Significances were calculated with One-way ANOVA:  # P < 0.05; ## P < 0.01 vs. BNP1-32 [n = 3 in 
triplicates]. 
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In all previous experiments bioactivity of the BNP metabolites has been determined 
by their ability to stimulate cGMP generation. To get a closer insight into the 
bioactivity of BNP1-32 and BNP metabolites, their vasoactivity has been investigated 
by determining their ability to induce vasorelaxation on isolated vessels in an ex vivo 
approach. 
3.6   Biological activity of BNP1-32 and BNP 
metabolites ex vivo  
Mesenteric arteries have been isolated from rats, mounted into a myograph system 
and stimulated with the peptides (see Method section 2.2.10). Since the myograph 
system allows a measurement of four vessel preparations in parallel, stimulations 
with BNP1-32, BNP1-30, BNP1-29, and water as a control have been performed 
simultaneously and were compared to each other.  
Experiments showed that all peptides were able to stimulate vasorelaxation of the 
vessels to a higher extend than natural vasorelaxation caused by water over time 
(Figure 45a). BNP1-29 was in trend more effective in relaxing the vessels compared 
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Figure 44:  Quantification of the cGMP levels after stimulation of a) human dermal microvascular 
endothelial cells (HDMEC) or b) mesangial cells (MC) with BNP1-32, BNP1-30, BNP1-29, BNP7-32 and 
BNP7-30 with a peptide concentration of 10-7 M. Significances were calculated with One-way ANOVA:  
# P < 0.05 vs. BNP1-32 [n = 3 in triplicates]. 
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to the other two metabolites however, without reaching statistical difference 
(Two-way ANOVA: P = 0.78 vs. BNP1-32 and P = 0.25 vs. BNP1-30). 
Figure 45b illustrates the difference in vasorelaxation with a peptide concentration 
of 10-6 M. BNP1-32 and BNP1-30 achieved a relaxation of about 72%, whereas 
BNP1-29 was with a value of 62% slightly more effective. 
The investigations revealed that the newly identified BNP metabolites BNP1-30 and 
BNP1-29 are able to induce vasorelaxation in isolated vessels similarly to BNP1-32. 
Thus, it is likely that BNP metabolites are also able to induce vasorelaxation under in 
vivo conditions, which would be indicated by a decrease in blood pressure. In the next 
chapter such experiments are described. 
3.7   Biological activity of BNP1-32 and BNP   
metabolites under normotensive conditions in 
vivo 
3.7.1  Rationale of the studies in vivo 
The bioactivity of the BNP metabolites has been characterized in vitro and ex vivo, 
whereby it was shown that all BNP metabolites investigated are bioactive. The two 
Figure 45:  a) Stimulation of isolated mesenteric arteries with different concentrations of BNP1-32, 
BNP1-30, and BNP1-29. Water stimulation functions as control; b) Summary of the stimulation of 
isolated mesenteric arteries with BNP1-32, BNP1-30 and BNP1-29 at a concentration of 10-6 M per 
peptide. Significances were calculated with One-way ANOVA: ** P < 0.01; *** P < 0.001 vs. control 
[n = 7]. 
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metabolites BNP1-30 and BNP1-29 were similarly or in the majority of experiments 
even more bioactive compared to BNP1-32.  Based on these findings, investigations to 
the effects of BNP metabolites under in vivo conditions have been considered. 
Therefore, an animal model has been utilized. In the following approaches, BNP1-32 
or BNP metabolites have been independently administered to mice in similar study 
designs in which their acute influence on blood pressure under normotensive 
conditions has been revealed.  
3.7.2   Acute effects of BNP metabolites on blood pressure in 
normotensive mice 
2.7.2.1 Study design 
In this approach, BNP1-32, the BNP metabolites, and saline, as a control, have been 
injected into the jugular vein of ventilated normotensive mice under anesthesia and 
hemodynamic parameters e.g. mean arterial blood pressure (MAP) and heart rate 
have been recorded by a millar catheter inserted into the left carotid artery (see 
Method section 2.2.11.1). The experiment was separated into three sets. Set1 
included the C-terminally truncated metabolites BNP1-30 and BNP1-29 in 
comparison to BNP1-32. Set2 included BNP7-32 and BNP7-30 compared to BNP1-32. 
Set3 included BNP1-32 and the peptide BNP1-45, an alternative variant of BNP found 
in rodents only (see Introduction section 1.2.1).  
3.7.2.2  BNP1-30 and BNP1-29 – Set1 
In the first experimental set the two new metabolites BNP1-30 and BNP1-29, which 
have been the most bioactive peptides in the in vitro studies, were characterized and 
compared with the actions of the mature BNP1-32.  
Figure 46 shows representative blood pressure curves for the infusion of either (a) 
saline, (b) BNP1-32, (c) BNP1-30, or (d) BNP1-29.  
Heart rate of mice under isoflurane anesthesia averaged between 450 to 600 bpm 
(grey scale). All peptide and saline injections did not change heart rate compared to 
the mean heart rate before injection. Figure 46a shows the changes in the MAP after 
injection of the peptides or saline. Saline injection did not change MAP compared to 
the baseline proving that the influence of volume expansion on the blood pressure is 
negligible (bp: +0.3 ± 1.4 mmHg, n = 5). In contrast, every peptide infusion resulted in 
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a transient decrease in blood pressure within the first minute after injection 
compared to their baselines. Interestingly, comparing the peptides, the newly 
identified metabolite BNP1-30 caused a two-fold higher decrease in the MAP 
(-6.8 ± 0.8 mmHg, n = 7) compared to BNP1-32 (-3.4 ± 0.65 mmHg, n = 7) without 
changing the action time. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This stronger effect of BNP1-30 confirms the data obtained in vitro, where BNP1-30 
was more potent compared to BNP1-32 in generating cGMP. However, BNP1-29, 
which was also more potent in NPRA-transfected cells compared to BNP1-32 had 
only comparable effect to BNP1-32 (-3.4 ± 0.5 mmHg, n = 7). BNP1-29 and BNP1-32 
injections decreased the MAP by 6% whereas BNP1-30 decreased MAP by 12% 
compared to baseline blood pressure.  
0 50 100 150 200
400
500
600
700
800
900
h
e
a
rt
ra
te
 (
b
p
m
)
BNP1-30
0 50 100 150 200
40
50
60
70
80
90
time (sec)

M
A
P
 [
m
m
H
g
]
BNP1-29
0 50 100 150 200
40
50
60
70
80
90
time (sec)

M
A
P
 [
m
m
H
g
]
0 50 100 150 200
400
500
600
700
800
900
h
e
a
rt
ra
te
 (
b
p
m
)
BNP1-32
0 50 100 150 200
40
50
60
70
80
90
time (sec)

M
A
P
 [
m
m
H
g
]
0 50 100 150 200
400
500
600
700
800
900
h
e
a
rt
ra
te
 (
b
p
m
)
0 50 100 150 200
300
400
500
600
700
h
e
a
rt
ra
te
 (
b
p
m
)
saline
0 50 100 150 200
40
50
60
70
80
90
time (sec)

M
A
P
 [
m
m
H
g
]
Figure 46: Representative blood pressure curves after a) saline, b) BNP1-32, c) BNP1-30 and d) 
BNP1-29 injection. Saline or peptides have been infused to normotensive mice after a stable baseline 
blood pressure was established (infusion indicated by red arrows). The left black scale shows the 
mean arterial blood pressure (MAP) in mmHg, the right grey scale shows the corresponding heart rate 
in beats per minute (bpm). 
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Figure 47b shows the cGMP levels in the blood taken by cardiac puncture after 
hemodynamic characterization. Since, the BNPs mediate their blood pressure effects 
trough NPR-stimulation, cGMP values should reflect their actions. Indeed it could be 
revealed that the values were elevated in the peptide-infused mice compared to the 
saline-infused animals. Moreover, cGMP values for BNP1-30-infused mice were 
significantly higher compared to the other BNP-infused groups, being congruent with 
the blood pressure data. 
 
3.7.2.3  BNP7-32 and BNP7-30 – Set2 
In a second set of normotensive animals, bioactivities of BNP7-32 and BNP7-30 have 
been compared to BNP1-32 and saline injections. Saline and BNP1-32 injections led 
to a very similar decrease in blood pressure as obtained in the first set proving 
reliability of the method (saline: +0.5 ± 0.8 mmHg, n = 5; BNP1-32: -3.4 ± 1.1 mmHg, 
n = 8; Figure 48a). Moreover, the data make clear that the BNP metabolites BNP7-32 
and BNP7-30 were both not able to significantly lower the blood pressure 
(BNP7-30: -1.6 ± 1.3 mmHg, n = 8; BNP7-32: -0.3 ± 0.4 mmHg, n = 8). These results 
are in part reflected by cGMP values measured in plasma of the same mice 
(Figure 48b). While the cGMP levels of the BNP1-32-injected mice were strongly 
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Figure 47:  a) Change in the mean arterial blood pressure (ΔMAP) in mmHg after bolus injection of 
BNP1-32, BNP1-30 or BNP1-29 in comparison to saline in an acute phase experiment in a 
normotensive mouse model; b) Quantification of cGMP levels in plasma samples obtained from the 
same mice after the injection of BNP1-32, BNP1-30, BNP1-29 and saline (in fold change). Significances 
have been calculated with One-way ANOVA:* P < 0.05, *** P < 0.001 vs. saline; # P < 0.05 vs. BNP1-32; 
§ P < 0.05 vs. BNP1-29 [n = 7 per peptide, n = 5 for saline]. 
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elevated compared to the saline-injected mice, tha levels in the BNP7-32-injected 
mice did not significantly differ from that of the control animals. The cGMP levels of 
BNP7-30-infused mice however were significantly elevated compared to saline and 
BNP7-32- infused mice but were lower compared to BNP1-32. Looking again on the 
blood pressure data and taking into account that since working with animals the SEM 
of parameters between different animals is naturally relatively high, the in trend 
decreased blood pressure and the elevated cGMP values after peptide injection 
indicate that BNP7-30 has some ability to decrease blood pressure. However, 
apparently BNP1-32 is more efficient in reducing the blood pressure compared to 
both BNP metabolites, BNP7-30 and BNP7-32. 
 
3.7.2.4  BNP1-30 and BNP1-45 – Set3 
In a third independent set of animals BNP1-30, which was revealed as the most 
potent BNP metabolite in vivo so far was compared to BNP1-45, a BNP metabolite 
generated by an alternative way of BNP processing found in rodents only (see 
Introduction 1.2.1).  
Both peptide injections caused a significant decrease of the blood pressure compared 
to the saline injection, whereby also here BNP1-30 was the more efficient peptide 
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Figure 48: a) Change in the mean arterial blood pressure (MAP) in mmHg after bolus injection of 
BNP1-32, BNP7-32 or BNP7-30 in comparison to saline in an acute phase experiment in a 
normotensive mouse model; b) Quantification of cGMP levels in plasma samples obtained from the 
same mice after the injection of BNP1-32, BNP7-32, BNP7-30and saline (in fold change). Significances 
were calculated with One-way ANOVA:  * P < 0.05, *** P < 0.001 vs. saline; # P < 0.05, ### P < 0.001 vs. 
BNP1-32 [n = 8 per peptide, n = 5 for saline]. 
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(BNP1-30: -6.3 ± 1.0 mmHg, n = 7 vs. BNP1-45: -3.6 ± 0.5 mmHg, n = 7 Figure 49a). 
BNP1-45 was similar effective compared to BNP1-32 in Set1 and Set2. The cGMP 
levels in blood samples of BNP1-30 and BNP1-45-infused animals were elevated 
compared to that of the control blood (Figure 49b). Although there was no 
significant difference between the cGMP levels of the two peptides, the 
concentrations in BNP1-30-infused mice were in trend higher compared to 
BNP1-45-infused mice.  
 
 
 
 
3.7.3  Summary of the metabolites’ bioactivity under 
normotensive conditions  
As suggested on the basis of the data in vitro and ex vivo, it could be shown that BNP 
metabolites BNP1-30, BNP1-29, and BNP7-30 exert biological activity under in vivo 
conditions. On the contrary, BNP7-32 did, if at all, only showed marginal influences on 
the blood pressure in this animal model. Importantly, it was revealed that the 
metabolite BNP1-30 is more effective in decreasing the blood pressure compared to 
BNP1-32 and other BNP metabolites. Apparently, the same concentration of the 
peptide even doubled the effect on the MAP compared to BNP1-32. Since BNP1-30 
showed these strong effects under normotensive conditions, it was decided to test its 
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Figure 49: a) Change in the mean arterial blood pressure (MAP) in mmHg after bolus injection of 
BNP1-30 and BNP1-45, a BNP metabolite generated by an alternative way of BNP processing found in 
rodents only, in comparison to saline in an acute phase experiment in a normotensive mouse model; b) 
Quantification of cGMP levels in plasma samples obtained from the same mice after the injection of 
BNP1-30, BNP1-45 and saline. Significances were calculated with One-way ANOVA: * P < 0.05, 
*** P < 0.001 vs. saline; § P < 0.05 vs. BNP1-30 [n = 7 per peptide, n = 5 for saline]. 
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actions also under pathophysiological conditions. The study design and the emerging 
results are described in the next chapter. 
3.8  Biological activity of BNP1-32 and BNP 
metabolites under hypertensive conditions  
3.8.1  Rationale of the approach 
Recombinant BNP1-32 (Nesiritide®) is approved for the treatment of cardiovascular 
diseases177. Since the previously performed approach in vivo (section 3.7) highlighted 
that the newly discovered BNP metabolite BNP1-30 exerts a stronger blood pressure-
lowering effect than BNP1-32 under normotensive conditions, it was aimed to 
compare the effects of both peptides under hypertensive conditions. An animal model 
of severe hypertension, the spontaneously hypertensive rat-model, has been chosen 
for such approach. 
3.8.2  The spontaneously hypertensive rat -model 
3.8.2.1 Study design 
Spontaneously hypertensive rats (SHR) develop hypertension without 
pharmacological intervention or surgical procedures around 5-6 weeks of age, 
reaching systolic pressures between 180 and 200 mmHg in adult age264. Due to this 
very high pressure, structural alterations like hypertrophy and fibrosis occur in the 
heart of these animals at the age of 6 month265. The model is similar to the 
etiopathology of essential hypertension in humans and is applicable to determine 
antihypertensive actions of drugs266, 267. The aim of this approach was to investigate 
the antihypertensive effects of the newly identified BNP1-30 in comparison to 
BNP1-32. 
In the experiment, minipumps filled with either saline or solutions of BNP1-32 or 
BNP1-30, have been implanted subcutaneously into 12-week-old animals and blood 
pressure has been measured after three days of continuous peptide administration 
(see Method section 2.2.11.2).  
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3.8.2.2 Influence on the blood pressure 
Animals in the control group that received saline had a systolic blood pressure (SBP) 
of 199.8 ± 2.1 mmHg (n = 6) indicating a state of severe hypertension in these animals 
(Figure 50). Administration of BNP1-32 and BNP1-30 over three days caused 
different alterations in the blood pressure. BNP1-32 administration did reduce SBP 
by approx. 13.5 mmHg (BNP1-32: 186.3 ± 4.4 mmHg, n = 6) compared to that of 
saline-treated animals without reaching statistical difference in the One-way ANOVA, 
but being equal to a P-value of 0.03 in the student’s t-test vs. saline. However, the 
treatment with the metabolite BNP1-30 led to a profound blood pressure drop-down. 
On average, SPB was reduced by 36.5 mmHg (BNP1-30: 163.3 ± 6.7 mmHg, n = 6). 
Thus, the reduction was almost 3-fold higher compared to that achieved with 
BNP1-32 treatment.   
The cGMP levels measured in the blood of the animals did not differ among the 
groups, but showed in trend increased values for both peptide-treated animals, 
whereby levels were highest in the BNP1-30-treated SHR (Figure 51). However, 
cGMP values of all groups have been very low and near the detection limit of the 
assay. Thus, variations in the cGMP levels appear large. Low cGMP levels have been 
reported before in these animals, likely caused by the cGMP-degrading enzyme 
phosphodiesterase 5 (PDE-5), which was shown to be up-regulated in SHR268. In 
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Figure 50: Systolic blood pressure (SBP) in mmHg of spontaneously hypertensive rats (SHR) treated 
with either saline, BNP1-32, or BNP1-30 by the administration through osmotic minipumps for three 
days; Significances have been calculated with One-way ANOVA: *** P < 0.001 vs. saline; # P < 0.05 vs. 
BNP1-32 [n = 6 per peptide or saline]. 
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parallel this indicates that the effects observed in these animals might not be solely 
mediated by a cGMP response. 
3.8.2.3 Analysis of cardiac markers 
Collagen 1 production was analysed by real-time polymerase chain reaction (rt-PCR, 
see Method section 2.2.5) in the hearts of the SHR by determining cardiac levels of 
COL1A1 mRNA, which is encoding for the pro-α1 chain of the collagen 1 precursor. 
COL1A1 mRNA levels were down-regulated in trend in both peptide-treated groups 
indicating that first improvements in cardiovascular remodeling took place within the 
three days (Figure 52a).  
Moreover, cardiac ANP and BNP mRNA levels have been measured by rt-PCR to 
reveal alterations of the cardiovascular status of the animals. ANP mRNA levels in the 
heart were down-regulated in both peptide-treated groups, but the effect was 
doubled through BNP1-30 administration (Figure 52b). Since the primary stimulus 
for ANP generation is wall stretch, and obviously this wall stretch was reduced 
through the decrease in blood pressure, the results of the ANP measurements are 
confirming the blood pressure data.  
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Figure 51: cGMP levels measured in blood of spontaneously hypertensive rats (SHR) treated with 
either saline, BNP1-32, or BNP1-30 by the administration through osmotic minipumps for three days; 
Significances have been calculated with One-way ANOVA [n = 6 per peptide or saline]. 
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For BNP1-32-treated SHR, there was no alteration of BNP mRNA levels compared to 
saline-treated animals. However, a significant down-regulation by around 40% in 
BNP1-30-treated animals compared to saline-treated rats was observed 
(Figure 52c). 
 
Similar to ANP, BNP generation is induced by wall stretch of the myocardium. Thus, 
the difference in BNP mRNA levels between the peptide-treated groups also here 
confirms the blood pressure data. A possible negative feedback mechanism on BNP 
generation through the administration of BNP seems not to be present, since BNP 
levels are unaltered in BNP1-32-treated animals. Since BNP is used as a biomarker for 
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Figure 52: a)  cardiac COL1A1 mRNA levels in fold change, b) cardiac ANP mRNA levels in fold change, 
and c) cardiac BNP mRNA levels measured in fold change of spontaneously hypertensive rats (SHR) 
treated with either saline, BNP1-32, or BNP1-30 by the administration through osmotic minipumps for 
three days; Significances have been calculated with One-way ANOVA: * P < 0.05, ** P < 0.01 vs. saline; # 
P < 0.05 vs. BNP1-32 [n = 6 per peptide or saline]. 
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the progression of cardiovascular diseases186-189, the decrease of BNP mRNA through 
the treatment of BNP1-30 indicates an improvement of cardiovascular health of the 
animals. Obviously this improvement was not achieved with the conventional 
BNP1-32-treatment. 
3.8.3  Summary of the actions of BNP1-32 and BNP1-30 under 
hypertensive conditions 
In a model of severe hypertension, it could be highlighted that the newly discovered 
BNP metabolite BNP1-30 was more efficient in reducing hypertension compared to 
BNP1-32. This effect was almost 3-fold higher than that achieved by the treatment of 
the conventional BNP1-32. This finding and also the results obtained from other in 
vivo experiments described in this thesis, strongly indicate that the newly discovered 
BNP metabolites and especially BNP1-30 are not just intermediate products in the 
metabolism of BNP on the way to BNP inactivation, but might represent comparable 
or even superior treatment options for hypertension and possible other blood 
pressure-associated diseases compared to BNP1-32. 
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4   DISCUSSION 
4.1  Significance of peptide metabolism 
Peptide metabolism plays an essential role for the efficiency of peptide systems. Such 
peptide metabolism has been investigated in major peptide systems like the renin-
angiotensin system, another important player in blood pressure homeostasis besides 
the natriuretic peptide system269, 270. A key peptide of the renin-angiotensin system, 
the octapepide AngII, is the bioactive form of angiotensinogen formed by the actions 
of renin271 and ACE174. AngII has been found to be metabolized into many truncated, 
but bioactive peptides. Such metabolites are e.g. AngIII (2-8)272, AngIV (3-8)273 and 
Ang-(1-7)274. But, they are not only biologically active, they also exert their biological 
effects in part through different receptors. While AngII and AngIII have similar 
affinities towards the AngII receptor subtypes (AT) AT1 and AT2275, 276, Ang-(1-7) was 
observed to be associated with Mas signaling277. The metabolite AngIV binds to the 
AT4, which is a transmembranal enzyme, the insulin-regulated membrane 
aminopeptidase (IRAP), indicating that AngIV is involved in glucose uptake278, 279 and 
thus has a different physiological function than its precursor AngII. Moreover, 
metabolites of AngII are formed by different peptidases as e.g. ACE2 (Ang-(1-7) from 
AngII)280 and aminopeptidase A (AngIII from AngII)281.  
Peptide metabolism appears also in other peptide systems. Bradykinin (BK), a 
vasoactive nonapeptide of the kinin-kallikrein system with cardioprotective effects, 
was shown to be metabolized in circulation forming BK(1-5)157 and  BK(1-7)282. 
Big-endothelin-1 (Big-ET-1) from the endothelin system, which is another important 
system in the homeostasis of blood pressure, is despite its activation to ET-1 with 
greater vasoconstrictive potency than any known substance283, also cleaved forming 
ET-1(1-31)158. This metabolite is amongst other properties also a potent 
vasoconstrictor. 
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Metabolism within the natriuretic peptide system has not been described intensively. 
In this thesis BNP metabolism has been investigated comprehensively and it was 
disclosed that BNP is, similarly to other vascoactive peptides, metabolized by 
different enzymes forming a variety of BNP metabolites and that this metabolism 
plays an essential role in many ways. 
4.2  The newly disclosed metabolism of BNP1-32 
4.2.1  The metabolism of BNP1-32 is organ-specific 
Processing of BNP starts with the formation of pro-BNP from pre-proBNP140. This 
precursor is than cleaved by the actions of corin and furin into the N-terminal 
fragment NT-proBNP and the bioactive mature fragment BNP1-3219. The work of this 
thesis revealed, that against the common view that BNP1-32 represents the endpoint 
of BNP processing, the peptide is further metabolized into BNP metabolites in a 
complex process. In fact, the very first approach described in this thesis already 
indicated that this metabolism must be complex. This first experiment showed that 
the velocity of BNP proteolysis is divergent among the organs although protein 
concentrations of all membrane preparations used had been normalized (see Results 
section 3.1.1.1). Furthermore, it was revealed that proteolysis of BNP1-32 is 
accompanied by the generation of a variety of BNP metabolites. Six novel BNP 
metabolites were discovered namely BNP1-31, BNP1-30, BNP1-29, BNP7-31, 
BNP7-30, and BNP7-29. Most BNP metabolites were only generated in particular 
organs, while others were not formed there. For example, it was disclosed that the 
BNP metabolite BNP1-30 was generated in heart, lung, liver, and spleen, but not in 
kidney (see Results section 3.1.1.2). Vice versa, it was shown that BNP7-32 is 
generated in kidney, but not in other organs investigated. Similarly, it was disclosed 
that BNP1-29 is initially generated in heart only and BNP1-31 was solely identified 
using blood preparations (see Results section 3.1.3.3). Thus, the first main conclusion 
from the work of this thesis is that BNP metabolism is organ-specific.  
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4.2.2  The coactions of different organs leads to the metabolism 
of BNP1-32 
Investigations revealed that some BNP metabolites generated in particular organs can 
be further metabolized in other organs. For example, it was observed that the BNP 
metabolite BNP7-32 formed in kidney can undergo a C-terminal truncation in lung 
and spleen to form BNP7-30 (see Results section 3.1.1.5). Furthermore, it was 
disclosed that BNP1-29 formed in heart can be truncated into BNP7-29 in kidney. In 
general it was observed that while in kidney mainly an N-terminal truncation takes 
place, in liver and spleen mostly a C-terminal truncation of BNP metabolites appears. 
Through the use of different organ membrane preparations it was however possible 
to successively generate every newly identified BNP metabolite including the shortest 
identified BNP metabolite BNP7-29. Only this stepwise truncation leads to full 
proteolysis of BNP1-32. Thus, according to these results, the second main conclusion 
from this work is that full proteolysis of BNP1-32 needs the involvement of several 
organs.  
All organs are connected to each other through the circulation, which allows the 
transport of dissolved compounds from organ to organ. It is thus conceivable that 
some BNP metabolites are specifically produced in one organ and are then 
transported through the circulation to another organ, in which further metabolism 
can be realized, whereby also the blood exerts its own proteolytic activity towards 
the peptides. Therefore, it is hypothesized that the connection of different organs 
through the circulation allows the formation of a network for full metabolism and 
degradation of BNP1-32. Such a network has been illustrated in Figure 53. 
4.2.3  Enzymes involved in BNP metabolism 
It was revealed that the generation of BNP metabolites is organ-specific and that full 
metabolism needs the coactions of different organs, since they harbor the different 
peptidase activities responsible for the formation of different BNP metabolites. To 
develop a new overview about BNP processing, the newly identified pathways in the 
formation of BNP metabolites including the role of particular enzymes are shortly 
summarized here. A variety of potential candidates being responsible for BNP1-32 
metabolism have been identified. Notably, the formation of every single BNP 
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metabolite identified during incubations with membrane preparations of organs and 
blood preparations could be reproduced with one or more recombinant enzymes. 
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BNP1-32 and BNP metabolites. All organs are connected to each other through blood circulation and 
thus, the transport of BNP metabolites to each organ is possible. All metabolites actually detected 
through the incubation of BNP1-32 or initial BNP metabolites with membrane preparations or blood 
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Two of these enzymes are involved in the generation of BNP1-30. Recombinant ECE-1 
is able to hydrolyze the C-terminal dipeptide from BNP1-32 generating BNP1-30. 
Similarly, ECE-1 hydrolyzed the same dipeptide at the C-terminus of BNP7-32 
generating BNP7-30. A second peptidase, CPA, was identified to catalyze the 
formation of BNP1-30 via the intermediate product BNP1-31. Similarly, CPA was able 
to form BNP7-30 from BNP7-32 through the intermediate product BNP7-31. In 
parallel it was shown that other recombinant carboxypeptidases like ACE, ACE2, 
CathA, and PRCP were not able to cleave BNP1-32. Furthermore, it could be disclosed 
that CPB is able to metabolize BNP1-30 into BNP1-29 and similarly BNP7-30 into 
BNP7-29. Finally, it was shown that meprin A is besides its role in the formation of 
BNP7-32 from BNP1-32 also able to hydrolyze substrates as BNP1-30 and BNP1-29 
forming BNP7-30 and BNP7-29. 
Notably, it could be shown that inhibitors of these enzymes supplemented into the 
incubations with membrane preparations or blood preparation were able to decrease 
BNP metabolite formation. The ECE-1 inhibitor SM19712 diminished the formation of 
BNP1-30 in lung and liver, while the carboxypeptidase inhibitor, inhibiting CPA, was 
attenuating BNP1-30 formation in heart and spleen. Furthermore, it was observed 
that the presence of the CPB inhibitor GEMSA completely abolished the formation of 
BNP1-29 and BNP7-29 in blood preparations. Since it could be proven that enzyme 
inhibitors were able to diminish BNP metabolite formation in the incubations, it can 
be hypothesized that these particular enzymes are likely responsible for BNP 
metabolite formation under physiological conditions. As a third main conclusion it 
can be stated that a variety of enzymes are involved in the formation of BNP 
metabolites framing a much more complex picture of BNP processing than described 
in the literature. 
4.2.4  The role of BNP metabolism for the degradation by NEP 
NEP was thought to be the main enzyme inactivating natriuretic peptides120, 122. 
However, in an approach of Walther et al. in 2004 it was shown that inhibition of NEP 
in tissues like kidney and heart, using the specific inhibitor candoxatrilat, does 
decrease proteolysis rates of the natriuretic peptides ANP but not of BNP1-32125. In 
the same work it was shown that proteolysis rate of BNP1-32 was unchanged in 
tissues from NEP knockout mice compared to wild type controls. Thus it was revealed 
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that BNP1-32 is not a primary substrate for NEP125. In own work prior to this thesis a 
model has been established showing that N-and C-terminal length are decisive for the 
degradability of natriuretic peptides20. The results of this thesis confirm this model, 
since it was revealed that shorter BNP metabolites are better substrates for NEP. 
Additional data of the work might give new insight into the mechanism of NEP. It was 
revealed that the newly identified metabolite BNP1-30 with a C-terminal truncation 
by two amino acids is still not degradable by NEP (see Results section 3.4). However, 
the additional truncation by the C-terminal lysine in the newly discovered BNP1-29 
markedly increased the degradability similar to that of the N-terminally truncated 
BNP7-32 and the likewise newly discovered BNP7-30. Obviously, the C-terminal 
lysine plays a decisive role in the adjustment of the peptide in the catalytic center of 
NEP. To date, a concrete model showing the interaction of particular amino acids of 
BNP1-32 with binding sites of NEP is not available. It might be possible that the 
missing lysine, which is positively charged, decreases the repulsion between the 
peptide and the peptidase and thus the peptides’ adjustment in the catalytic cavity of 
NEP is favored. The new metabolites BNP7-31 and BNP7-29 have not been available 
as recombinant peptides, however, according to the derived model for the 
degradation of natriuretic peptides by NEP (see Introduction section 1.1.5.3) it was 
anticipated that they are degradable by the enzyme. 
The increased degradability of the majority of the BNP metabolites in comparison to 
BNP1-32 highlights the importance of the BNP metabolism for the clearance of 
circulating BNP. 
4.2.5  A new model of BNP processing 
Based on the results of this thesis a new overview about BNP processing is drawn in 
Figure 54. The upper part of the scheme shows the conventional pathway of BNP 
processing as described in the literature and leading to the formation of NT-proBNP 
(76 aa) and the bioactive BNP1-32 (32 aa), which has been designated as the mature 
BNP19, 284. All newly disclosed pathways leading to BNP metabolism have been added 
to this overview. All enzymes discovered being able to metabolize BNP1-32 or BNP 
metabolites are displayed. NEP cleavage sites have been indicated at the respective 
BNP metabolites. 
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Figure 54: Overview about the possible processing of BNP in the murine system starting from the 
precursor pre-pro BNP towards the metabolite BNP7-29. Known enzymes able to catalyze the 
cleavages towards BNP metabolites are named. The NEP cleavage site in particular BNP metabolites 
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(ECE-1); carboxypeptidase A (CPA); carboxypeptidase B (CPB), neprilysin (NEP) 
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4.2.6  Limitations of the incubation studies 
It might be possible that more metabolites emerge from BNP processing in other 
organs. Moreover, it is possible that metabolites like BNP7-30 or BNP7-29 are, 
despite their inactivation by NEP, further metabolized leading to the generation of 
more BNP metabolites. However, there are methodical reasons that might have lead 
some BNP metabolites undetected in the approaches performed. The presence of a 
peak in the chromatograms is dependent on the generation, but also on the 
proteolysis of the peptide behind that peak. A peak can only be seen in the 
chromatogram, when its generation is faster than its proteolysis. The preparations 
harbor a multitude of enzymatic activities. In case a newly formed peptide is directly 
further proteolyzed and this reaction has faster kinetics than its generation, the peak 
will not rise in the chromatogram. Such phenomena might be seen in blood 
incubations. It was revealed, that BNP metabolites have different stability in serum 
compared to BNP1-32 due to their truncations on the N-and C-termini (see Results 
section 3.1.3.4). While BNP1-29 was similarly stable as BNP1-32, BNP1-30 has 
drastically reduced stability. The same was true for BNP7-30, while its subsequent 
cleavage product BNP7-29 was more stable. Thus, only precursors or proteolysis 
products of these peptides can be seen in the chromatogram. 
Furthermore, all peptidase activities present on blood cells could not be considered, 
since cells have been removed during preparation of serum and plasma. Thus, it 
might be that more BNP metabolites are formed under physiological conditions. 
Additionally, it needs to be noted, that the blood preparations have been diluted to 
perform the experiments. The reason for this was on the one hand, that proteolysis of 
e.g. BNP1-30 in undiluted blood is so fast that minimal differences (e.g. pupating) in 
the handling time of repeated measurements cause very big changes in proteolysis 
time. On the other hand, undiluted serum samples would massively contaminate the 
HPLC system and lead to a blockage of the column. The dilution of the blood was done 
with water, which causes changes in the colloid osmotic pressure in the blood 
samples. Thus, proteolysis times revealed in the experiments cannot be extrapolated, 
and thus exact kinetics could not be determined. To reveal real half-life times of the 
metabolites, an approach in vivo could be performed. An overview about such an 
experiment is given in section 4.2.8. 
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4.2.7  The different impact of proteolytic activities in BNP1-32 
metabolism 
As stated above it is anticipated that metabolism of BNP needs the coactions of 
enzymes of different organs including blood. It remains to be clarified which of the 
peptidase activities has the highest impact on BNP metabolism. Certainly, the blood 
represents a major proteolytic activity towards BNP1-32, however, perfusion of huge 
organs like lung and liver surely plays a significant role in BNP metabolism. In 
contrast to heart and spleen preparations, faster proteolysis of BNP1-32 was 
observed in lung, liver, and kidneys (see Results section 3.1.1.1). In parallel, these 
organs represent the organs with the highest perfusion rates in the body as measured 
by their percentage of bodymass285. The lung itself has the highest perfusion rate and 
measured by this, the perfusion of the heart is less than 10%. Thus, BNP processing 
might be, despite in blood, most significant in these organs. Moreover, it is possible 
that more metabolites are generated in other organs and tissues of the body that have 
not been examined during this study. Organs in which BNP processing might be 
significant could be thyroid, adrenal, and small intestine where small quantities of 
BNP transcripts have been found26 and a local processing might be conceivable.  
Moreover, it is essential to investigate BNP metabolism in a gender-dependent 
manner. The presence of gender-dependent physiological characteristics e.g. sexual 
organs could be accompanied with a qualitatively and quantitatively altered 
expression on gene and protein-level, subsequently leading to a differentially 
regulated BNP metabolism. Different expression profiles of enzymes have been 
documented in males and females e.g. higher ACE2 activity in males than females286, 
or different expression of CPB in aged males and females287. Moreover, BNP 
transcripts have been specifically discovered in ovary and uterus26, indicating that a 
specific mode of BNP processing might have been developed in females but not in 
males. A gender-dependent regulation of BNP processing might be a prerequisite for 
the significant differences observed in the development of cardiovascular diseases in 
males and females, evidenced by numerous reports288-291. Thus, processing of BNP1-
32 should be investigated apart from an approach targeting BNP metabolism in the 
body as a whole proteolytic system also in a gender-dependent manner. 
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4.2.8  The complexity of BNP metabolism - a future study 
The investigation of BNP metabolism as a whole could be realized by a targeted 
infusion of BNP1-32 into female and male animal models. This kind of approach 
would allow the distribution of the peptide to all organs and would thus give 
indications about BNP metabolism under physiological conditions including all 
proteolytic activity present towards BNP1-32 and also towards BNP metabolites. The 
experimental setting of such an approach needs to include precise calculations of the 
time BNP would need to pass the system. In theory, in an adult mouse with an approx. 
blood volume of 2.5 ml, a typical ejection fraction of 55 µl292 and a heart rate of 
approx. 500 bpm, the total volume would be pumped within approx. 12 seconds 
through the body. Thus, after such time period, blood samples for the identification of 
emerging BNP metabolites need to be taken. The correct handling of these blood 
samples is essential. As revealed in this thesis, some BNP metabolites are quickly 
degraded within the blood. Thus, blood samples need to be collected in the presence 
of enzyme inhibitors to avoid further metabolism of BNPs in the test-tube. Such 
enzyme inhibitors should be aprotinin, EDTA, and carboxypeptidase inhibitors 
especially the CPB inhibitor, since CPB was suggested to be the enzyme tremendously 
fast metabolizing BNP1-30 and BNP7-30 in serum (see Results section 3.3.2.3). 
Finally, a method needs to be assessed to allow identification of BNP metabolites 
present in these blood samples. The identification of those will however be the most 
challenging step. Since peptide quantities infused must not be too high to allow 
reasonable investigations under physiological conditions, concentrations of the single 
emerging BNP metabolites will be too low for the detection with UV-light as used in 
the HPLC approaches before analyzing BNP metabolites in the incubation studies. An 
alternative approach would be a targeted labeling of the peptide being infused, to 
increase the sensitivity of its detection. Such labeling could be performed with 
fluorescent- or radioactive compounds, whereby the position of the label plays a 
decisive role. A C- or N-terminal labeling would not make sense, since the formation 
of BNP metabolites through truncations on their C and N-termini would lead to a loss 
of the signal. Thus, a labeling must be realized within the ring-structure of the 
peptide. Such labeling must not influence the tertiary structure of the peptide as such, 
that peptidases are no longer able to cleave the peptide. Other than for the 
fluorescent labeling which often utilizes large compounds such as fluorescein, which 
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was also shown to influence detection methods like electrophoresis293, radiolabeling 
with the e.g. very small tritium would be more suitable294, 295. The detection of 
radiolabeled peptides requires the use of a liquid scintillation counter (LSC) when 
using an HPLC approach. Otherwise, the use of radio immune assays or 
autoradiography with primary separation of the BNP metabolites with gel 
electrophoresis could be considered. Since there are no specific antibodies for the 
single BNP metabolites, a standard radio immune assay cannot be performed. The use 
of autoradiography would require a sufficient separation of BNP metabolites by gel 
electrophoresis beforehand. Since BNP metabolites mostly differ just in one or very 
few amino acids, such a method needs to be optimized first. Appropriate preliminary 
experiments separating BNP metabolites with gel electrophoresis have been 
performed using tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(tricine-SDS-PAGE) according to Schaegger et al. as a start point226. Through an 
optimization of the method it was possible to separate BNP1-32 from BNP7-32 and 
even BNP1-30 (see supplements Figure S1).  
In summary, such approach would disclose the BNP metabolism resulting from the 
actual network of organs and circulation under physiological conditions. A 
simultaneous infusion of enzyme inhibitors inhibiting peptidases responsible for BNP 
metabolism, would moreover allow the identification of the impact of distinct 
enzymes such as ECE-1 in BNP metabolism.  
Besides this reasonable approach it is however of overriding interest to establish a 
method for the detection of endogenously occurring BNP metabolites. The 
development of such a method is very challenging, since endogenous metabolite 
quantities are potentially very small. A description of possible methodogical 
procedures can be found in section 4.7. 
4.3  Bioactivity of the newly discovered BNP 
metabolites 
The bioactivity of the BNP metabolites has been characterized in vitro (see Results 
section 3.5), ex vivo (see Results section 3.6) and in vivo (see Results section 3.7 and 
3.8). It was shown that all BNP metabolites investigated are bioactive. Notably, the 
two metabolites BNP1-30 and BNP1-29 were in the majority of experiments even 
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more bioactive compared to BNP1-32. The metabolite BNP7-32 was less bioactive 
compared to BNP1-32 and all other BNP metabolites. The additional truncation on 
the C-terminus in BNP7-30 seems to have a favorable effect on bioactivity, since its 
activity was in the majority of experiments higher compared to BNP7-32 or even 
comparable to BNP1-32.   
The N- and C-termini of the peptides obviously play an important role in the 
stimulation of the natriuretic peptide receptors. The C-terminal truncation of two 
amino acids like in BNP1-30 increases the formation of cGMP by the NPRA. The 
truncation of one more amino acid like in BNP1-29 seems to have an additional 
favorable effect on cGMP generation via the NPRA. Labrecque et al. hypothesized a 
model in which the dimerization of NPRA takes place either in a tight and loose 
conformation296. Thereby, binding of natriuretic peptides on the receptor tightens the 
contact of both receptor subunits. The tight state exerts high guanylyl cyclase 
activation. It was hypothesized that binding of BNP is less efficiently tightening the 
receptor subunits than the smaller ANP. Since the C-terminal-truncated BNP 
metabolites show increased stimulation of the NPRA it might be possible that the 
effects seen are caused by an increased induction of tight NPRA dimerization. 
Notably, BNP1-30 increased cGMP generation on the NPRB compared to BNP1-32 
and all other BNP metabolites. Also during acute infusion of BNP metabolites into 
normotensive mice, BNP1-30 was by far the most effective metabolite (see Results 
section 3.7). The reduction of blood pressure by this peptide was doubled compared 
to BNP1-32. Notably, the increased bioactivity of BNP1-29 compared to BNP1-32 in 
vitro was not seen in this in vivo study. Although the peptide has higher activity on 
NPRA- and NPRA & NPRB-double-transfected HEK293 cells, on smooth muscle and 
endothelial cells, it is not more potent in blood pressure reduction during acute 
infusion compared to BNP1-32. In contrast BNP1-30, which was also more potent, 
compared to BNP1-32 in the just specified in vitro experiments, was more potent in 
reducing the blood pressure. However, BNP1-29 shows less bioactivity compared to 
BNP1-30 in two experiments: the stimulation of NPRB-transfected cells and the 
stimulation of mesangial cells, both showing the actions of the peptides on NPRB. This 
indicates that NPRB might play a distinctive role during blood pressure regulation in 
the acute infusion experiment. It might also be possible, that an additional unknown 
receptor of BNP is present, mediating the observed effects. Some groups 
hypothesized the existence of an unknown receptor for BNP56, 297. Such a receptor 
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must have a higher binding affinity towards BNP1-30 compared to BNP1-32 and 
BNP1-29.  
Concrete binding studies of the metabolites towards their receptors should be 
performed to reveal the specific effects of the missing amino acids on the binding 
affinities towards NPRA and NPRB. 
4.4  The newly identified metabolite BNP1-30 
4.4.1  The generation of BNP1-30 is an additional activation of 
BNP1-32 
The generation of BNP1-30 seems to be a common pathway of BNP processing. The 
metabolite is formed in lung, liver, heart, and spleen preparations. Moreover, it was 
proven that it is formed in an intact liver after perfusion with BNP1-32 (see Results 
section 3.1.2.1). Although the metabolite is abundantly formed, the enzymes 
responsible for its generation differ among the organs. Both ECE-1 and CPA are able 
to form BNP1-30 from BNP1-32 and it might be that an additional peptidase in heart 
and spleen is able to catalyze its generation (see Results section 3.2.2 and 3.2.5). The 
multitude of enzymes involved in the generation of the metabolite and its abundant 
formation in many organs is highlighting that generation of BNP1-30 must be a 
volitional and essential step in the processing of BNP1-32. This is supported by the 
fact that BNP1-30 is more bioactive compared to BNP1-32, especially under in vivo 
conditions and even under pathological circumstances. This increased bioactivity is 
summating from an increased activity on the NPRA and in parallel from an increased 
activity on the NPRB. Thus, it can be concluded that the formation of BNP1-30 
represents a further activation of BNP1-32.  
4.4.2  The altered receptor profile of BNP1-30  
4.4.2.1  Implications for the design of recombinant natriuretic peptides 
BNP1-30 represents an exceptional case among the BNP metabolites including 
BNP1-32. It was discovered, that the generation of cGMP via the NPRB is about 3-fold 
higher for this newly identified metabolite compared to all others (see Results 
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3.5.1.3). The removal of the two C-terminal amino acids enables the peptide to better 
stimulate the receptor than its precursor BNP1-32 or its subsequent cleavage product 
BNP1-29. Thus, BNP1-30 is besides its ability to strongly induce cGMP generation via 
the NPRA axis, also able to stimulate the NPRB axis and represents a unique receptor 
profile among all BNPs investigated and moreover among all endogenously expressed 
natriuretic peptides known. A similar receptor profile, although more pronounced for 
the NPRB, was observed for the chimeric peptide ACNP consisting of the ring 
structure of CNP and the N-and C-terminus of ANP129. However here, the C-terminus 
of the peptide is not truncated but the incorporation of fragments of peptides either 
stimulating NPRA or NPRB seems to be decisive for the receptor profile (see 
Introduction section 1.1.6). Apart from that, it might also be conceivable that 
metabolites of other natriuretic peptides like ANP and CNP, which have not been 
investigated so far, do have altered receptor affinities. Thus, it would be highly 
interesting to measure binding affinities of recombinant natural or chimeric 
natriuretic peptides towards the natriuretic peptide receptors and to reveal the 
particular amino acids that interact with the receptors. It might be conceivable that a 
chimeric peptide of the CNP ring-structure and the C- and N-terminal arms of 
BNP1-30 can stronger activate both receptors. Own appropriate experimental studies 
following this approach have been initiated. 
4.4.2.2  Implications for pathophysiology 
The increased activity of BNP1-30 towards the NPRB might be an explanation for a 
physiological phenomenon observed in a model of BNP-overexpression. Suda et al. 
described that animals having more than 3-fold higher copy numbers of the BNP 
transgene, have long bone growth including an elongation of limbs, paws, and tails 
and other skeletal malformations like kyphosis108 (see Introduction 1.2.3). Notably, 
ANP-overexpressing mice with plasma ANP concentrations elevated at least 8-fold, as 
compared with nontransgenic littermates, do not show skeletal alterations298. 
Interestingly, BNP-overexpressing mice that are additionally knocked down for the 
NPRA, the receptor for ANP and BNP1-32, continue to exhibit marked longitudinal 
growth of vertebrae and long bones comparably to the BNP-overexpressing mice with 
normal NPRA expression297. Originally it was observed, that the CNP/NPRB axis is 
responsible for the skeletal development and that NPRB knockout mice develop a 
severe phenotype of dwarfism and bon malformation93. Assuming that BNP-
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overexpressing mice also have higher levels of the metabolite BNP1-30, which is able 
to markedly stimulate the NPRB, this additional action on the NPRB axis possibly 
explains the observed effects. In early years a report has been published suggesting a 
correlation between scoliosis and congenital heart diseases299 and Liu et al. reported 
recently high incidences of cardiac abnormality in Asian patients with adolescent 
idiopathic scoliosis300. Since BNP levels are markedly upregulated during certain 
cardiac diseases there might be a significant influence of BNP on this malformation, 
although very little reports can be found investigating the correlation between 
skeletal and cardiac disorders, respectively. 
4.4.3  BNP1-30 under hypertensive conditions 
Since BNP1-30 had a profound and much stronger effect on blood pressure reduction 
under normotensive conditions compared to BNP1-32 and other BNP metabolites 
(see Results section 3.7) a model of severe hypertension, the SHR model, has been 
used to reveal the actions of BNP1-30 in comparison to BNP1-32 under pathological 
conditions. Within the study it was mainly focused on their actions on blood pressure 
but first insights into their effects on fibrosis have also been revealed. It was decided 
to use minipumps continuously administering the peptides rather than performing 
repeated injections, since dosing by injections can increase plasma levels exceeding 
the drugs’ effective concentration, resulting in toxicity or simply wasting of the 
compound. Likewise, the therapeutic effect of the injected drug can vanish between 
the injections because of its decrease below effective doses. 
4.4.3.1  Effects of BNP1-30 on blood pressure under hypertensive 
conditions 
A massive difference in the blood pressure measured after three days was observed 
between the groups. While there was no significant difference between the saline and 
the BNP1-32-treated animal groups, BNP1-30 reduced the blood pressure by more 
than 30 mmHg (see Results section 3.8.2.2). Several reasons for this substantial 
difference between the effects of the peptides are conceivable. 
It was revealed that both, BNP1-32 and BNP1-30, show the same vasorelaxing effects 
on isolated mesenteric arteries of rats in the ex vivo approach performed during the 
work of this thesis (see Results section 3.6). Thus, the more potent effects of BNP1-30 
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on blood pressure seen in the SHR might not be related to its actions on mesenteric 
arteries. However, these experiments have been performed on mesenteric arteries 
from healthy animals. It might be that effects of the peptides are different in 
pathologically altered mesenteric arteries from SHR. It has been reported that smooth 
muscle cells in mesenteric arteries of the SHR have a slower relaxation rate and 
contract more and faster301. Ex vivo experiments using arteries from SHR might shed 
light on possible differential effects of BNPs under pathological conditions compared 
to normal conditions. However, it has been shown in this thesis that BNP1-30 has 
increased bioactivity on isolated primary VSMC from aortas and on mesangial cells 
isolated from kidneys compared to BNP1-32. It has been reported that mesangial cells 
from SHR show a significantly higher growth rate than those from Wistar Kyoto rats 
(WKY) probably being involved in the development of hypertension in this animal 
model302. It might be that the increased vasorelaxing activity of BNP1-30 in 
comparison to BNP1-32 on these cells is of special importance in the reduction of 
blood pressure in SHR. 
It has been described in the literature that NPRA is downregulated during 
cardiovascular diseases but NPRB is not77. It might be that NPRB-levels are also 
downregulated in SHR due to their severe hypertension and the accompanied adverse 
effects on heart function. Thus, the strong effects seen for BNP1-30-treatment might 
be in part mediated by its unique effects on the NPRB. However, no significant 
increases in cGMP levels have been observed in the blood of the BNP1-30-treated 
SHR (see Results section 3.8.2.2). In general cGMP levels found in blood of the 
untreated SHRs and peptide-treated animals were similarly low. The accumulation of 
cGMP is dependent of its generation and clearance. The clearance of cGMP is realized 
by phosphodiesterase-5 (PDE5) that degrades cGMP intracellularly303 and by the 
multidrug resistance protein 5 (MRP5/ABCC5), which functions as a cellular export 
pump for cGMP304. Thus, the potential effects of the second messenger are limited to 
its generation, export and degradation. Generation of cGMP is on the one hand 
mediated by the stimulation of natriuretic peptides on their receptors and the 
subsequent activation of receptor-bound guanylyl cyclase catalyzing the formation of 
cGMP from GTP305. On the other hand, cGMP production can be derived by nitric-
oxide stimulation of soluble guanylyl cyclase306. PDE5 was shown to be responsible 
for the hydrolysis of cGMP derived from the latter mentioned mechanism307. 
However, recently, evidence was generated for a functional retargeting of PDE5 from 
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one cellular compartment to another, revealing a role for natriuretic peptide-derived 
cGMP hydrolysis by this esterase in diseased heart myocardium308. Since PDE5 
expression is highly increased in the hearts of SHR309, cGMP degradation is likely 
highly increased in these animals. Thus, less cGMP can be exported through the cGMP 
transporter, which could at least in part explain the low cGMP values measured in 
blood. Moreover, there is indication that the ABCC5 transporter expression is 
differently regulated in cardiovascular diseases310 probably also in hypertension. 
Measurement of cGMP levels in tissues of the SHR might give an explicit insight in the 
effects of BNP-treatment on cGMP homeostasis.  
4.4.3.2  Effects of BNP1-30 on fibrosis under hypertensive conditions 
It was shown before, that BNP1-32 exerts antifibrotic activity by antagonizing the 
production of collagen I through TGF-β stimulation311. Collagen I is the most 
abundant collagen in the body and forms thin fibrils that cross-link to one another in 
the spaces around cells312. Already in 1956, it was discovered that extensive 
production of collagen yields in the formation of fibrosis313. In the thesis mRNA of 
COL1A1 was determined. The gene encodes for the pro-α1 chain which forms 
together with the pro-α2 chain the type I procollagen312. Procollagen I is processed 
forming collagen I. COL1A1 mRNA was slightly reduced in BNP1-32 and also 
BNP1-30-treated SHR showing that both peptides are exerting antifibrotic effects (see 
Results section 3.8.2.3). Impressingly, this effect was seen already after three days of 
treatment. Cardiac fibrosis is developing in early age in the SHRs. The results revealed 
that the peptides might be able to reverse also existing fibrosis as indicated by a 
decreased production of pro-α1 mRNA. Interestingly, both peptides had similar 
effects in this manner although their ability to reduce blood pressure was divergent. 
It is thus indicated that both peptides have direct, blood pressure-independent effects 
on the development of cardiac fibrosis. It has been suggested, that BNP possibly 
mediates its anti-proliferative effects in cardiac fibroblasts also through the NPRC 
axis101. It is thus conceivable that BNP1-32 and BNP1-30 have similar affinities 
towards this receptor just as observed for all classical natriuretic peptides50. 
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4.4.4  Is BNP1-30 a better drug than Nesiritide®? 
In chronic heart failure, circulating natriuretic peptide concentrations are increased 
but their effects are attenuated due to several reasons, for example the increased 
local natriuretic peptide degradation through NEP314, reduced NPRA activity due to 
receptor degradation315 and downregulation77, 316. The latter mentioned process was 
described by Potter et al. in 200777, where they showed that NPRA is downregulated 
in failing hearts of mice but NPRB is not. They found that CNP exerted twice as much 
activity as ANP due to dramatic reductions in NPRA activity without changes in NPRB 
activity. Thus, NPRB accounts for the majority of the natriuretic peptide-dependent 
activity in the failing heart. Recently, they disclosed an upregulation of NPRB in 
human failing hearts317. Since NPRB seems to play an essential role in failing hearts, a 
drug targeting both natriuretic peptide receptors may be a more beneficial treatment 
option than a drug like Nesiritide® (= BNP1-32) that targets NPRA only. BNP1-30 was 
shown to be three times more effective on the NPRB, although its actions were still 
low compared to that of CNP. However, since BNP1-30 is not only more active on the 
NPRB, but in parallel, is also more active on the NPRA it might be better targeting the 
altered receptor profile in failing hearts than Nesiritide®. Further parameters 
including its effects on natriuresis and diuresis need to be assessed. Since it has been 
reported the NPRB axis rather acts anti-natriuretic87 it might be that the diuretic 
effects of BNP1-30 are reduced compared to Nesiritide®. Dose-response curves 
should moreover reveal if the peptide exerts adverse effects on renal function, which 
was observed during treatment with Nesiritide® in some studies182. 
4.4.5  Possible role of endogenous BNP1-30 during anti-
hypertensive treatment in SHR 
In September 2012 a paper was published describing the effects of an combined 
inhibitor of NEP and ECE-1, namely SOL1, for the treatment of hypertension in the 
SHR-model318. The authors revealed that the inhibitor had, opposing to their 
expectations, no effect on blood pressure in these animals. The data revealed from 
this thesis might give an explanation for the results observed in that study. In 
conclusion of this data it is likely that the NEP inhibitor and the ECE-1 inhibitor have 
opposing effects and thus SOL1 shows no effect on hypertension. ECE-1 has sequence 
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homologies to NEP, which is also a zinc-dependent metallopeptidase319 and both 
enzymes have similarities in their substrate specificity. However, their specificity 
towards natriuretic peptides is different. As revealed in this thesis, ECE-1 is 
converting BNP1-32 towards BNP1-30, whereas NEP has very low affinity towards 
BNP1-32, but can inactivate shorter BNP metabolites. Thus, the two enzymes have 
opposing effects in the processing of BNP. Whereas ECE-1 is additionally activating 
BNP1-32 by forming the more bioactive BNP1-30, NEP is inactivating BNP 
metabolites. Thus, on the one hand, NEP inhibition could increase BNP activityi, since 
levels of BNP metabolites such as BNP1-29 would increase. Indeed, it was observed 
that blood pressure was reduced upon NEP inhibition in SHR320 and other 
hypertensive animal models321. On the other hand, treatment with an ECE-1 inhibitor 
in vivo should in part decrease the formation of BNP1-30. Since it was shown in this 
thesis that BNP1-30 has very pronounced effects of blood pressure compared to 
BNP1-32 in the SHR-model, inhibition of BNP1-30 formation would decrease BNP 
activityi. Thus, the decrease of BNP activityi by an ECE-1 inhibitor and the increase of 
BNP activityi by an NEP inhibitor might be compensatory and explain the 
ineffectiveness of SOL1 in decreasing blood pressure. The same missing effect on 
blood pressure was seen with the ECE-1/NEP inhibitor SLV 338 in stroke prone 
SHR322. However, the use of the triple inhibitor CGS 35601, inhibiting NEP, ECE-1 and 
additionally ACE reduced blood pressure in SHR significantly323. Also the dual 
ACE/NEP inhibitor, omapatrilat significantly decreases blood pressure in SHR324.   
The use of enzyme inhibitors represents a common treatment option for the therapy 
of cardiovascular diseases. In the next chapters the impact of several enzymes 
involved in BNP metabolism for the treatment of cardiovascular diseases is discussed. 
Thereby the inhibition of these enzymes and the accompanied effects on BNP 
metabolism and thus cardiovascular health is of special interest. 
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4.5  The role of particular BNP-metabolizing enzymes 
in cardiovascular diseases 
4.5.1  Endothelin-converting enzyme-1 (ECE-1) 
In this thesis it could be revealed that inhibition of ECE-1 in lung and liver tissues 
strongly decreases BNP1-30 accumulation (see Results section 3.2.3 and 3.2.4). ECE-1 
is an integral membrane zinc peptidase present in endothelial cells325 and was 
specifically also purified from lung326. There is a second isoform of ECE, ECE-2, having 
59% homology with ECE-1327. However, its pH optimum is 5.5 with virtually no 
activity at neutral pH indicating that ECE-2 is involved in intracellular processes 
rather than extracellular ones. ECE-1 is the main enzyme catalyzing the conversion of 
Big ET-1 to the very potent vasoconstrictor ET-1325. Notably, ECE-1 is also involved in 
the reduction of levels of BK282, substance P249, neurotensin328, and AngI328.  
The decrease of BNP1-30 concentration through ECEC-1 inhibition under 
normotension could have two opposing effects. On the one hand biological BNP 
activityi could be decreased, since the concentrations of BNP1-30 are reduced. On the 
other hand, biological BNP activityi could be increased, since the half-life of BNP pool 
would be increased because BNP metabolites like BNP1-29 generated from BNP1-30 
are quickly degraded by NEP. Supporting the latter hypothesis, Ruvanova et al. 
reported about a decrease of blood pressure after acute heart failure by 
administration of the ECE-1 inhibitor PP36, which could be caused by less generated 
ET-1. Interestingly, the concentration of ET-1, did not change between the treated 
and untreated groups329. It might be conceivable that the inhibition of ECE-1 led to an 
increased half-life of BNP activityi, which subsequently could have caused blood 
pressure reduction. Supporting the first statement, Telemaque et al. demonstrated 
that overexpression of ECE-1 does not lead to systemic hypertension although levels 
of the vasoconstrictor ET-1 are increased330. A possible explanation for this might be 
that increased ECE-1 activity also increases the formation of BNP1-30 with higher 
biological activity acting against hypertension. 
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4.5.2  Carboxypeptidase A (CPA) 
Since it could be revealed that the carboxypeptidase inhibitor decreased BNP1-30 
formation in heart and spleen (see Results section 3.2.2 and 3.2.5), different 
carboxypeptidases have been evaluated for their ability to form BNP1-30. ACE and 
ACE2 as the key players of the renin-angiotensin system were not able to cleave 
BNP1-32 (see Results section 3.3.2.1). ACE is a dipeptidylcarboxypeptidase, being 
able to cleave dipeptides at the C-terminus that do not harbor a penultimate proline 
or an asparagine and glutamine at the very last position. Although, BNP1-32 does not 
harbor such amino acids in these positions it is not cleaved by the enzyme with the 
specific activity used. Its classical substrate AngI harbors 10 amino acids and is thus 
much smaller compared to BNP1-32. The size might be an exclusion factor for the 
inability of the enzyme to metabolize the peptide. The same might be true for ACE2. 
However, it could be shown that recombinant CPA was forming BNP1-30 through the 
intermediate product BNP1-31. CPA has been described before to mediate the 
formation of Ang(1-9) form AngI259. In this step, the C-terminal leucine is removed, 
similarly to the reactions forming BNP1-31 and BNP1-30, where also the C-terminal 
leucine is removed. CPA expression was described in the heart but was not found in 
lung, liver and kidney331. An isoform of CPA the CPA-6 is expressed in brain and 
spleen also having a prevalence for the removal of a C-terminal leucine332. Thus, CPA 
or an isoform of CPA is highly likely also the enzyme generating BNP1-30 in spleen. 
Notably, CPA is a metallopeptidase but EDTA was not able to inhibit BNP1-30 
formation in heart and spleen, but it was observed that aprotinin has a significant 
effect. However, it was implicated before that CPA inhibition by EDTA might be a slow 
reaction333. In subsequent experiments, recombinant CPA was incubated with EDTA 
but no inhibition in its activity has been observed while the carboxypeptidase 
inhibitor diminished its activity by 90% (see supplementary, Figure S2). In the same 
approach, it was shown that aprotinin, which had a significant inhibitory effect on 
BNP1-30 formation in the heart, did not inhibit CPA. This indicates that at least one 
more peptidase might be responsible for the formation of BNP1-30 in heart and 
spleen, which is sensitive to aprotinin. 
The inhibition of CPA was investigated over the last decade, since it is used as a model 
enzyme for developing design strategies of inhibitors that restrain the catalytic 
activity of zinc proteases334-336.  A specific inhibitor of CPA should be tested for its 
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ability to decrease BNP1-30 formation in heart and spleen incubations. Although, as 
described before, it cannot be anticipated that formation of BNP1-30 is diminished 
completely by this inhibitor, since it is likely that another peptidase, being sensitive to 
aprotinin, is able to form BNP1-30. According to a literature search in Pubmed, CPA 
inhibition in vivo has not been performed yet. It is likely that inhibition of CPA in vivo 
will have effects on blood pressure homeostasis, since the enzyme exerts both, effects 
on the renin-angiotensin system by catalyzing the formation of Ang1-9259 and likely 
also effects on the natriuretic peptide system by catalyzing the formation of BNP1-30. 
4.5.3  Carboxypeptidase B (CPB) 
Recombinant CPB was revealed to catalyze the formation of BNP1-29 and BNP7-29 
from BNP1-30 and BNP7-30 (see Results section 3.3.2.3). CPB is a component of the 
coagulation pathway that protects blood clots from fibrinolysis337. Its alternative 
name is thrombin-activatable fibrinolysis inhibitor [TAFI]. It is produced mainly by 
the liver as the zymogen proCPB, which is activated through the removal of the N-
terminus during thrombotic events337, 338. It was shown that plasmin catalyzes this 
activation in vitro, but especially the thrombin/thrombomodulin complex is 
considered as the physiological activator of proCBP339. CPB is regarded as a 
procoagulant, since it removes C-terminal lysines from fibrins and thereby supports 
the maintenance of fibrin clots340. CPB is able to cleave BK341 and osteopontin, a 
proinflammatory cytokine that plays an important role in the pathogenesis of 
rheumatoid arthritis342. Thus, CPB is regarded as a regulator of vascular 
inflammation341, 343. The presence of activated CPB in serum samples might explain 
the fast degradation seen for BNP1-30 and BNP7-30 in comparison to other BNP 
metabolites. However, this also indicates that both metabolites might not be this fast 
degraded under in vivo conditions, when CPB is rather inactive. It was shown that 
homozygous CPB-deficient mice do not show any differences in intravascular 
coagulation, nor survival or fertility344. However, no cardiovascular parameters such 
as blood pressure or cardiac function have been determined in these studies, 
respectively. It was published before that CPB activity is increased in a canine model 
of myocardial infarction338. From the perspective of this work it would be interesting 
to evaluate the influence of CPB deficiency in a model of myocardial infarction (MI). 
An increase of CPB would lead to a decrease of BNP1-30 levels in the circulation. 
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BNP1-30 was shown to be more potent in decreasing blood pressure compared to 
BNP1-32 in this thesis. Thus, it is conceivable that CPB deficient mice undergoing MI 
experience some beneficial effects in comparison to their wild-type litter mates 
undergoing MI, since the metabolism of BNP1-30 by this enzyme would at least be 
decelerated and thus circulating BNP1-30 levels would be increased. 
During BNP1-32 proteolysis in heparin plasma it was revealed that BNP1-31 and 
BNP1-29 were formed but no formation of BNP1-30 was observed (see section 3.1.4). 
It was however hypothesized that BNP1-30 is formed in blood preparations but 
significant quantities cannot accumulate, since it was disclosed that its stability in 
blood samples is dramatically reduced by its fast metabolism into BNP1-29. This 
metabolism was completely inhibited by the CPB inhibitor GEMSA (see Results 
section 3.3.2.3). Thus, in a subsequent experiment, GEMSA should be supplemented 
into the incubation of BNP1-32 and serum to disclose whether the inhibition of 
BNP1-30 metabolizing activity would lead to an accumulation of BNP1-30 during 
BNP1-32 proteolysis as a prove that BNP1-30 is indeed generated in serum. However, 
it might be that over time other peptidases than CPB proteolyze BNP1-30 similarly as 
seen for BNP1-32 proteolysis when inhibiting ECE-1 in lung tissues. Thus, it needs to 
be assessed first, if BNP1-30 in the presence of GEMSA is similarly stable as BNP1-32 
over time. 
4.5.4  Meprin A 
Meprin A is another enzyme responsible for BNP1-32 metabolism. Meprin A is a 
multimeric metalloendopeptidase that is expressed mainly in mammalian kidney and 
intestine345. The recombinant enzyme is beside the formation of BNP7-32 also able to 
form BNP7-30 and BNP7-29 from BNP1-30 and BNP1-29. It can be anticipated that 
BNP1-31 is also a substrate for meprin A. 
It could be shown before that infusion of actinonin, an inhibitor of meprin A, 
increases circulating immunoreactive BNP levels160. However, no data investigating 
blood pressure or cardiac function has been published, and thus it is not clear 
whether the increase of circulating immunoreactive BNP indeed increases BNP 
activityi. However, the latter scenario is highly likely, since meprin A inhibition should 
increase the half-life of meprin A substrates as BNP1-32, BNP1-30, and BNP1-29, 
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which moreover have increased biological activity compared to the cleavage products 
of meprin A. 
4.5.5  Main conclusion 
Inhibition of relevant enzymes metabolizing BNP1-32 might change circulating 
concentrations of BNP metabolites and thus BNP activityi. Notably, depending on the 
enzyme being inhibited, two opposing effects can occur. On the one hand, the 
inhibition of BNP-metabolizing enzymes e.g. of ECE-1 might lead to a decrease of BNP 
activityi, since the formation of BNP metabolites with higher biological activity 
compared to BNP1-32 is decreased. On the other hand, BNP activityi might be 
increased e.g. by inhibition of CPB, since the generation of BNP metabolites, which are 
in part degradable by NEP, is blunted and thus clearance of BNP is reduced. Thus, the 
discovery of the particular enzymes being able to metabolize BNP1-32 and form 
distinct BNP metabolites with unique bioactivity and degradability represents an 
essential gain of knowledge for the development of pharmaceutical drugs on the basis 
of enzyme inhibition, e.g. dual enzyme inhibitors (see section 4.4.5). Due to the 
disclosure of the different pathways in BNP metabolism involving distinct enzymes it 
might be possible to balance possible beneficial and adverse effects of drugs like 
enzyme inhibitors on e.g. blood pressure regulating systems and thus for the 
treatment of cardiovascular diseases. 
4.6  Implications for BNP metabolism in other species 
In this thesis BNP metabolism has been investigated representatively for the murine 
system. The availability of cells, tissues, and different genetically modified animal 
models is tremendous, which enabled research from scratch towards the 
approvement in the whole living system. Primary because of the good availability, a 
multitude of different applications including murine cells (primary cells like VSMC 
and MC), murine tissues (membrane preparations) and blood, vessel preparations (ex 
vivo experiments), and the animals as physiological system itself (liver perfusion, 
peptide administration during normo- and hypertension) could be utilized to 
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characterize BNP metabolism. The identification of BNP metabolism is also seen as a 
substantial gain of knowledge for the use of the murine system, being the basic 
animal model in so many research applications. Several examples have been 
discussed in this thesis were BNP metabolism might play a role in these animals 
models. 
Although differences in amino acid sequence are present between the BNPs of all 
mammalian species, it can be anticipated that BNP metabolism is similarly important 
to that revealed in the murine system. Indeed, some own preliminary experiments 
showed that BNP metabolism is similarly complex in human organ preparations. 
Human BNP exerts a similar N-terminus compared to murine BNP1-32. Human 
BNP1-32 harbors a positively charged arginine at position 30 similar the positively 
charged lysine in murine BNP1-30. Moreover, both peptides harbor the leucine at 
position 29, thus formation of human BNP1-29 and effects on natriuretic peptides 
receptors might be highly similar to murine BNP1-29. Own unpublished work and 
work by others219 indicate that the generation of human BNP metabolites like BNP3-
32, BNP1-30 and BNP1-29 is present in the human system too. Thus, this work also 
represents a template for the investigation of BNP metabolism in humans and is 
according to own preliminary studies applicable to it. Ongoing studies will be 
resolved soon.  
Besides the investigation of BNP metabolism in different species, it is of special 
interest to develop a method for the detection of endogenously generated BNP 
metabolites. In the next chapters strategies as well as preliminary results are 
introduced and clinical implications of the detection of distinct BNP metabolites are 
discussed. 
4.7  Strategies for the detection of endogenous BNP 
metabolites 
Normal concentrations of the total BNP pool in healthy subjects range in the lower 
picomolar field171, 346, 347. Thus, the concentration of distinct BNP metabolites can be 
expected to be 10 to 100 fold lower reaching the femtomolar range. Despite the very 
low concentrations, the detection of endogenous BNP fragments in such a complex 
biological fluid like blood increases the complicacy of such an approach. 
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Own strategies for the detection of endogenous BNP metabolites have been designed 
and preliminary studies have been made. Such efforts included, besides the work on 
blood sample preparation including C18 extraction and size exclusion filters, the use 
of analytical methods like MALDI-TOF-MS in collaboration with the Protein Analytics 
Group at the Institute of Biochemistry, Giessen, and of the triple-quadroupole mass 
spectrometry in collaboration with the Clinical Institute of Medical and Chemical 
Laboratory Diagnostics, Graz, Austria. First preliminary investigations revealed that 
detection of endogenous BNP metabolites might require the use of antibodies 
enabling a prior purification of all BNP fragments from blood.  
Niederkofler et al.219 developed an automated method utilizing antibody derivatived 
affinity pipettes for the specific binding of BNP fragments from blood samples 
followed by the elution of those on a MALDI-target. Such approach revealed the 
occurrence of some BNP metabolites in blood of heart failure patients. However, 
despite the use of an antibody binding within the ring-structure of BNP1-32, the 
authors used a second antibody in parallel binding to the amino acids 27 to 32 within 
the peptide. Thus, the detection of all fragments emerging from a C-terminal 
truncation of BNP1-32 was not given. Notably, the quantification of the found 
metabolites revealed that their concentration in blood was higher compared to that of 
BNP1-32.  
Hawkridge et al.348 developed a dual-antibody immunoaffinity purification assay to 
purify BNP1-32 from plasma. In solid-phase extraction, they used a primary antibody 
against human BNP1-32 to capture BNP1-32 and a secondary antibody to isolate and 
purify the antibody-antigen complex. For the analysis of extracted samples they used 
nano-liquid chromatography (LC) electrospray ionization (ESI) Fourier transform 
(FT) ion cyclotron resonance (ICR) mass spectrometry (MS). As a control they 
compared levels of BNP1-32 measured with their method with BNP levels obtained 
from a commercially available BNP test (Triage® test, Biosite). Notably, they found, 
that levels of BNP1-32 were 50% lower in the samples compared to immunoreactive 
BNP levels detected with the Triage® test. 
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4.8  Detection of endogenous BNP metabolites – 
clinical implications 
Mass spectrometry tests revealed first insights into the qualitative composition of the 
BNP pool in plasma219, 348. As stated above, Hawkridge et al. compared BNP levels 
measured by the Triage® test with levels of BNP1-32 determined by their developed 
method using nano-LC-ESI-FT-ICR MS in plasma of patient with severe heart failure 
and found that levels of BNP1-32 in these samples were much lower compared to 
immunoreactive BNP levels found with the Triage® test348. They suggested the 
occurrence of ‘cross-reactive species’ detected by the antibodies of the test 
contributing to the measured values. Niederkofler et al. who detected also only small 
quantities of endogenous BNP1-32 but revealed the occurrence of other BNP 
fragments suggested that immunoreactive BNP assays might overrepresent the actual 
presence of biological BNP activityi 9. Both conclusions do not give consideration to 
the possible biological activity of these BNP fragments. According to the results 
presented in this thesis, the occurrence of bioactive BNP metabolites like BNP1-30, 
BNP1-31, BNP1-29, BNP7-32, BNP7-30, and BNP7-29 extremely expands the pool of 
immunoreactive BNP. Commercially available kits like the Triage® BNP kit are based 
on the detection of BNP by a monoclonal antibody directed against an epitope within 
the 17 aa ring structure of the peptide. Thus, the antibody binds the mature BNP1-32 
and all BNP fragments with an intact ring structure, respectively (see Introduction 
section 1.2.6). All new metabolites still harbor the intact ring structure, which is the 
requirement of biological activity of these peptides. Assumedly, a test with an 
antibody directed against an internal epitope will detect all BNP fragments. Thus, the 
result of such a test will be the quantification of all BNP fragments rather than the 
specific quantification of BNP1-32 only. 
On the one hand, the detection of the whole BNP pool by these assays has proven to 
be clinically relevant in the diagnosis and prognosis of cardiovascular diseases and 
does not change the general conclusion made by the results of such assays. However, 
the concentrations determined in such assays do not reflect the actual presence of 
bioactive and thus beneficial BNP. Assuming that a value of 100 pg/ml of BNP 
measured with a commercially available BNP test in a murine blood sample equates 
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100% of the bioactivity of BNP1-32. However, the composition of the BNP pool 
measured with this test does not only include BNP1-32, but highly likely a variety of 
other BNP metabolites. Assuming that the measured BNP pool is composed of equal 
parts of BNP1-32, BNP1-30, and BNP1-29, the theoretical bioactivity of this pool 
would be significantly higher compared to a BNP pool composed of BNP1-32 only. 
Calculating this excess of bioactivity on the basis of their ability to stimulate NPRA & 
NPRB-double transfected cells (see Results section 3.5.1.4), such bioactivity would 
reach a value of 135.2%. Vice versa, this value can also be decreased assuming that 
the majority of the BNP pool is composed of metabolites like BNP7-32 or BNP7-30 
which exert less biological activity compared to BNP1-32. Thus, it can be concluded 
that the BNP bioactivity present in a sample is depending on the composition of 
different BNP metabolites.  
4.9  Specific diagnosis of cardiovascular diseases with 
BNP metabolites 
The early diagnosis of cardiovascular pathologies through the general practitioner 
before the manifestation of a cardiac event or in the clinical setting, when heart 
failure is often already present, is pivotal. A variety of biomarkers have been utilized 
during the last decades to make diagnosis faster and more efficient349-351. However, 
the limitation of many tests determining biomarkers including the conventional BNP-
test is their lack in the differentiation between specific cardiovascular diseases220, 352, 
353. 
Many cardiovascular diseases have in common that gene and protein expression is 
altered, which in turn is depending on the specific pathology. It was found that gene 
expression is altered during heart failure. Heidecker et al. found forty-six genes that 
are overexpressed in patients with heart failure having a good outcome compared to 
patients with heart failure having a poor outcome354. Alexander et al. found the 
concentration of sixty-one metabolites significantly different between patients with 
primary dilated cardiomyopathy and control individuals355, indicating that also levels 
of peptidases generating these metabolites are altered. Viral infection (e.g., 
parvovirus) or nonviral infection (e.g. Chagas disease) might lead to an altered 
peptidase expression. For example it was found that mRNA levels of ECE-1 are 
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elevated in Chagas Disease356. Furthermore higher activity of ECE-1 is associated with 
pulmonary arterial hypertension357. Meprin is markedly downregulated in chronic 
renal dysfunction358, whereby renal dysfunction is often associated with cardiac 
dysfunction359. NEP expression associates with cardiometabolic risk and plasma 
levels of NEP increase with obesity, a disease which is frequently accompanied by 
cardiac pathologies360. Circulating levels of DPPIV, the peptidase generating the 
human BNP3-32, is associated with left ventricular dysfunction. 
This up or down-regulation of peptidases due to specific cardiovascular diseases will 
subsequently also change the concentrations of their substrates and products, e.g. 
that of BNP1-32 and BNP metabolites. An up-regulation of e.g. ECE-1 would increase 
concentrations of BNP1-30 a down-regulation of Meprin A would decrease levels of 
BNP7-32. Besides altered metabolite-generation it might also be that metabolite-
degradation is specifically altered in a disease. It was for example shown in patients 
with idiopathic cardiomyopathy, that degradation of natriuretic peptides is markedly 
changed even in early stages of the disease361. Thus, the composition of the BNP pool 
is depending on the generation or degradation of BNP metabolites. Generation and 
degradation is in turn depending on enzymes whose expression level or activity is 
potentially altered during the development and etiopathology of a distinct 
cardiovascular diseases. It can therefore be hypothesized that patients with specific 
cardiovascular diseases have specific BNP metabolite profiles. The collection of such 
BNP metabolite profiles for every cardiovascular disease including different stages of 
the disease would allow the establishment of a database, which could be used for a 
rapid and specific diagnosis once the BNP metabolite profile of a patient has been 
assessed. In contrast to that, a conventional BNP assays will only determine the 
concentration of the whole BNP pool in a patients’ blood sample. Thus, increases in 
levels of the BNP pool allow the discrimination between healthy and diseased 
patients. If BNP levels of a patient are above a certain cut-off level the patient will 
have to undergo more examinations to specify the cardiovascular disease. Applying a 
BNP-test being able to distinguish between the different BNP metabolites and to 
quantify them opens the avenue for a more specific diagnosis of heart diseases and 
might even make further clinical assessment unnecessary. Taking metabolite-specific 
antibodies as a basis of this test, such an assay would only require a blood sample for 
the analysis. Such a non-invasive test would be usable in the clinic, e.g. emergency 
room, but might also be helpful in a pre-clinical setting e.g. in the physician's office. 
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The compilation of a BNP metabolite profile as a standard method during medical 
check-ups could contribute to risk stratification and early diagnosis of developing 
diseases, since a significant proportion of cardiovascular pathologies have a genetic 
background or develop without symptoms. For instance, a coronary artery disease 
might be present for years with symptoms occurring only late in the etiology, 
however, peptidase and metabolite levels might be already changed in an early onset. 
Just as well, the determination of BNP metabolite profiles during the individual 
treatment of a patient with a cardiovascular disease could be used for the monitoring 
of etiopathology and guidance of therapy. Thus, the collection of BNP metabolite 
profiles throughout the life span of patients could contribute to the health status of 
the individual. An overview about the possible usage of the compilation of a BNP 
metabolite profile in the diagnosis and risk stratification of cardiovascular diseases 
has been pictured in Figure 55. 
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Figure 55: Comparison of two diagnostic strategies for the determination of BNP in patients. The 
upper part of the figure shows the quantification of the whole BNP pool with a conventional BNP-test. 
The lower part shows a new strategy for the diagnosis of specific cardiovascular diseases by 
identifying and quantifying BNP metabolites leading to a compilation of a specific BNP metabolite 
profile for each patient. Abbreviations: B-type natriuretic peptide (BNP), B-type natriuretic peptide 
metabolites (BNPx-x) 
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Figure S1: optimized trycine-gel after electrophoresis displaying single BNP metabolites as well as 
their separation from each other. In particular, lane 3 shows the separation of BNP1-32 (upper band) 
and BNP1-30 (lower band). Lane 5 shows the separation of BNP1-32 (upper band) and BNP7-32 
(lower band). M = marker. For method see section 2.2.7 
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Figure S2 
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Figure S2: Quantification of the generation of BNP1-30 with recombinant carboxypeptidase A (CPA) in 
the presence of the carboxypeptidase inhibitor (CP inhib), EDTA, or aprotinin. 
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6 SUMMARY 
 
The B-type natriuretic peptide (BNP1-32) is secreted in large amounts upon 
increasing blood pressure and other cardiopathological conditions to protect the 
body by its vasoactive and antifibrotic effects. It is routinely measured in the clinic as 
a biomarker for the diagnosis and prognosis of heart failure and is used as a drug 
(Nesiritide®) for the therapy of such. In circulation, BNP1-32 is constantly exposed 
towards proteolytic activity and it was thus hypothesised that, similar to other 
vasoactive peptides, BNP1-32 is truncated forming BNP metabolites with analog or 
altered bioactivity, before it is degraded. 
Through this thesis it is possible to give a detailed overview about BNP1-32 
metabolism including the discovery of different pathways and enzymes leading to the 
formation of a variety of BNP metabolites. The main findings are: firstly, BNP 
metabolism is organ-specific. Secondly, this organ-specific BNP metabolism leads to 
the generation of numerous different BNP metabolites, namely BNP1-31, BNP1-30, 
BNP1-29, BNP7-32, BNP7-31, BNP7-30, and BNP7-29. Thirdly, this generation of BNP 
metabolites involves a variety of different enzymes, of which one is the endothelin-
converting enzyme-1 (ECE-1). Fourthly, full metabolism of BNP1-32 needs the 
concerted action of these enzymes. Fifthly, BNP metabolism also serves as a 
prerequisite for BNP clearance by neprilysin (NEP), since BNP metabolites such as 
BNP1-29 and BNP7-30 are degradable by the enzyme, whereas BNP1-32 is not. On 
the basis of these five main results, a comprehensive model of BNP processing was 
developed. As a sixth essential finding it was revealed that all newly identified BNP 
metabolites investigated exert biological activity in vitro, ex vivo, and in vivo. In 
particular, one of these BNP metabolites, BNP1-30, is able to reduce blood pressure 
substantially more strongly compared to BNP1-32 under normotensive and 
hypertensive conditions at least in part as a result of its altered receptor profile.  
The work presented shows for the first time that the metabolism of BNP1-32 is 
complex and involves a variety of enzymes forming different BNP metabolites with 
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unique bioactivity and is thus representing an essential process for the 
cardioprotective actions of BNP. On the basis of this work it is implied that BNP 
processing is not purposed to generate BNP1-32 alone, but is aimed to generate BNP 
metabolites with similar and in part higher bioactivity compared to BNP1-32. It is 
thus concluded that the virtually mature BNP1-32 is rather a precursor for BNP1-30 
or other BNP metabolites, a finding that suggests a fundamental revision and 
extension of the natriuretic peptide system. The experimental data also indicate that 
there might exist more metabolites of BNP, and surely also of other natriuretic 
peptides, exerting unique biological properties. 
Furthermore, the results of this thesis can be translated into clinical applications. The 
newly identified BNP metabolites, but also the manipulation of enzymes being 
involved in their formation, represent new tools for the therapy of heart failure. In 
particular, the metabolite BNP1-30 might be a better treatment option of 
cardiovascular diseases than Nesiritide®. The identification of BNP metabolites also 
allows the development of new diagnostic strategies in the assessment of 
cardiovascular diseases. In this manner, the compilation of a specific BNP metabolite 
profile could, as opposed to the current BNP measurement in the clinic that does not 
distinguish between the various forms of BNP, give detailed information about risk 
stratification, etiopathology, and therapeutic success.  
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7 ZUSAMMENFASSUNG 
 
 
Das B-Typ Natriuretische Peptid wird in Folge von erhöhtem Blutdruck und anderen 
kardiovaskulären Erkrankungen vermehrt sekretiert, um den Körper durch seine 
vasoaktiven und antifibrotischen Effekte zu schützen. In der Klinik wird es 
routinemäßig als Biomarker zur Diagnose und Prognose von Herzversagen, sowie als 
Medikament (Nesiritide®) zur Therapie solcher verwendet. Da zirkulierendes BNP 
konstant proteolytischer Aktivität ausgesetzt ist, wurde die Hypothese aufgestellt, 
dass BNP1-32, ähnlich wie andere vasoaktive Peptide, zu Metaboliten trunkiert wird, 
bevor es abgebaut wird. 
Diese Arbeit ermöglicht die Aufstellung einer umfangreichen Übersicht über den 
Metabolismus des BNP1-32, welche die Entdeckung unterschiedlicher Wege und 
Enzyme, die zur Bildung einer Vielzahl an BNP Metaboliten führt, einschließt. Die 
wichtigsten Ergebnisse sind: Erstens, der Metabolismus von BNP ist spezifisch für 
jedes Organ. Zweitens, dieser organspezifische BNP-Metabolismus führt zur 
Generierung folgender BNP Metaboliten: BNP1-31, BNP1-30, BNP1-29, BNP7-32, 
BNP7-31, BNP7-30 und BNP7-29. Drittens, die Herstellung der BNP Metaboliten wird 
von mehreren unterschiedlichen Enzymen durchgeführt, zum Beispiel durch das 
Endothelin-konvertierende Enzym 1 (ECE-1). Viertens, der vollständige 
Metabolismus von BNP1-32 ist abhängig vom Zusammenwirken dieser Enzyme. 
Fünftens, der Metabolismus von BNP dient außerdem als Voraussetzung für den 
Abbau durch Neprilysin (NEP), da BNP Metaboliten wie BNP1-29 und BNP7-30 durch 
dieses Enzym degradiert werden können, jedoch nicht BNP1-32. Auf der Grundlage 
dieser fünf Ergebnisse wurde ein umfassendes Model für die Prozessierung von BNP 
entwickelt. Als sechstes Ergebnis kann formuliert werden, dass alle untersuchten und 
neu identifizierten BNP Metaboliten biologische Aktivität in vitro, ex vivo und in vivo 
aufweisen. Besondere Aufmerksamkeit kommt dem Metaboliten BNP1-30 entgegen, 
der den Blutdruck unter normotensiven und hypertensiven Bedingungen signifikant 
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stärker senken kann als BNP1-32, was zumindest teilweise durch seine veränderte 
Rezeptorspezifizität hervorgerufen wird.  
Die Arbeit zeigt erstmalig, dass BNP1-32 einem komplexen Metabolismus unterliegt, 
der eine Vielzahl von Enzymen, die verschiedene BNP Metaboliten mit einzigartigen 
Aktivitäten generieren, einschließt, sodass er einen essentiellen Prozess darstellt, der 
zu den kardioprotektiven Eigenschaften des BNPs beiträgt. Die Arbeit impliziert, dass 
die Prozessierung von BNP nicht nur der Herstellung von BNP1-32 dient, sondern 
vielmehr die Generierung von BNP Metaboliten mit gleicher oder zum Teil sogar 
höherer Bioaktivität ermöglichen soll. Daraus wird gefolgert, dass das eigentliche, 
reife BNP1-32 eher ein Precursor für die Herstellung von BNP1-30 oder anderen BNP 
Metaboliten darstellt, was eine entscheidende Änderung und Erweiterung des 
Natriuretischen Peptid Systems zur Folge hat. Außerdem indizieren die 
experimentellen Daten das Vorkommen von zusätzlichen BNP Metaboliten sowie von 
Metaboliten anderer natriuretischer Peptide, die einzigartige biologische Funktionen 
aufweisen könnten. 
Die Ergebnisse dieser Arbeit können außerdem klinische Anwendung finden. Die neu 
identifizierten BNP Metaboliten selbst, sowie die Beeinflussung von Enzymen, die 
diese herstellen, legen neue Behandlungsansätze in der Therapie von Herzversagen 
nahe. Im Besonderen ist der neue Metabolit BNP1-30 möglicherweise ein besseres 
Medikament zur Behandlung von kardiovaskulären Erkrankungen als Nesiritide®. Die 
Identifizierung von BNP Metaboliten ermöglicht außerdem die Entwicklung von 
neuen diagnostischen Strategien zur Bewertung von kardiovaskulären Erkrankungen. 
Beispielsweise könnte das Erstellen eines spezifischen BNP Metaboliten Profils im 
Vergleich zur konventionellen Messung von BNP, die nicht zwischen den einzelnen 
BNP Metaboliten unterscheidet, genauere Informationen über Risikostratifikation, 
Krankheitsverlauf sowie Therapieerfolg geben. 
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9 ABBREVIATIONS 
Amino acids and nucleic acids have been abbreviated according to the common 
one-letter code. Elements have been abbreviated as stated in the periodic system.  
 
aa    amino acid 
ABCC5   multidrug resistance protein 5 
ACE   angiotensin-converting enzyme 
ACN   acetonitrile 
Ang    angiotensin  
ANP   atrial natriuretic peptide 
approx.   approximately 
ATP   adenosine triphosphate 
BK    bradykinin 
BNP   B-type natriuretic peptide 
BSA   bovine serum albumin 
bpm   beats per minute 
cDNA   complementary deoxyribonucleic acid 
cGMP   cyclic guanylyl monophosphate 
cAMP   cyclic adenosine monophosphate 
CathA   cathepsin A, carboxypeptidase C 
CPA   carboxypeptidase A 
CPB   carboxypeptidase B 
C-C    disulfide bridge 
CP inhib.   carboxypeptidase inhibitor 
CNG   cGMP-dependent ion-gated channels 
CNP   C-type natriuretic peptide 
CT    threshold cycle 
C-terminus   carboxyl-terminus  
DMEM   Dulbecco's modified eagle medium 
DNA    deoxyribonucleic acid 
DNP   dendroapsis natriuretic peptide 
DPPIV   dipeptidyl-peptidase IV 
DMSO   dimethyl sulfoxide 
EC    European commission number 
EC50   half maximal effective concentration  
ECE   endothelin-converting enzyme 
EDTA   ethylenediaminetetraacetic acid 
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ELISA   enzyme-linked-immunosorbent assay 
ET-1   endothelin-1 
et al.    and others 
FDA   Federal Drug Administration 
FCS    fetal calf serum 
GC    guanylyl cyclase 
GDP   guanosine diphosphat 
GIRK   G protein-gated inwardly rectifying K+ channel 
GTP   guanosine triphosphat 
HEK293   hamster endothelial kidney cells 293 
HDMEC   human dermal microvascular endothelial cells 
HEPES   2-(4-(2-Hydroxyethyl)- 1-piperazinyl)-ethansulfonic acid 
HF    heart failure 
HPLC   high performance liquid chromatography 
HPRT1   hypoxanthine phosphoribosyltransferase 1 
Ig    immunglobulin 
Il    interleukin 
i.p.     intraperitoneal 
KHD   kinase homology domain 
LB    Luria--Bertani 
MALDI-TOF-MS Matrix-assisted-laser-ionization time-of-flight mass 
spectrometry 
MAP   mean arterial blood pressure 
MAPK   mitogen activated protein kinase (MAPK) 
MC    mesangial cells 
MRP-5   multidrug resistance protein 5 
MI    myocardial infarction 
MS    mass spectrometry 
mRNA   messenger ribonucleic acid 
LC-ESI-FT-ICR MS liquid chromatography electrospray ionization Fourier 
transform ion cyclotron resonance mass spectrometry 
n     number of experiments 
NF-ĸB renal nuclear factor ‘kappa-light-chain-enhancer’ of 
activated B-cells 
NFAT   calcineurin-nuclear factor of activated T cells 
NEP   neutral endopeptidase, neprilysin 
N-Terminus   amino-terminus  
NPR   natriuretic peptide receptors 
NPRA   natriuretic peptide receptor A 
NPRB   natriuretic peptide receptor B 
NO     nitrogen monooxide 
NOS   nitrogen monooxide synthase 
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P    p-value, probability 
NPS   natriuretic peptide system 
PBS    phosphate-buffered solution 
RT-PCR   real-time polymerase chain reaction 
PDE-5   phosphodiesterase-5 
PIP3   phosphatidylinositol (3,4,5)-trisphosphat 
PKC   protein kinase C 
PLC    phospholipase C 
PB    peak blood  
PLP    peak liver perfusion 
PM    peak membrane preparations 
P/S    Penicillin / Streptomycin 
PRCP   prolylcarboxypeptidase 
PREP   prolylendopeptidase 
RGS4   G protein signaling subtype 4 
RAS   renin-angiotensin system 
RNA    Ribonucleic acid 
RT    room temperature 
rt    retention time 
Rpm   rotations per minute 
SBP    systolic blood pressure 
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis 
s.c.     subcutaneous 
SEM    standard error of mean 
SHR   Spontaneously hypertensive rats 
t1/2   half-life  
TAFI thrombin-activatable fibrinolysis inhibitor  
TFA trifluoracetic acids  
TGF-β    transforming growth factor 
TNF-α    tumor necrosis factor alpha 
Trp.inhib.   trypsin inhibitor   
UV    ultraviolet 
URO   urodilatin 
vs.    versus 
VSMC   vascular smooth muscle cells 
WKY   Wistar Kyoto rats 
ZPP    Z-pro-prolinal 
Δ    Delta    
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Orders of magnitude 
 
µ     micro (10-6) 
c     centi (10-2) 
f    femto (10-15) 
k     kilo (103) 
m     milli (10-3) 
n    nano (10-9) 
p    pico (10-12) 
 
 
Units of measurements 
 
%     percent 
°C     degrees of Celsius 
AU    absorbance units 
Da    dalton 
g     gram 
h     hour 
L     liter 
m     meter 
M     molar 
min    minute 
mmHg   millimeter mercury 
pH    hydrogen ion concentration 
s    second 
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